,ID,Event,Item,Dictionary,Verbatim Term,Preferred Term,RXCUI,Drug Name,Normalized RxNorm Id,Approximate RxNorm Id,Best RxNorm Id,Requires Review,DISPOS_isa_disposition,STRUCT_isa_structure,MESHPA,DISEASE_ci_with,DISEASE_may_treat,CHEM_has_ingredient,PE_ci_pe,PE_has_pe,MOA_has_moa,EPC_has_epc,ATC1-4,THERAP_isa_therapeutic,DISEASE_may_prevent,TC_has_tc,VA_has_VAClass,VA_has_VAClass_extended,SCHEDULE_has_schedule,CHEM_has_chemical_structure,CHEM_ci_chemclass,DISEASE_may_diagnose,MOA_ci_moa,PK_has_pk,PK_site_of_metabolism,DISEASE_induces
0,1,Concomitant Medications,Generic Name,RxNorm,escitalopram,Escitalopram 20 MG,353383.0,Escitalopram 20 MG,321988.0,321988.0,321988,False,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,Benzofuran-containing product;Medicinal product categorized by structure,Neurotransmitter Uptake Inhibitors;Membrane Transport Modulators;Serotonin Agents;Neurotransmitter Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Selective Serotonin Reuptake Inhibitors;Molecular Mechanisms of Pharmacological Action,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Disease;Depressive Disorder, Major;Depressive Disorder;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mental Disorders;Mood Disorders","Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Escitalopram;Substances;Amines;Organic Chemicals;Benzofurans;Substances and Cells (CHEM);Propylamines;Nitriles",,Immunologically Active Molecule Activity Alteration;Serotonin Activity Alteration;Increased Immunologic Activity;Organ System Specific Effects;Increased Serotonin Activity;Immunologic Activity Alteration;Increased Immunologically Active Molecule Activity;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Increased Immunologically Active Biogenic Amine Activity;Physiologic Effect (PE);Increased Central Nervous System Serotonin Activity;Generalized Systemic Effects,Mechanism of Action (MoA);Neurotransmitter Transporter Interactions;Receptor Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Membrane Transporter Interactions;Symporter Interactions;Ion Transporter Interactions,Serotonin Reuptake Inhibitor;Established Pharmacologic Class (EPC);Nervous System Agent,PSYCHOANALEPTICS;ANTIDEPRESSANTS;Selective serotonin reuptake inhibitors;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM,Medicinal product categorized by therapeutic role;Antidepressant agent,,,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS,OTHER;ANTIDEPRESSANTS;VA CLASSES","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS,OTHER;ANTIDEPRESSANTS;VA CLASSES",,,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Substances;Pimozide;Substances and Cells (CHEM);Benzimidazoles",,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
1,30,Concomitant Medications,Generic Name,RxNorm,escitalopram,Escitalopram,321988.0,Escitalopram,321988.0,321988.0,321988,False,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,Benzofuran-containing product;Medicinal product categorized by structure,Neurotransmitter Uptake Inhibitors;Membrane Transport Modulators;Serotonin Agents;Neurotransmitter Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Selective Serotonin Reuptake Inhibitors;Molecular Mechanisms of Pharmacological Action,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Disease;Depressive Disorder, Major;Depressive Disorder;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mental Disorders;Mood Disorders","Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Escitalopram;Substances;Amines;Organic Chemicals;Benzofurans;Substances and Cells (CHEM);Propylamines;Nitriles",,Immunologically Active Molecule Activity Alteration;Serotonin Activity Alteration;Increased Immunologic Activity;Organ System Specific Effects;Increased Serotonin Activity;Immunologic Activity Alteration;Increased Immunologically Active Molecule Activity;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Increased Immunologically Active Biogenic Amine Activity;Physiologic Effect (PE);Increased Central Nervous System Serotonin Activity;Generalized Systemic Effects,Mechanism of Action (MoA);Neurotransmitter Transporter Interactions;Receptor Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Membrane Transporter Interactions;Symporter Interactions;Ion Transporter Interactions,Serotonin Reuptake Inhibitor;Established Pharmacologic Class (EPC);Nervous System Agent,PSYCHOANALEPTICS;ANTIDEPRESSANTS;Selective serotonin reuptake inhibitors;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM,Medicinal product categorized by therapeutic role;Antidepressant agent,,,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS,OTHER;ANTIDEPRESSANTS;VA CLASSES","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS,OTHER;ANTIDEPRESSANTS;VA CLASSES",,,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Substances;Pimozide;Substances and Cells (CHEM);Benzimidazoles",,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
2,1,Concomitant Medications,Generic Name,RxNorm,mirena,Mirena,152061.0,Mirena,152061.0,152061.0,152061,False,Progesterone receptor agonist-containing product;Medicinal product categorized by disposition;Hormone-containing product,Steroid-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Contraceptives, Oral, Synthetic;Contraceptive Agents;Contraceptives, Oral;Contraceptive Agents, Female;MeSH Pharmacologic Actions (MESHPA);Reproductive Control Agents;Contraceptive Agents, Hormonal;Physiological Effects of Drugs","Endocrine System Diseases;Male Urogenital Diseases;Adenoma, Liver Cell;Reproduction;Nutritional and Metabolic Diseases;Reproductive Physiological Phenomena;Vascular Diseases;Cardiovascular Diseases;Neoplasms;Signs and Symptoms;Coronary Disease;Mental Disorders;Thrombosis;Venous Thrombosis;Thrombophlebitis;Urogenital Neoplasms;Substance-Related Disorders;Pregnancy;Myocardial Ischemia;Urologic Diseases;Digestive System Diseases;Genital Neoplasms, Female;Breast Neoplasms;Hypertension;Heart Valve Diseases;Jaundice;Skin Manifestations;Skin and Connective Tissue Diseases;Neoplasms by Histologic Type;Liver Neoplasms;Vasculitis;Pathological Conditions, Signs and Symptoms;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Uterine Diseases;Brain Diseases;Neoplasms, Glandular and Epithelial;Hyperbilirubinemia;Chemically-Induced Disorders;Thromboembolism;Kidney Diseases;Embolism and Thrombosis;Female Urogenital Diseases and Pregnancy Complications;Adenoma;Disease;Endometrial Neoplasms;Breast Diseases;Digestive System Neoplasms;Tobacco Use Disorder;Headache Disorders;Uterine Neoplasms;Neoplasms by Site;Drug Hypersensitivity;Heart Diseases;Genital Diseases, Female;Peripheral Vascular Diseases;Hemorrhage;Nervous System Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Genital Diseases;Drug-Related Side Effects and Adverse Reactions;Uterine Hemorrhage;Female Urogenital Diseases;Phlebitis;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Liver Diseases;Pathologic Processes;Skin Diseases;Cerebrovascular Disorders",,Polycyclic Compounds;Substances;Norpregnanes;Steroids;Substances and Cells (CHEM);Norsteroids;Fused-Ring Compounds;Levonorgestrel;Norpregnenes;Norgestrel,Organ System Specific Effects;Cardiovascular Activity Alteration;Blood Pressure Alteration;Increased Blood Pressure;Physiologic Effect (PE),Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Inhibit Ovulation;Ovarian Function Alteration;Organ System Specific Effects;Inhibit Ovum Fertilization;Endocrine Activity Alteration;Ovulation Alteration;Reproductive System Activity Alteration;Female Reproductive System Activity Alteration;Physiologic Effect (PE);Decreased Embryonic Implantation;Hypothalamic Endocrine Activity Alteration;Ovum Fertilization Alteration,Mechanism of Action (MoA);Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Sex Hormone Receptor Agonists;Receptor Interactions;Hormone Receptor Agonists;Progestational Hormone Receptor Agonists,Hormone;Progestin-containing Intrauterine Device;Chemical Structure;Progestin;Established Pharmacologic Class (EPC),HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;Emergency contraceptives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES,Medicinal product categorized by therapeutic role;Contraceptive agent,"Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena",,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,"Hormones;Substances;Gonadal Hormones;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones;Progesterone Congeners",,,,,,"Pregnancy;Female Urogenital Diseases and Pregnancy Complications;Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pregnancy Complications;Pregnancy Outcome;Reproduction;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena;Abortion, Spontaneous"
3,16,Concomitant Medications,Generic Name,RxNorm,Mirena,Mirena Drug Implant Product,1181044.0,Mirena Drug Implant Product,152061.0,152061.0,152061,False,Progesterone receptor agonist-containing product;Medicinal product categorized by disposition;Hormone-containing product,Steroid-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Contraceptives, Oral, Synthetic;Contraceptive Agents;Contraceptives, Oral;Contraceptive Agents, Female;MeSH Pharmacologic Actions (MESHPA);Reproductive Control Agents;Contraceptive Agents, Hormonal;Physiological Effects of Drugs","Endocrine System Diseases;Male Urogenital Diseases;Adenoma, Liver Cell;Reproduction;Nutritional and Metabolic Diseases;Reproductive Physiological Phenomena;Vascular Diseases;Cardiovascular Diseases;Neoplasms;Signs and Symptoms;Coronary Disease;Mental Disorders;Thrombosis;Venous Thrombosis;Thrombophlebitis;Urogenital Neoplasms;Substance-Related Disorders;Pregnancy;Myocardial Ischemia;Urologic Diseases;Digestive System Diseases;Genital Neoplasms, Female;Breast Neoplasms;Hypertension;Heart Valve Diseases;Jaundice;Skin Manifestations;Skin and Connective Tissue Diseases;Neoplasms by Histologic Type;Liver Neoplasms;Vasculitis;Pathological Conditions, Signs and Symptoms;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Uterine Diseases;Brain Diseases;Neoplasms, Glandular and Epithelial;Hyperbilirubinemia;Chemically-Induced Disorders;Thromboembolism;Kidney Diseases;Embolism and Thrombosis;Female Urogenital Diseases and Pregnancy Complications;Adenoma;Disease;Endometrial Neoplasms;Breast Diseases;Digestive System Neoplasms;Tobacco Use Disorder;Headache Disorders;Uterine Neoplasms;Neoplasms by Site;Drug Hypersensitivity;Heart Diseases;Genital Diseases, Female;Peripheral Vascular Diseases;Hemorrhage;Nervous System Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Genital Diseases;Drug-Related Side Effects and Adverse Reactions;Uterine Hemorrhage;Female Urogenital Diseases;Phlebitis;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Liver Diseases;Pathologic Processes;Skin Diseases;Cerebrovascular Disorders",,Polycyclic Compounds;Substances;Norpregnanes;Steroids;Substances and Cells (CHEM);Norsteroids;Fused-Ring Compounds;Levonorgestrel;Norpregnenes;Norgestrel,Organ System Specific Effects;Cardiovascular Activity Alteration;Blood Pressure Alteration;Increased Blood Pressure;Physiologic Effect (PE),Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Inhibit Ovulation;Ovarian Function Alteration;Organ System Specific Effects;Inhibit Ovum Fertilization;Endocrine Activity Alteration;Ovulation Alteration;Reproductive System Activity Alteration;Female Reproductive System Activity Alteration;Physiologic Effect (PE);Decreased Embryonic Implantation;Hypothalamic Endocrine Activity Alteration;Ovum Fertilization Alteration,Mechanism of Action (MoA);Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Sex Hormone Receptor Agonists;Receptor Interactions;Hormone Receptor Agonists;Progestational Hormone Receptor Agonists,Hormone;Progestin-containing Intrauterine Device;Chemical Structure;Progestin;Established Pharmacologic Class (EPC),HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;Emergency contraceptives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES,Medicinal product categorized by therapeutic role;Contraceptive agent,"Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena",,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,"Hormones;Substances;Gonadal Hormones;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones;Progesterone Congeners",,,,,,"Pregnancy;Female Urogenital Diseases and Pregnancy Complications;Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pregnancy Complications;Pregnancy Outcome;Reproduction;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena;Abortion, Spontaneous"
4,2,Concomitant Medications,Generic Name,RxNorm,norethindrone,,,,7514.0,7514.0,7514,False,Progesterone receptor agonist-containing product;Medicinal product categorized by disposition;Hormone-containing product,Steroid-containing product;Medicinal product categorized by structure,"Contraceptives, Oral, Combined;Therapeutic Uses;Contraceptives, Oral, Synthetic;Contraceptive Agents;Contraceptives, Oral;Contraceptive Agents, Female;Contraceptives, Oral, Sequential;MeSH Pharmacologic Actions (MESHPA);Reproductive Control Agents;Contraceptive Agents, Hormonal;Physiological Effects of Drugs;Contraceptives, Oral, Hormonal","Lung Diseases;Respiratory Tract Diseases;Reproduction;Cardiovascular Diseases;Vascular Diseases;Neoplasms;Venous Thrombosis;Thrombophlebitis;Pregnancy;Digestive System Diseases;Pathologic Processes;Breast Neoplasms;Skin and Connective Tissue Diseases;Pulmonary Embolism;Vasculitis;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Chemically-Induced Disorders;Thromboembolism;Embolism;Embolism and Thrombosis;Female Urogenital Diseases and Pregnancy Complications;Disease;Breast Diseases;Neoplasms by Site;Drug Hypersensitivity;Genital Diseases, Female;Peripheral Vascular Diseases;Hemorrhage;Life Phases, Behavior Mechanisms and Physiologic States;Genital Diseases;Drug-Related Side Effects and Adverse Reactions;Uterine Hemorrhage;Female Urogenital Diseases;Phlebitis;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Reproductive Physiological Phenomena;Skin Diseases;Thrombosis","Endocrine System Diseases;Endometriosis;Acneiform Eruptions;Menorrhagia;Gonadal Disorders;Sebaceous Gland Diseases;Hypogonadism;Skin and Connective Tissue Diseases;Acne Vulgaris;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Genital Diseases;Endometrial Hyperplasia;Uterine Hemorrhage;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Skin Diseases",Norethindrone;Polycyclic Compounds;Substances;Norpregnanes;Steroids;Norethindrone Acetate;Substances and Cells (CHEM);Norsteroids;Fused-Ring Compounds;Norpregnenes,,Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Inhibit Ovulation;Ovarian Function Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Pituitary Gland Activity Alteration;Decreased Luteinizing Hormone Secretion;Ovulation Alteration;Reproductive System Activity Alteration;Female Reproductive System Activity Alteration;Physiologic Effect (PE);Decreased Embryonic Implantation;Hypothalamic Endocrine Activity Alteration;Gonadotropin Releasing Hormone Alteration,Mechanism of Action (MoA);Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Sex Hormone Receptor Agonists;Receptor Interactions;Hormone Receptor Agonists;Progestational Hormone Receptor Agonists,Progestin;Hormone;Established Pharmacologic Class (EPC);Chemical Structure,"HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Progestogens and estrogens, fixed combinations;PROGESTOGENS;SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens and estrogens, sequential preparations;Progestogens;Estren derivatives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES",Medicinal product categorized by therapeutic role;Contraceptive agent,"Pregnancy;Musculoskeletal Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Disease;Reproduction;Nutritional and Metabolic Diseases;Bone Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Bone Diseases, Metabolic;Metabolic Diseases;Reproductive Physiological Phenomena;Osteoporosis",,"CONTRACEPTIVES,SYSTEMIC;ANTINEOPLASTICS;VA CLASSES;ANTINEOPLASTIC HORMONES;PROGESTINS;HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS","CONTRACEPTIVES,SYSTEMIC;ANTINEOPLASTICS;VA CLASSES;ANTINEOPLASTIC HORMONES;PROGESTINS;HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS",,"Hormones;Substances;Gonadal Hormones;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones;Progesterone Congeners",,,,,,
5,33,Concomitant Medications,Generic Name,RxNorm,norethi,{28 (Norethindrone 0.35 MG Oral Tablet) } Pack [Nora-BE 28 Day],748977.0,{28 (Norethindrone 0.35 MG Oral Tablet) } Pack [Nora-BE 28 Day],,7514.0,7514,True,Progesterone receptor agonist-containing product;Medicinal product categorized by disposition;Hormone-containing product,Steroid-containing product;Medicinal product categorized by structure,"Contraceptives, Oral, Combined;Therapeutic Uses;Contraceptives, Oral, Synthetic;Contraceptive Agents;Contraceptives, Oral;Contraceptive Agents, Female;Contraceptives, Oral, Sequential;MeSH Pharmacologic Actions (MESHPA);Reproductive Control Agents;Contraceptive Agents, Hormonal;Physiological Effects of Drugs;Contraceptives, Oral, Hormonal","Lung Diseases;Respiratory Tract Diseases;Reproduction;Cardiovascular Diseases;Vascular Diseases;Neoplasms;Venous Thrombosis;Thrombophlebitis;Pregnancy;Digestive System Diseases;Pathologic Processes;Breast Neoplasms;Skin and Connective Tissue Diseases;Pulmonary Embolism;Vasculitis;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Chemically-Induced Disorders;Thromboembolism;Embolism;Embolism and Thrombosis;Female Urogenital Diseases and Pregnancy Complications;Disease;Breast Diseases;Neoplasms by Site;Drug Hypersensitivity;Genital Diseases, Female;Peripheral Vascular Diseases;Hemorrhage;Life Phases, Behavior Mechanisms and Physiologic States;Genital Diseases;Drug-Related Side Effects and Adverse Reactions;Uterine Hemorrhage;Female Urogenital Diseases;Phlebitis;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Reproductive Physiological Phenomena;Skin Diseases;Thrombosis","Endocrine System Diseases;Endometriosis;Acneiform Eruptions;Menorrhagia;Gonadal Disorders;Sebaceous Gland Diseases;Hypogonadism;Skin and Connective Tissue Diseases;Acne Vulgaris;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Genital Diseases;Endometrial Hyperplasia;Uterine Hemorrhage;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Skin Diseases",Norethindrone;Polycyclic Compounds;Substances;Norpregnanes;Steroids;Norethindrone Acetate;Substances and Cells (CHEM);Norsteroids;Fused-Ring Compounds;Norpregnenes,,Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Inhibit Ovulation;Ovarian Function Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Pituitary Gland Activity Alteration;Decreased Luteinizing Hormone Secretion;Ovulation Alteration;Reproductive System Activity Alteration;Female Reproductive System Activity Alteration;Physiologic Effect (PE);Decreased Embryonic Implantation;Hypothalamic Endocrine Activity Alteration;Gonadotropin Releasing Hormone Alteration,Mechanism of Action (MoA);Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Sex Hormone Receptor Agonists;Receptor Interactions;Hormone Receptor Agonists;Progestational Hormone Receptor Agonists,Progestin;Hormone;Established Pharmacologic Class (EPC);Chemical Structure,"HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Progestogens and estrogens, fixed combinations;PROGESTOGENS;SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens and estrogens, sequential preparations;Progestogens;Estren derivatives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES",Medicinal product categorized by therapeutic role;Contraceptive agent,"Pregnancy;Musculoskeletal Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Disease;Reproduction;Nutritional and Metabolic Diseases;Bone Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Bone Diseases, Metabolic;Metabolic Diseases;Reproductive Physiological Phenomena;Osteoporosis",,"CONTRACEPTIVES,SYSTEMIC;ANTINEOPLASTICS;VA CLASSES;ANTINEOPLASTIC HORMONES;PROGESTINS;HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS","CONTRACEPTIVES,SYSTEMIC;ANTINEOPLASTICS;VA CLASSES;ANTINEOPLASTIC HORMONES;PROGESTINS;HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS",,"Hormones;Substances;Gonadal Hormones;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones;Progesterone Congeners",,,,,,
6,3,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,"Endocrine System Diseases;Male Urogenital Diseases;Acid-Base Imbalance;Renal Insufficiency;Diabetes Complications;Nutritional and Metabolic Diseases;Diabetic Ketoacidosis;Urologic Diseases;Digestive System Diseases;Acidosis;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Chemically-Induced Disorders;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Drug Hypersensitivity;Ketosis;Drug-Related Side Effects and Adverse Reactions;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases",Substances;Guanidines;Organic Chemicals;Metformin;Substances and Cells (CHEM);Biguanides;Amidines,,Glucose Metabolism Alteration;Polysaccharide Metabolism Alteration;Decreased Glycogenesis;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Decreased Gluconeogenesis;Glycogen Metabolism Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Generalized Systemic Effects,Mechanism of Action (MoA);Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Receptor Interactions;Insulin Receptor Agonists,Blood Glucose Regulator;Biguanide;Established Pharmacologic Class (EPC);Chemical Structure,"ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Biguanides;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Substances;Guanidines;Organic Chemicals;Substances and Cells (CHEM);Biguanides;Amidines,,,,Elimination;Renal Excretion;Pharmacokinetics (PK);Route of Excretion,,
7,5,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,"Endocrine System Diseases;Male Urogenital Diseases;Acid-Base Imbalance;Renal Insufficiency;Diabetes Complications;Nutritional and Metabolic Diseases;Diabetic Ketoacidosis;Urologic Diseases;Digestive System Diseases;Acidosis;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Chemically-Induced Disorders;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Drug Hypersensitivity;Ketosis;Drug-Related Side Effects and Adverse Reactions;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases",Substances;Guanidines;Organic Chemicals;Metformin;Substances and Cells (CHEM);Biguanides;Amidines,,Glucose Metabolism Alteration;Polysaccharide Metabolism Alteration;Decreased Glycogenesis;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Decreased Gluconeogenesis;Glycogen Metabolism Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Generalized Systemic Effects,Mechanism of Action (MoA);Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Receptor Interactions;Insulin Receptor Agonists,Blood Glucose Regulator;Biguanide;Established Pharmacologic Class (EPC);Chemical Structure,"ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Biguanides;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Substances;Guanidines;Organic Chemicals;Substances and Cells (CHEM);Biguanides;Amidines,,,,Elimination;Renal Excretion;Pharmacokinetics (PK);Route of Excretion,,
8,8,Concomitant Medications,Generic Name,RxNorm,metformin,,,,6809.0,6809.0,6809,False,,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,"Endocrine System Diseases;Male Urogenital Diseases;Acid-Base Imbalance;Renal Insufficiency;Diabetes Complications;Nutritional and Metabolic Diseases;Diabetic Ketoacidosis;Urologic Diseases;Digestive System Diseases;Acidosis;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Chemically-Induced Disorders;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Drug Hypersensitivity;Ketosis;Drug-Related Side Effects and Adverse Reactions;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases",Substances;Guanidines;Organic Chemicals;Metformin;Substances and Cells (CHEM);Biguanides;Amidines,,Glucose Metabolism Alteration;Polysaccharide Metabolism Alteration;Decreased Glycogenesis;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Decreased Gluconeogenesis;Glycogen Metabolism Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Generalized Systemic Effects,Mechanism of Action (MoA);Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Receptor Interactions;Insulin Receptor Agonists,Blood Glucose Regulator;Biguanide;Established Pharmacologic Class (EPC);Chemical Structure,"ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Biguanides;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Substances;Guanidines;Organic Chemicals;Substances and Cells (CHEM);Biguanides;Amidines,,,,Elimination;Renal Excretion;Pharmacokinetics (PK);Route of Excretion,,
9,24,Concomitant Medications,Generic Name,RxNorm,metformin,,,,6809.0,6809.0,6809,False,,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,"Endocrine System Diseases;Male Urogenital Diseases;Acid-Base Imbalance;Renal Insufficiency;Diabetes Complications;Nutritional and Metabolic Diseases;Diabetic Ketoacidosis;Urologic Diseases;Digestive System Diseases;Acidosis;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Chemically-Induced Disorders;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Drug Hypersensitivity;Ketosis;Drug-Related Side Effects and Adverse Reactions;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases",Substances;Guanidines;Organic Chemicals;Metformin;Substances and Cells (CHEM);Biguanides;Amidines,,Glucose Metabolism Alteration;Polysaccharide Metabolism Alteration;Decreased Glycogenesis;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Decreased Gluconeogenesis;Glycogen Metabolism Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Generalized Systemic Effects,Mechanism of Action (MoA);Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Receptor Interactions;Insulin Receptor Agonists,Blood Glucose Regulator;Biguanide;Established Pharmacologic Class (EPC);Chemical Structure,"ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Biguanides;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Substances;Guanidines;Organic Chemicals;Substances and Cells (CHEM);Biguanides;Amidines,,,,Elimination;Renal Excretion;Pharmacokinetics (PK);Route of Excretion,,
10,28,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,"Endocrine System Diseases;Male Urogenital Diseases;Acid-Base Imbalance;Renal Insufficiency;Diabetes Complications;Nutritional and Metabolic Diseases;Diabetic Ketoacidosis;Urologic Diseases;Digestive System Diseases;Acidosis;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Chemically-Induced Disorders;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Drug Hypersensitivity;Ketosis;Drug-Related Side Effects and Adverse Reactions;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases",Substances;Guanidines;Organic Chemicals;Metformin;Substances and Cells (CHEM);Biguanides;Amidines,,Glucose Metabolism Alteration;Polysaccharide Metabolism Alteration;Decreased Glycogenesis;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Decreased Gluconeogenesis;Glycogen Metabolism Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Generalized Systemic Effects,Mechanism of Action (MoA);Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Receptor Interactions;Insulin Receptor Agonists,Blood Glucose Regulator;Biguanide;Established Pharmacologic Class (EPC);Chemical Structure,"ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Biguanides;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Substances;Guanidines;Organic Chemicals;Substances and Cells (CHEM);Biguanides;Amidines,,,,Elimination;Renal Excretion;Pharmacokinetics (PK);Route of Excretion,,
11,3,Concomitant Medications,Generic Name,RxNorm,Epesin,,,,,,,True,,,,,,,,,,,,,,,,,,,,,,,,
12,4,Concomitant Medications,Generic Name,RxNorm,tylenol,,,,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
13,10,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
14,17,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
15,18,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
16,20,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
17,21,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
18,22,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
19,26,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol Pill,1187315.0,Tylenol Pill,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
20,28,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
21,41,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol Pill,1187315.0,Tylenol Pill,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
22,43,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
23,45,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antipyretics;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Sensory System Agents","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Anilides;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
24,5,Concomitant Medications,Generic Name,RxNorm,Lisinopril,Lisinopril,29046.0,Lisinopril,29046.0,29046.0,29046,False,Hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,Peptide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Antihypertensive Agents;Cardiotonic Agents;Cardiovascular Agents;Angiotensin-Converting Enzyme Inhibitors;Protease Inhibitors,"Endocrine System Diseases;Angioedema;Skin Diseases, Vascular;Reproduction;Cardiovascular Diseases;Vascular Diseases;Urticaria;Hypotension;Pregnancy;Skin and Connective Tissue Diseases;Chemically-Induced Disorders;Hypersensitivity;Disease;Adrenocortical Hyperfunction;Drug Hypersensitivity;Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Hyperaldosteronism;Immune System Diseases;Adrenal Gland Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Reproductive Physiological Phenomena;Skin Diseases","Endocrine System Diseases;Male Urogenital Diseases;Ischemia;Diabetes Complications;Infarction;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Vascular Diseases;Myocardial Ischemia;Diabetic Nephropathies;Urologic Diseases;Pathologic Processes;Hypertension;Ventricular Dysfunction, Left;Pathological Conditions, Signs and Symptoms;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Myocardial Infarction;Heart Diseases;Heart Failure;Necrosis;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction","Oligopeptides;Substances;Lisinopril;Substances and Cells (CHEM);Dipeptides;Peptides;Amino Acids, Peptides, and Proteins",,Immunologically Active Molecule Degradation Alteration;Hematologic Activity Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Increased Renal Na+ Excretion;Physiologic Effect (PE);Blood & Lymphatic Fluid Function Alteration;Renal Ion Transport Alteration;Decreased Renal Ion Excretion;Decreased Renal K+ Excretion;Decreased Immunologically Active Molecule Degradation;Decreased Blood Pressure;Immunologic Activity Alteration;Renal Arterial Vasodilation;Renal/Urological Activity Alteration;Generalized Systemic Effects;Arterial Vasodilation;Vasodilation;Cardiovascular Activity Alteration;Decreased Bradykinin Degradation;Vascular Tone Alteration;Decreased Intravascular Volume;Hemic/Lymphatic Activity Alteration;Adrenal Cortical Activity Alteration;Decreased Kinin Degradation;Blood Pressure Alteration;Intravascular Volume Alteration;Decreased Mineralocorticoid Secretion;Decreased Immunologic Activity;Vascular Alterations;Increased Renal Ion Excretion,Angiotensin-converting Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Inhibitors;Protease Inhibitors;Enzyme Interactions,Angiotensin Converting Enzyme Inhibitor;Cardiovascular Agent;Enzyme Inhibitor;Enzyme Interaction;Protease Inhibitor;Anti-infective;Antimicrobial;Established Pharmacologic Class (EPC),"ACE INHIBITORS, PLAIN;ACE inhibitors, plain;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM",,"Endocrine System Diseases;Male Urogenital Diseases;Diabetes Complications;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Diabetic Nephropathies;Urologic Diseases;Pathological Conditions, Anatomical;Ventricular Dysfunction, Left;Pathological Conditions, Signs and Symptoms;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Hypertrophy, Left Ventricular;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Hypertrophy;Heart Diseases;Cardiomegaly;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction",,ANTIHYPERTENSIVE COMBINATIONS;ACE INHIBITORS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,ANTIHYPERTENSIVE COMBINATIONS;ACE INHIBITORS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,,,,,,,
25,8,Concomitant Medications,Generic Name,RxNorm,lisinopril,,,,29046.0,29046.0,29046,False,Hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,Peptide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Antihypertensive Agents;Cardiotonic Agents;Cardiovascular Agents;Angiotensin-Converting Enzyme Inhibitors;Protease Inhibitors,"Endocrine System Diseases;Angioedema;Skin Diseases, Vascular;Reproduction;Cardiovascular Diseases;Vascular Diseases;Urticaria;Hypotension;Pregnancy;Skin and Connective Tissue Diseases;Chemically-Induced Disorders;Hypersensitivity;Disease;Adrenocortical Hyperfunction;Drug Hypersensitivity;Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Hyperaldosteronism;Immune System Diseases;Adrenal Gland Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Reproductive Physiological Phenomena;Skin Diseases","Endocrine System Diseases;Male Urogenital Diseases;Ischemia;Diabetes Complications;Infarction;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Vascular Diseases;Myocardial Ischemia;Diabetic Nephropathies;Urologic Diseases;Pathologic Processes;Hypertension;Ventricular Dysfunction, Left;Pathological Conditions, Signs and Symptoms;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Myocardial Infarction;Heart Diseases;Heart Failure;Necrosis;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction","Oligopeptides;Substances;Lisinopril;Substances and Cells (CHEM);Dipeptides;Peptides;Amino Acids, Peptides, and Proteins",,Immunologically Active Molecule Degradation Alteration;Hematologic Activity Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Increased Renal Na+ Excretion;Physiologic Effect (PE);Blood & Lymphatic Fluid Function Alteration;Renal Ion Transport Alteration;Decreased Renal Ion Excretion;Decreased Renal K+ Excretion;Decreased Immunologically Active Molecule Degradation;Decreased Blood Pressure;Immunologic Activity Alteration;Renal Arterial Vasodilation;Renal/Urological Activity Alteration;Generalized Systemic Effects;Arterial Vasodilation;Vasodilation;Cardiovascular Activity Alteration;Decreased Bradykinin Degradation;Vascular Tone Alteration;Decreased Intravascular Volume;Hemic/Lymphatic Activity Alteration;Adrenal Cortical Activity Alteration;Decreased Kinin Degradation;Blood Pressure Alteration;Intravascular Volume Alteration;Decreased Mineralocorticoid Secretion;Decreased Immunologic Activity;Vascular Alterations;Increased Renal Ion Excretion,Angiotensin-converting Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Inhibitors;Protease Inhibitors;Enzyme Interactions,Angiotensin Converting Enzyme Inhibitor;Cardiovascular Agent;Enzyme Inhibitor;Enzyme Interaction;Protease Inhibitor;Anti-infective;Antimicrobial;Established Pharmacologic Class (EPC),"ACE INHIBITORS, PLAIN;ACE inhibitors, plain;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM",,"Endocrine System Diseases;Male Urogenital Diseases;Diabetes Complications;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Diabetic Nephropathies;Urologic Diseases;Pathological Conditions, Anatomical;Ventricular Dysfunction, Left;Pathological Conditions, Signs and Symptoms;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Hypertrophy, Left Ventricular;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Hypertrophy;Heart Diseases;Cardiomegaly;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction",,ANTIHYPERTENSIVE COMBINATIONS;ACE INHIBITORS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,ANTIHYPERTENSIVE COMBINATIONS;ACE INHIBITORS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,,,,,,,
26,9,Concomitant Medications,Generic Name,RxNorm,Lisinopril,Lisinopril,29046.0,Lisinopril,29046.0,29046.0,29046,False,Hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,Peptide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Antihypertensive Agents;Cardiotonic Agents;Cardiovascular Agents;Angiotensin-Converting Enzyme Inhibitors;Protease Inhibitors,"Endocrine System Diseases;Angioedema;Skin Diseases, Vascular;Reproduction;Cardiovascular Diseases;Vascular Diseases;Urticaria;Hypotension;Pregnancy;Skin and Connective Tissue Diseases;Chemically-Induced Disorders;Hypersensitivity;Disease;Adrenocortical Hyperfunction;Drug Hypersensitivity;Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Hyperaldosteronism;Immune System Diseases;Adrenal Gland Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Reproductive Physiological Phenomena;Skin Diseases","Endocrine System Diseases;Male Urogenital Diseases;Ischemia;Diabetes Complications;Infarction;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Vascular Diseases;Myocardial Ischemia;Diabetic Nephropathies;Urologic Diseases;Pathologic Processes;Hypertension;Ventricular Dysfunction, Left;Pathological Conditions, Signs and Symptoms;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Myocardial Infarction;Heart Diseases;Heart Failure;Necrosis;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction","Oligopeptides;Substances;Lisinopril;Substances and Cells (CHEM);Dipeptides;Peptides;Amino Acids, Peptides, and Proteins",,Immunologically Active Molecule Degradation Alteration;Hematologic Activity Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Increased Renal Na+ Excretion;Physiologic Effect (PE);Blood & Lymphatic Fluid Function Alteration;Renal Ion Transport Alteration;Decreased Renal Ion Excretion;Decreased Renal K+ Excretion;Decreased Immunologically Active Molecule Degradation;Decreased Blood Pressure;Immunologic Activity Alteration;Renal Arterial Vasodilation;Renal/Urological Activity Alteration;Generalized Systemic Effects;Arterial Vasodilation;Vasodilation;Cardiovascular Activity Alteration;Decreased Bradykinin Degradation;Vascular Tone Alteration;Decreased Intravascular Volume;Hemic/Lymphatic Activity Alteration;Adrenal Cortical Activity Alteration;Decreased Kinin Degradation;Blood Pressure Alteration;Intravascular Volume Alteration;Decreased Mineralocorticoid Secretion;Decreased Immunologic Activity;Vascular Alterations;Increased Renal Ion Excretion,Angiotensin-converting Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Inhibitors;Protease Inhibitors;Enzyme Interactions,Angiotensin Converting Enzyme Inhibitor;Cardiovascular Agent;Enzyme Inhibitor;Enzyme Interaction;Protease Inhibitor;Anti-infective;Antimicrobial;Established Pharmacologic Class (EPC),"ACE INHIBITORS, PLAIN;ACE inhibitors, plain;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM",,"Endocrine System Diseases;Male Urogenital Diseases;Diabetes Complications;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Diabetic Nephropathies;Urologic Diseases;Pathological Conditions, Anatomical;Ventricular Dysfunction, Left;Pathological Conditions, Signs and Symptoms;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Hypertrophy, Left Ventricular;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Hypertrophy;Heart Diseases;Cardiomegaly;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction",,ANTIHYPERTENSIVE COMBINATIONS;ACE INHIBITORS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,ANTIHYPERTENSIVE COMBINATIONS;ACE INHIBITORS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,,,,,,,
27,5,Concomitant Medications,Generic Name,RxNorm,Atorvastatin,atorvastatin,83367.0,atorvastatin,83367.0,83367.0,83367,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;HMG-CoA reductase inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Azole-containing product,Therapeutic Uses;Membrane Transport Modulators;Enzyme Inhibitors;Hypolipidemic Agents;MeSH Pharmacologic Actions (MESHPA);Lipid Regulating Agents;Antihypertensive Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Physiological Effects of Drugs;Antimetabolites;Calcium-Regulating Hormones and Agents;Calcium Channel Blockers;Cardiovascular Agents;Molecular Mechanisms of Pharmacological Action;Anticholesteremic Agents,"Chemically-Induced Disorders;Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Digestive System Diseases;Disease;Liver Failure;Drug-Related Side Effects and Adverse Reactions;Reproduction;Reproductive Physiological Phenomena;Lactation;Postpartum Period;Hepatic Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Drug Hypersensitivity","Lipid Metabolism Disorders;Myocardial Ischemia;Hypercholesterolemia;Hypertriglyceridemia;Disease;Hyperlipidemias;Hyperlipoproteinemias;Nutritional and Metabolic Diseases;Arteriosclerosis;Arterial Occlusive Diseases;Cardiovascular Diseases;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Coronary Disease;Dyslipidemias;Metabolic Diseases;Coronary Artery Disease;Heart Diseases","Heterocyclic Compounds;Substances;Heptanoic Acids;Azoles;Substances and Cells (CHEM);Fatty Acids;Heterocyclic Compounds, 1-Ring;Lipids;Pyrroles;Atorvastatin",,Cholesterol Synthesis Alteration;Cholesterol Metabolism Alteration;Lipid Metabolism Alteration;Sterol Metabolism Alteration;Metabolic Activity Alteration;Decreased Cholesterol Synthesis;Physiologic Effect (PE);Generalized Systemic Effects,Mechanism of Action (MoA);Enzyme Inhibitors;Sterol Synthesis Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Cholesterol Synthesis Inhibitors;Enzyme Interactions,Cardiovascular Agent;Enzyme Inhibitor;Enzyme Interaction;HMG-CoA Reductase Inhibitor;Established Pharmacologic Class (EPC),"Combinations of various lipid modifying agents;LIPID MODIFYING AGENTS;HMG CoA reductase inhibitors;LIPID MODIFYING AGENTS, COMBINATIONS;LIPID MODIFYING AGENTS, PLAIN;Lipid modifying agents in combination with other drugs;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",,"Myocardial Ischemia;Disease;Arteriosclerosis;Arterial Occlusive Diseases;Cardiovascular Diseases;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Coronary Disease;Coronary Artery Disease;Heart Diseases",,ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;VA CLASSES,ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;VA CLASSES,,,,,,Hepatic Metabolism;Site of Metabolism;Elimination;Pharmacokinetics (PK);Metabolism,,
28,8,Concomitant Medications,Generic Name,RxNorm,atorvastatin,,,,83367.0,83367.0,83367,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;HMG-CoA reductase inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Azole-containing product,Therapeutic Uses;Membrane Transport Modulators;Enzyme Inhibitors;Hypolipidemic Agents;MeSH Pharmacologic Actions (MESHPA);Lipid Regulating Agents;Antihypertensive Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Physiological Effects of Drugs;Antimetabolites;Calcium-Regulating Hormones and Agents;Calcium Channel Blockers;Cardiovascular Agents;Molecular Mechanisms of Pharmacological Action;Anticholesteremic Agents,"Chemically-Induced Disorders;Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Digestive System Diseases;Disease;Liver Failure;Drug-Related Side Effects and Adverse Reactions;Reproduction;Reproductive Physiological Phenomena;Lactation;Postpartum Period;Hepatic Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Drug Hypersensitivity","Lipid Metabolism Disorders;Myocardial Ischemia;Hypercholesterolemia;Hypertriglyceridemia;Disease;Hyperlipidemias;Hyperlipoproteinemias;Nutritional and Metabolic Diseases;Arteriosclerosis;Arterial Occlusive Diseases;Cardiovascular Diseases;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Coronary Disease;Dyslipidemias;Metabolic Diseases;Coronary Artery Disease;Heart Diseases","Heterocyclic Compounds;Substances;Heptanoic Acids;Azoles;Substances and Cells (CHEM);Fatty Acids;Heterocyclic Compounds, 1-Ring;Lipids;Pyrroles;Atorvastatin",,Cholesterol Synthesis Alteration;Cholesterol Metabolism Alteration;Lipid Metabolism Alteration;Sterol Metabolism Alteration;Metabolic Activity Alteration;Decreased Cholesterol Synthesis;Physiologic Effect (PE);Generalized Systemic Effects,Mechanism of Action (MoA);Enzyme Inhibitors;Sterol Synthesis Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Cholesterol Synthesis Inhibitors;Enzyme Interactions,Cardiovascular Agent;Enzyme Inhibitor;Enzyme Interaction;HMG-CoA Reductase Inhibitor;Established Pharmacologic Class (EPC),"Combinations of various lipid modifying agents;LIPID MODIFYING AGENTS;HMG CoA reductase inhibitors;LIPID MODIFYING AGENTS, COMBINATIONS;LIPID MODIFYING AGENTS, PLAIN;Lipid modifying agents in combination with other drugs;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",,"Myocardial Ischemia;Disease;Arteriosclerosis;Arterial Occlusive Diseases;Cardiovascular Diseases;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Coronary Disease;Coronary Artery Disease;Heart Diseases",,ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;VA CLASSES,ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;VA CLASSES,,,,,,Hepatic Metabolism;Site of Metabolism;Elimination;Pharmacokinetics (PK);Metabolism,,
29,24,Concomitant Medications,Generic Name,RxNorm,atorvastatin,atorvastatin,83367.0,atorvastatin,83367.0,83367.0,83367,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;HMG-CoA reductase inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Azole-containing product,Therapeutic Uses;Membrane Transport Modulators;Enzyme Inhibitors;Hypolipidemic Agents;MeSH Pharmacologic Actions (MESHPA);Lipid Regulating Agents;Antihypertensive Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Physiological Effects of Drugs;Antimetabolites;Calcium-Regulating Hormones and Agents;Calcium Channel Blockers;Cardiovascular Agents;Molecular Mechanisms of Pharmacological Action;Anticholesteremic Agents,"Chemically-Induced Disorders;Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Digestive System Diseases;Disease;Liver Failure;Drug-Related Side Effects and Adverse Reactions;Reproduction;Reproductive Physiological Phenomena;Lactation;Postpartum Period;Hepatic Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Drug Hypersensitivity","Lipid Metabolism Disorders;Myocardial Ischemia;Hypercholesterolemia;Hypertriglyceridemia;Disease;Hyperlipidemias;Hyperlipoproteinemias;Nutritional and Metabolic Diseases;Arteriosclerosis;Arterial Occlusive Diseases;Cardiovascular Diseases;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Coronary Disease;Dyslipidemias;Metabolic Diseases;Coronary Artery Disease;Heart Diseases","Heterocyclic Compounds;Substances;Heptanoic Acids;Azoles;Substances and Cells (CHEM);Fatty Acids;Heterocyclic Compounds, 1-Ring;Lipids;Pyrroles;Atorvastatin",,Cholesterol Synthesis Alteration;Cholesterol Metabolism Alteration;Lipid Metabolism Alteration;Sterol Metabolism Alteration;Metabolic Activity Alteration;Decreased Cholesterol Synthesis;Physiologic Effect (PE);Generalized Systemic Effects,Mechanism of Action (MoA);Enzyme Inhibitors;Sterol Synthesis Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Cholesterol Synthesis Inhibitors;Enzyme Interactions,Cardiovascular Agent;Enzyme Inhibitor;Enzyme Interaction;HMG-CoA Reductase Inhibitor;Established Pharmacologic Class (EPC),"Combinations of various lipid modifying agents;LIPID MODIFYING AGENTS;HMG CoA reductase inhibitors;LIPID MODIFYING AGENTS, COMBINATIONS;LIPID MODIFYING AGENTS, PLAIN;Lipid modifying agents in combination with other drugs;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",,"Myocardial Ischemia;Disease;Arteriosclerosis;Arterial Occlusive Diseases;Cardiovascular Diseases;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Coronary Disease;Coronary Artery Disease;Heart Diseases",,ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;VA CLASSES,ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;CALCIUM CHANNEL BLOCKERS;VA CLASSES,,,,,,Hepatic Metabolism;Site of Metabolism;Elimination;Pharmacokinetics (PK);Metabolism,,
30,5,Concomitant Medications,Generic Name,RxNorm,benzonatate,benzonatate 100 MG,315473.0,benzonatate 100 MG,18993.0,18993.0,18993,False,,Nitrogen and/or nitrogen compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Therapeutic Uses;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Respiratory System Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Respiratory;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders","Substances;Alkanes;Butanes;Amines;Organic Chemicals;Hydrocarbons, Acyclic;Substances and Cells (CHEM);Hydrocarbons;Butylamines",,Tracheobronchial Stretch Receptor Alteration;Organ System Specific Effects;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Sodium-Potassium Exchanging ATPase Interactions;Mechanism of Action (MoA);Antiporter Interactions;Receptor Interactions;Membrane Transporter Interactions;Ion Transporter Interactions,Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),"RESPIRATORY SYSTEM;Other cough suppressants;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",Respiratory System Agent;Antitussive Agent;Therapeutic Categories,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,,,,,,,,
31,21,Concomitant Medications,Generic Name,RxNorm,Benzonatate,benzonatate,18993.0,benzonatate,18993.0,18993.0,18993,False,,Nitrogen and/or nitrogen compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Therapeutic Uses;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Respiratory System Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Respiratory;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders","Substances;Alkanes;Butanes;Amines;Organic Chemicals;Hydrocarbons, Acyclic;Substances and Cells (CHEM);Hydrocarbons;Butylamines",,Tracheobronchial Stretch Receptor Alteration;Organ System Specific Effects;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Sodium-Potassium Exchanging ATPase Interactions;Mechanism of Action (MoA);Antiporter Interactions;Receptor Interactions;Membrane Transporter Interactions;Ion Transporter Interactions,Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),"RESPIRATORY SYSTEM;Other cough suppressants;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",Respiratory System Agent;Antitussive Agent;Therapeutic Categories,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,,,,,,,,
32,41,Concomitant Medications,Generic Name,RxNorm,benzonatate,benzonatate 100 MG,315473.0,benzonatate 100 MG,18993.0,18993.0,18993,False,,Nitrogen and/or nitrogen compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Therapeutic Uses;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Respiratory System Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Respiratory;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders","Substances;Alkanes;Butanes;Amines;Organic Chemicals;Hydrocarbons, Acyclic;Substances and Cells (CHEM);Hydrocarbons;Butylamines",,Tracheobronchial Stretch Receptor Alteration;Organ System Specific Effects;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Sodium-Potassium Exchanging ATPase Interactions;Mechanism of Action (MoA);Antiporter Interactions;Receptor Interactions;Membrane Transporter Interactions;Ion Transporter Interactions,Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),"RESPIRATORY SYSTEM;Other cough suppressants;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",Respiratory System Agent;Antitussive Agent;Therapeutic Categories,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,,,,,,,,
33,5,Concomitant Medications,Generic Name,RxNorm,beclomethasone dipropionate,Beclomethasone Dipropionate,1348.0,Beclomethasone Dipropionate,1348.0,1348.0,1348,False,,Medicinal product categorized by structure;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Steroid-containing product;Pregnane-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Hormones;MeSH Pharmacologic Actions (MESHPA);Glucocorticoids;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Respiratory System Agents;Anti-Asthmatic Agents","Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Lung Diseases;Status Asthmaticus;Lung Diseases, Obstructive;Hypersensitivity;Respiratory Tract Diseases;Disease;Drug-Related Side Effects and Adverse Reactions;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Drug Hypersensitivity","Respiratory Tract Infections;Respiratory Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Hypersensitivity;Disease;Respiratory Tract Diseases;Rhinitis, Allergic;Rhinitis, Allergic, Perennial;Inflammation;Immune System Diseases;Pathological Conditions, Signs and Symptoms;Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pathologic Processes;Rhinitis","Pregnadienetriols;Pregnadienes;Polycyclic Compounds;Substances;Beclomethasone;Steroids;Substances and Cells (CHEM);Fused-Ring Compounds;Steroids, Chlorinated;Pregnanes",,Organ System Specific Effects;Endocrine Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Cellular Activity Alteration;Decreased Glucocorticoid Secretion;Generalized Systemic Effects;Vasoconstriction;Cellular Degradation/Digestion Alteration;Cardiovascular Activity Alteration;Decreased Cellular Migration;Cellular Motion Alteration;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Translation Alteration;Lysosomal Function Alteration;Vascular Tone Alteration;Decreased Lysosomal Function;Striated Muscle Anabolism Alteration;Adrenal Cortical Activity Alteration;Musculoskeletal Activity Alteration;Vascular Alterations;Decreased Protein Synthesis,Mechanism of Action (MoA);Glucocorticoid Receptor Agonists;Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Corticosteroid Hormone Receptor Agonists,Hormone;Receptor Interaction;Corticosteroid;Chemical Structure;Receptor Agonist;Established Pharmacologic Class (EPC),"NASAL PREPARATIONS;Corticosteroids acting locally;RESPIRATORY SYSTEM;CORTICOSTEROIDS, PLAIN;ALIMENTARY TRACT AND METABOLISM;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Glucocorticoids;DERMATOLOGICALS;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Corticosteroids, potent (group III);Corticosteroids;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;INTESTINAL ANTIINFLAMMATORY AGENTS",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Polyps;Pathological Conditions, Anatomical;Lung Diseases, Obstructive;Nose Diseases;Hypersensitivity;Respiratory Tract Diseases;Disease;Otorhinolaryngologic Diseases;Bronchial Diseases;Immune System Diseases;Nasal Polyps;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",,"VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,NASAL;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION;NASAL AND THROAT AGENTS,TOPICAL","VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,NASAL;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION;NASAL AND THROAT AGENTS,TOPICAL",,,,,,Renal Excretion;Fecal Excretion;Route of Excretion;Elimination;Pharmacokinetics (PK),,
34,6,Concomitant Medications,Generic Name,RxNorm,Augmentin,Amoxicillin 1000 MG / Clavulanate 62.5 MG [Augmentin],618037.0,Amoxicillin 1000 MG / Clavulanate 62.5 MG [Augmentin],151392.0,151392.0,151392,False,Broad spectrum penicillin antibacterial agent;Aminopenicillin antibacterial agent;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Penicillin-containing product;Beta-lactam-containing product;Medicinal product categorized by structure;Aminopenicillin antibacterial agent;Broad spectrum penicillin antibacterial agent;Beta-lactam antibacterial agent;Penicillin antibacterial agent,Therapeutic Uses;Enzyme Inhibitors;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Infective Agents;Molecular Mechanisms of Pharmacological Action;beta-Lactamase Inhibitors,"Chemically-Induced Disorders;Biliary Tract Diseases;Cholestasis, Extrahepatic;Digestive System Diseases;Disease;Bile Duct Diseases;Drug-Related Side Effects and Adverse Reactions;Cholestasis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Drug Hypersensitivity","Male Urogenital Diseases;Lyme Disease;Vector Borne Diseases;Ear Diseases;Duodenal Ulcer;Sinusitis;Respiratory Tract Diseases;Actinomycosis;Listeriosis;Borrelia Infections;Helicobacter Infections;Poisoning;Spirochaetales Infections;Gastrointestinal Diseases;Sexually Transmitted Diseases;Urologic Diseases;Digestive System Diseases;Otorhinolaryngologic Diseases;Staphylococcal Infections;Wounds and Injuries;Duodenal Diseases;Streptococcal Infections;Tick-Borne Diseases;Peptic Ulcer;Paranasal Sinus Diseases;Skin and Connective Tissue Diseases;Bacterial Infections;Sexually Transmitted Diseases, Bacterial;Pathological Conditions, Signs and Symptoms;Disease Attributes;Haemophilus Infections;Chemically-Induced Disorders;Gram-Negative Bacterial Infections;Intestinal Diseases;Female Urogenital Diseases and Pregnancy Complications;Bacterial Infections and Mycoses;Skin Diseases, Bacterial;Gram-Positive Bacterial Infections;Chlamydia Infections;Bites, Human;Disease;Urinary Tract Infections;Infections;Actinomycetales Infections;Respiratory Tract Infections;Otitis;Nose Diseases;Genital Diseases;Chlamydiaceae Infections;Soft Tissue Infections;Skin Diseases, Infectious;Otitis Media;Pasteurellaceae Infections;Bites and Stings;Female Urogenital Diseases;Urogenital Diseases;Stomach Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Skin Diseases;Communicable Diseases","Heterocyclic Compounds, Fused-Ring;Ampicillin;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Sulfur Compounds;Clavulanic Acids;Substances;Lactams;beta-Lactams;Organic Chemicals;Amides;Penicillin G;Heterocyclic Compounds, 1-Ring;Substances and Cells (CHEM);Clavulanic Acid;Amoxicillin;Inorganic Chemicals;Penicillins",,Decreased Cell Wall Synthesis & Repair;Cell Wall Alteration;Cellular Structure Alteration;Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Enzyme Inhibitors;beta Lactamase Inhibitors;Transpeptidase Inhibitors;Enzyme Interactions,,"ANTIINFECTIVES FOR SYSTEMIC USE;Penicillins with extended spectrum;BETA-LACTAM ANTIBACTERIALS, PENICILLINS;ANTIBACTERIALS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4)",Antibacterial agent;Antiinfective agent;Aminopenicillin antibacterial agent;Medicinal product categorized by therapeutic role;Broad spectrum penicillin antibacterial agent;Beta-lactam antibacterial agent;Penicillin antibacterial agent,"Bacterial Infections and Mycoses;Endocarditis, Bacterial;Disease;Bacterial Infections;Cardiovascular Diseases;Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Infections;Endocarditis;Heart Diseases",Anti-infective Agent;Antibacterial Agent;Therapeutic Categories,"ANTIMICROBIALS;PENICILLINS,AMINO DERIVATIVES;VA CLASSES;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS","ANTIMICROBIALS;PENICILLINS,AMINO DERIVATIVES;VA CLASSES;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS",,,"Hydrogen Sulfide;beta-Lactams;Ions;Heterocyclic Compounds, 1-Ring;Disulfiram;Sulfur Compounds;Inorganic Chemicals;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Acids, Noncarboxylic;Carbamates;Anions;Thiocarbamates;Disulfides;Heterocyclic Compounds;Carboxylic Acids;Electrolytes;Substances and Cells (CHEM);Amides;Acids, Acyclic;Acids;Substances;Lactams;Gases;Organic Chemicals;Sulfides;Ditiocarb;Penicillins",,,Elimination;Renal Excretion;Pharmacokinetics (PK);Route of Excretion,,
35,6,Concomitant Medications,Generic Name,RxNorm,Doxycycline,Doxycycline,3640.0,Doxycycline,3640.0,3640.0,3640,False,,Tetracycline structure-containing product;Medicinal product categorized by structure;Tetracycline antibacterial agent,Therapeutic Uses;Anti-Bacterial Agents;Antiparasitic Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Infective Agents;Antimalarials;Antiprotozoal Agents,"Chemically-Induced Disorders;Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Digestive System Diseases;Drug Hypersensitivity;Disease;Drug-Related Side Effects and Adverse Reactions;Reproduction;Child;Age Groups;Child, Preschool;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Reproductive Physiological Phenomena","Lung Diseases;Vector Borne Diseases;Respiratory Tract Diseases;Eye Infections, Bacterial;Borrelia Infections;Enterobacteriaceae Infections;Plague;Spirochaetales Infections;Sexually Transmitted Diseases;Eye Diseases;Pleural Diseases;Pleural Effusion;Chlamydophila Infections;Treponemal Infections;Rocky Mountain Spotted Fever;Syphilis;Tick-Borne Diseases;Skin and Connective Tissue Diseases;Bacterial Infections;Conjunctival Diseases;Sexually Transmitted Diseases, Bacterial;Pathological Conditions, Signs and Symptoms;Disease Attributes;Vibrio Infections;Yersinia Infections;Anthrax;Psittacosis;Gram-Negative Bacterial Infections;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Granuloma Inguinale;Skin Diseases, Bacterial;Chlamydia Infections;Conjunctivitis;Disease;Rickettsiaceae Infections;Conjunctivitis, Bacterial;Corneal Diseases;Pneumonia, Bacterial;Infections;Relapsing Fever;Eye Infections;Rickettsia Infections;Respiratory Tract Infections;Campylobacter Infections;Bacillaceae Infections;Spotted Fever Group Rickettsiosis;Trachoma;Skin Diseases, Infectious;Genital Diseases;Chlamydiaceae Infections;Mycoplasmatales Infections;Cholera;Pneumonia;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mycoplasma Infections;Pathologic Processes;Skin Diseases;Communicable Diseases","Hydrocarbons, Cyclic;Polycyclic Compounds;Substances;Tetracyclines;Naphthacenes;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Polycyclic Aromatic Hydrocarbons;Doxycycline;Hydrocarbons, Aromatic",,Cell Membrane Alteration;Striated Muscle Anabolism Alteration;Cellular Division Phase Alteration;Mitosis Alteration;Cellular Cycle Alteration;Organ System Specific Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Musculoskeletal Activity Alteration;Translation Alteration;Cellular Structure Alteration;Decreased Mitosis;Physiologic Effect (PE);Cellular Activity Alteration;Decreased Protein Synthesis;Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Enzyme Interactions,Tetracycline-class Drug;Established Pharmacologic Class (EPC);Chemical Structure,TETRACYCLINES;STOMATOLOGICAL PREPARATIONS;ANTIINFECTIVES FOR SYSTEMIC USE;Tetracyclines;ALIMENTARY TRACT AND METABOLISM;ANTIBACTERIALS FOR SYSTEMIC USE;Antiinfectives and antiseptics for local oral treatment;Anatomical Therapeutic Chemical (ATC1-4),Antiparasitic-containing product;Antimalarial agent;Antiinfective agent;Antibacterial agent;Medicinal product categorized by therapeutic role;Tetracycline antibacterial agent;Antiprotozoal agent,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Vector Borne Diseases;Disease;Infections;Protozoan Infections;Malaria;Parasitic Diseases",,ANTIMICROBIALS;TETRACYCLINES;VA CLASSES,ANTIMICROBIALS;TETRACYCLINES;VA CLASSES,,"Hydrocarbons, Cyclic;Polycyclic Compounds;Substances;Tetracyclines;Naphthacenes;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Polycyclic Aromatic Hydrocarbons;Hydrocarbons, Aromatic","Hydrocarbons, Cyclic;Polycyclic Compounds;Substances;Tetracyclines;Naphthacenes;Organic Chemicals;Tetracycline;Substances and Cells (CHEM);Hydrocarbons;Polycyclic Aromatic Hydrocarbons;Hydrocarbons, Aromatic",,,,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sclerosis;Pathological Conditions, Signs and Symptoms;Pathologic Processes"
36,6,Concomitant Medications,Generic Name,RxNorm,Advair,,,,301543.0,301543.0,301543,False,Selective beta-2 agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product,Androstane-containing product;Medicinal product categorized by structure;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Fluorinated corticosteroid-containing product;Steroid-containing product;Phenol structure-containing product,"Therapeutic Uses;Neurotransmitter Agents;Anti-Allergic Agents;Adrenergic Agonists;Anti-Inflammatory Agents;Sympathomimetics;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Autonomic Agents;Bronchodilator Agents;Adrenergic Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Dermatologic Agents;Adrenergic beta-Agonists;Adrenergic beta-2 Receptor Agonists;Hormones;Glucocorticoids;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Anti-Asthmatic Agents","Lung Diseases;Status Asthmaticus;Respiratory Tract Diseases;Milk Hypersensitivity;Acute Disease;Bronchial Diseases;Skin and Connective Tissue Diseases;Disease Attributes;Pathological Conditions, Signs and Symptoms;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Skin Diseases, Infectious;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Food Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pathologic Processes;Skin Diseases","Lung Diseases;Respiratory Tract Diseases;Bronchial Spasm;Otorhinolaryngologic Diseases;Bronchial Diseases;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nose Diseases;Rhinitis, Allergic;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Androstenes;Salmeterol Xinafoate;Ethanol;Steroids;Phenethylamines;Androstadienes;Alcohols;Albuterol;Polycyclic Compounds;Fluticasone;Substances and Cells (CHEM);Ethylamines;Androstanes;Substances;Amines;Organic Chemicals;Fused-Ring Compounds;Ethanolamines;Amino Alcohols,,Decreased Vascular Permeability;Smooth Muscle Tone Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Decreased Fibroblast Migration;Nervous System Activity Alteration;Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Cellular Cycle Alteration;Decreased Glucocorticoid Secretion;Cellular Activity Alteration;Respiratory/Pulmonary Activity Alteration;Generalized Systemic Effects;Cellular Degradation/Digestion Alteration;Bronchial Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Decreased Cellular Migration;Cellular Motion Alteration;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Translation Alteration;Lysosomal Function Alteration;Decreased Lysosomal Function;Bronchodilation;Vascular Permeability Alteration;Striated Muscle Anabolism Alteration;Adrenal Cortical Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Decreased Capillary Permeability;Peripheral Nervous System Activity Alteration;Vascular Alterations;Decreased Protein Synthesis,Mechanism of Action (MoA);Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Glucocorticoid Receptor Agonists;Hormone Receptor Interactions;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Adrenergic beta-Agonists;Corticosteroid Hormone Receptor Agonists,Hormone;Receptor Interaction;Sympathomimetic Agent;Corticosteroid;Adrenergic Receptor Agonist;Chemical Structure;beta2-Adrenergic Agonist;Receptor Agonist;beta-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,"NASAL PREPARATIONS;RESPIRATORY SYSTEM;CORTICOSTEROIDS, PLAIN;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;Glucocorticoids;DERMATOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Corticosteroids, potent (group III);ADRENERGICS, INHALANTS;Corticosteroids;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Selective beta-2-adrenoreceptor agonists;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",,"Lung Diseases;Polyps;Respiratory Tract Diseases;Pathological Conditions, Anatomical;Bronchial Spasm;Otorhinolaryngologic Diseases;Bronchial Diseases;Nasal Polyps;Pathological Conditions, Signs and Symptoms;Exercise-Induced Allergies;Asthma;Respiratory Hypersensitivity;Asthma, Exercise-Induced;Lung Diseases, Obstructive;Hypersensitivity;Disease;Nose Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",,"RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;VA CLASSES;ANTIASTHMA,OTHER","RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;VA CLASSES;ANTIASTHMA,OTHER",,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
37,6,Concomitant Medications,Generic Name,RxNorm,Prednisone,Prednisone 10 MG,317663.0,Prednisone 10 MG,8640.0,8640.0,8640,False,Medicinal product categorized by disposition;Immunomodulator-containing product,Medicinal product categorized by structure;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Steroid-containing product;Pregnane-containing product,"Antineoplastic Agents;Therapeutic Uses;Anti-Inflammatory Agents;Hormones;MeSH Pharmacologic Actions (MESHPA);Glucocorticoids;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Antineoplastic Agents, Hormonal","Virus Diseases;Mycoses;Chemically-Induced Disorders;Bacterial Infections and Mycoses;Drug Hypersensitivity;Disease;Drug-Related Side Effects and Adverse Reactions;Chickenpox;Infections;Herpesviridae Infections;Varicella Zoster Virus Infection;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;DNA Virus Infections","Inflammatory Bowel Diseases;Purpura, Thrombocytopenic;Nutritional and Metabolic Diseases;Panuveitis;Signs and Symptoms;Anemia, Hemolytic, Autoimmune;Demyelinating Autoimmune Diseases, CNS;Digestive System Diseases;Spondylarthropathies;Bronchial Diseases;Inflammation;Neoplasms by Histologic Type;Conjunctival Diseases;Metabolic Diseases;Hypersensitivity, Delayed;Purpura, Thrombocytopenic, Idiopathic;Kidney Diseases;Collagen Diseases;Spondylitis;Gram-Positive Bacterial Infections;Hypersensitivity;Skin Diseases, Vesiculobullous;Gastroenteritis;Berylliosis;Rheumatic Diseases;Pemphigus;Spinal Diseases;Rhinitis;Anemia, Hemolytic;Dermatitis, Contact;Nervous System Diseases;Water-Electrolyte Imbalance;Iris Diseases;Serum Sickness;Psoriasis;Nephrotic Syndrome;Uveitis;Female Urogenital Diseases;Central Nervous System Diseases;Sarcoidosis;Blood Coagulation Disorders;Adrenal Insufficiency;Thyroiditis;Lung Diseases;Arthritis;Calcium Metabolism Disorders;Dermatitis Herpetiformis;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Thoracic Injuries;Tuberculosis, Pulmonary;Colitis;Hemorrhagic Disorders;Urologic Diseases;Erythema;Ankylosis;Bacterial Infections;Female Urogenital Diseases and Pregnancy Complications;Bacterial Infections and Mycoses;Synovitis;Lung Diseases, Obstructive;Conjunctivitis;Blood Platelet Disorders;Respiratory Tract Infections;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Iritis;Skin Diseases;Endocrine System Diseases;Autoimmune Diseases of the Nervous System;Tuberculosis;Spondylarthritis;Skin Diseases, Genetic;Skin Diseases, Papulosquamous;Graft vs Host Disease;Bone Diseases;Arthritis, Psoriatic;Bursitis;Colonic Diseases;Dermatitis;Uveal Diseases;Axial Spondyloarthritis;Gastrointestinal Diseases;Musculoskeletal Diseases;Sebaceous Gland Diseases;Eye Diseases;Dermatitis, Seborrheic;Otorhinolaryngologic Diseases;Leukemia;Pneumoconiosis;Wounds and Injuries;Skin and Connective Tissue Diseases;Colitis, Ulcerative;Mycobacterium Infections;Pathological Conditions, Signs and Symptoms;Brain Diseases;Immunoproliferative Disorders;Asthma;Respiratory Hypersensitivity;Conjunctivitis, Allergic;Uveitis, Anterior;Thrombotic Microangiopathies;Lymphoproliferative Disorders;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Bone Diseases, Infectious;Drug Eruptions;Hemorrhage;Adrenal Gland Diseases;Thrombocytopenia;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Leukoencephalopathies;Genetic Diseases, Inborn;Lymphoma;Male Urogenital Diseases;Erythema Multiforme;Connective Tissue Diseases;Multiple Sclerosis;Respiratory Tract Diseases;Neoplasms;Anemia;Lupus Erythematosus, Systemic;Autoimmune Diseases;Spondylitis, Ankylosing;Lung Injury;Thyroid Diseases;Nephrosis;Skin Manifestations;Occupational Diseases;Purpura;Hypercalcemia;Chemically-Induced Disorders;Intestinal Diseases;Disease;Lung Diseases, Interstitial;Infections;Actinomycetales Infections;Demyelinating Diseases;Lymphatic Diseases;Skin Diseases, Eczematous;Rhinitis, Allergic;Joint Diseases;Dermatitis, Atopic;Immune System Diseases;Urogenital Diseases;Hypersensitivity, Immediate;Hematologic Diseases",Polycyclic Compounds;Pregnadienes;Substances;Steroids;Substances and Cells (CHEM);Prednisone;Fused-Ring Compounds;Pregnadienediols;Pregnanes,,Decreased Vascular Permeability;Immunologically Active Molecule Activity Alteration;Decreased Prostaglandin Activity;Decreased Eicosanoid Activity;Endocrine Activity Alteration;Organ System Specific Effects;Decreased Fibroblast Migration;Decreased Lipid Derived Immunologically Active Molecule Activity;Physiologic Effect (PE);Carbohydrate Metabolism Alteration;Cellular Cycle Alteration;Immunologic Activity Alteration;Decreased Thromboxane Activity;Decreased Glucocorticoid Secretion;Cellular Activity Alteration;Generalized Systemic Effects;Metabolic Activity Alteration;Cellular Degradation/Digestion Alteration;Cardiovascular Activity Alteration;Decreased Cellular Migration;Cellular Motion Alteration;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Translation Alteration;Lysosomal Function Alteration;Decreased Lysosomal Function;Vascular Permeability Alteration;Striated Muscle Anabolism Alteration;Adrenal Cortical Activity Alteration;Decreased Immunologically Active Molecule Activity;Lipid Metabolism Alteration;Decreased Polymorphonuclear Leukocyte Migration;Decreased Capillary Permeability;Musculoskeletal Activity Alteration;Decreased Immunologic Activity;Vascular Alterations;Decreased Leukotriene Activity;Decreased Protein Synthesis,Mechanism of Action (MoA);Lipoxygenase Inhibitors;Enzyme Inhibitors;Glucocorticoid Receptor Agonists;Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Enzyme Interactions;Corticosteroid Hormone Receptor Agonists,Hormone;Receptor Interaction;Corticosteroid;Chemical Structure;Receptor Agonist;Established Pharmacologic Class (EPC),"Corticosteroids acting locally;CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;ALIMENTARY TRACT AND METABOLISM;Glucocorticoids;CORTICOSTEROIDS FOR SYSTEMIC USE;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;Anatomical Therapeutic Chemical (ATC1-4);ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;INTESTINAL ANTIINFLAMMATORY AGENTS",,"Arthritis;Connective Tissue Diseases;Genetic Diseases, Inborn;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Signs and Symptoms;Pain;Peripheral Nervous System Diseases;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Neuralgia;Skin and Connective Tissue Diseases;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Metabolic Diseases;Arthritis, Gouty;Disease;Polymyositis;Rheumatic Diseases;Myositis;Dermatomyositis;Gout;Muscular Diseases;Nervous System Diseases;Joint Diseases;Immune System Diseases;Metabolism, Inborn Errors;Neuromuscular Diseases;Arthritis, Rheumatoid;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases;Purine-Pyrimidine Metabolism, Inborn Errors",,ADRENAL CORTICOSTERIODS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;GLUCOCORTICOIDS,ADRENAL CORTICOSTERIODS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;GLUCOCORTICOIDS,,,,,,,,
38,7,Concomitant Medications,Generic Name,RxNorm,truvada,emtricitabine 133 MG / Tenofovir disoproxil fumarate 200 MG [Truvada],1744006.0,emtricitabine 133 MG / Tenofovir disoproxil fumarate 200 MG [Truvada],495430.0,495430.0,495430,False,Reverse transcriptase inhibitor-containing product;Medicinal product categorized by disposition;Transferase inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Pyrimidine-containing product,Therapeutic Uses;Anti-Retroviral Agents;Enzyme Inhibitors;Reverse Transcriptase Inhibitors;MeSH Pharmacologic Actions (MESHPA);Nucleic Acid Synthesis Inhibitors;Anti-HIV Agents;Anti-Infective Agents;Antiviral Agents;Molecular Mechanisms of Pharmacological Action,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Hepatitis, Viral, Human;Hepadnaviridae Infections;Hepatitis B;Lentivirus Infections;Acquired Immunodeficiency Syndrome;Hepatitis;Chronic Disease;Virus Diseases;Sexually Transmitted Diseases;Digestive System Diseases;Slow Virus Diseases;Sexually Transmitted Diseases, Viral;Disease Attributes;Pathological Conditions, Signs and Symptoms;DNA Virus Infections;HIV Infections;Disease;RNA Virus Infections;Infections;Hepatitis B, Chronic;Hepatitis, Chronic;Retroviridae Infections;Blood-Borne Infections;Genital Diseases;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Pathologic Processes;Communicable Diseases;Immunologic Deficiency Syndromes","Adenine;Cytidine;Heterocyclic Compounds, 1-Ring;Deoxyribonucleosides;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Pyrimidines;Emtricitabine;Purines;Heterocyclic Compounds;Nucleic Acids, Nucleotides, and Nucleosides;Pyrimidine Nucleosides;Organophosphorus Compounds;Tenofovir;Substances and Cells (CHEM);Deoxycytidine;Organophosphonates;Carbohydrates;Glycosides;Substances;Ribonucleosides;Organic Chemicals;Nucleosides",,Reverse Transcription to DNA Alteration;Immunologically Active Molecule Activity Alteration;Increased Immunologic Activity;Cellular Cycle Alteration;Decreased Reverse Transcription to DNA;Cellular Synthetic Activity Alteration;Immunologic Activity Alteration;Increased Immunologically Active Molecule Activity;Physiologic Effect (PE);Nucleic Acid Transcription Alteration;Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Reverse Transcriptase Inhibitors;Enzyme Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleic Acid Synthesis Inhibitors;Enzyme Interactions,Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor;Enzyme Inhibitor;Enzyme Interaction;Nucleic Acid Related Agent;Nucleoside Analog Antiviral;Anti-infective;Nucleic Acid Synthesis Inhibitor;Antimicrobial;Established Pharmacologic Class (EPC),"Nucleoside and nucleotide reverse transcriptase inhibitors;ANTIINFECTIVES FOR SYSTEMIC USE;Antivirals for treatment of HIV infections, combinations;ANTIVIRALS FOR SYSTEMIC USE;DIRECT ACTING ANTIVIRALS;Anatomical Therapeutic Chemical (ATC1-4)",Medicinal product categorized by therapeutic role;Antiviral agent;Antiretroviral agent,,,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,,"Nucleic Acids, Nucleotides, and Nucleosides;Glycosides;Substances;Substances and Cells (CHEM);Nucleosides;Carbohydrates",,,,,,
39,23,Concomitant Medications,Generic Name,RxNorm,truvada,Truvada Pill,1185615.0,Truvada Pill,495430.0,495430.0,495430,False,Reverse transcriptase inhibitor-containing product;Medicinal product categorized by disposition;Transferase inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Pyrimidine-containing product,Therapeutic Uses;Anti-Retroviral Agents;Enzyme Inhibitors;Reverse Transcriptase Inhibitors;MeSH Pharmacologic Actions (MESHPA);Nucleic Acid Synthesis Inhibitors;Anti-HIV Agents;Anti-Infective Agents;Antiviral Agents;Molecular Mechanisms of Pharmacological Action,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Hepatitis, Viral, Human;Hepadnaviridae Infections;Hepatitis B;Lentivirus Infections;Acquired Immunodeficiency Syndrome;Hepatitis;Chronic Disease;Virus Diseases;Sexually Transmitted Diseases;Digestive System Diseases;Slow Virus Diseases;Sexually Transmitted Diseases, Viral;Disease Attributes;Pathological Conditions, Signs and Symptoms;DNA Virus Infections;HIV Infections;Disease;RNA Virus Infections;Infections;Hepatitis B, Chronic;Hepatitis, Chronic;Retroviridae Infections;Blood-Borne Infections;Genital Diseases;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Pathologic Processes;Communicable Diseases;Immunologic Deficiency Syndromes","Adenine;Cytidine;Heterocyclic Compounds, 1-Ring;Deoxyribonucleosides;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Pyrimidines;Emtricitabine;Purines;Heterocyclic Compounds;Nucleic Acids, Nucleotides, and Nucleosides;Pyrimidine Nucleosides;Organophosphorus Compounds;Tenofovir;Substances and Cells (CHEM);Deoxycytidine;Organophosphonates;Carbohydrates;Glycosides;Substances;Ribonucleosides;Organic Chemicals;Nucleosides",,Reverse Transcription to DNA Alteration;Immunologically Active Molecule Activity Alteration;Increased Immunologic Activity;Cellular Cycle Alteration;Decreased Reverse Transcription to DNA;Cellular Synthetic Activity Alteration;Immunologic Activity Alteration;Increased Immunologically Active Molecule Activity;Physiologic Effect (PE);Nucleic Acid Transcription Alteration;Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Reverse Transcriptase Inhibitors;Enzyme Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Nucleic Acid Synthesis Inhibitors;Enzyme Interactions,Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor;Enzyme Inhibitor;Enzyme Interaction;Nucleic Acid Related Agent;Nucleoside Analog Antiviral;Anti-infective;Nucleic Acid Synthesis Inhibitor;Antimicrobial;Established Pharmacologic Class (EPC),"Nucleoside and nucleotide reverse transcriptase inhibitors;ANTIINFECTIVES FOR SYSTEMIC USE;Antivirals for treatment of HIV infections, combinations;ANTIVIRALS FOR SYSTEMIC USE;DIRECT ACTING ANTIVIRALS;Anatomical Therapeutic Chemical (ATC1-4)",Medicinal product categorized by therapeutic role;Antiviral agent;Antiretroviral agent,,,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,,"Nucleic Acids, Nucleotides, and Nucleosides;Glycosides;Substances;Substances and Cells (CHEM);Nucleosides;Carbohydrates",,,,,,
40,8,Concomitant Medications,Generic Name,RxNorm,glipizide,,,,4821.0,4821.0,4821,False,,Nitrogen and/or nitrogen compound-containing product;Sulfonamide-containing product;Urea and/or urea derivative-containing product;Medicinal product categorized by structure;Sulfonylurea-containing product;Sulfur and/or sulfur compound-containing product,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,"Chemically-Induced Disorders;Endocrine System Diseases;Diabetes Mellitus, Type 1;Diabetic Ketoacidosis;Acid-Base Imbalance;Diabetes Complications;Autoimmune Diseases;Acidosis;Disease;Drug-Related Side Effects and Adverse Reactions;Nutritional and Metabolic Diseases;Immune System Diseases;Glucose Metabolism Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Diabetes Mellitus;Metabolic Diseases;Drug Hypersensitivity;Ketosis","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases",Sulfur Compounds;Substances;Organic Chemicals;Amides;Sulfones;Sulfonylurea Compounds;Urea;Substances and Cells (CHEM);Inorganic Chemicals;Glipizide,,Decreased Glycolysis;Pancreatic Islet Activity Alteration;Glucose Metabolism Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Increased Insulin Secretion;Generalized Systemic Effects,Mechanism of Action (MoA);Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Receptor Interactions;Insulin Receptor Agonists,Blood Glucose Regulator;Established Pharmacologic Class (EPC);Sulfonylurea;Chemical Structure,"Sulfonylureas;ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Substances;Organic Chemicals;Amides;Sulfones;Sulfonylurea Compounds;Urea;Substances and Cells (CHEM);Inorganic Chemicals;Sulfur Compounds,,,,,Hepatic Metabolism;Site of Metabolism;Elimination;Pharmacokinetics (PK);Metabolism,
41,24,Concomitant Medications,Generic Name,RxNorm,glipizide,glipiZIDE,4821.0,glipiZIDE,4821.0,4821.0,4821,False,,Nitrogen and/or nitrogen compound-containing product;Sulfonamide-containing product;Urea and/or urea derivative-containing product;Medicinal product categorized by structure;Sulfonylurea-containing product;Sulfur and/or sulfur compound-containing product,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,"Chemically-Induced Disorders;Endocrine System Diseases;Diabetes Mellitus, Type 1;Diabetic Ketoacidosis;Acid-Base Imbalance;Diabetes Complications;Autoimmune Diseases;Acidosis;Disease;Drug-Related Side Effects and Adverse Reactions;Nutritional and Metabolic Diseases;Immune System Diseases;Glucose Metabolism Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Diabetes Mellitus;Metabolic Diseases;Drug Hypersensitivity;Ketosis","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases",Sulfur Compounds;Substances;Organic Chemicals;Amides;Sulfones;Sulfonylurea Compounds;Urea;Substances and Cells (CHEM);Inorganic Chemicals;Glipizide,,Decreased Glycolysis;Pancreatic Islet Activity Alteration;Glucose Metabolism Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Increased Insulin Secretion;Generalized Systemic Effects,Mechanism of Action (MoA);Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Receptor Interactions;Insulin Receptor Agonists,Blood Glucose Regulator;Established Pharmacologic Class (EPC);Sulfonylurea;Chemical Structure,"Sulfonylureas;ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Substances;Organic Chemicals;Amides;Sulfones;Sulfonylurea Compounds;Urea;Substances and Cells (CHEM);Inorganic Chemicals;Sulfur Compounds,,,,,Hepatic Metabolism;Site of Metabolism;Elimination;Pharmacokinetics (PK);Metabolism,
42,28,Concomitant Medications,Generic Name,RxNorm,Glipizide,Glipizide 10 MG,317379.0,Glipizide 10 MG,4821.0,4821.0,4821,False,,Nitrogen and/or nitrogen compound-containing product;Sulfonamide-containing product;Urea and/or urea derivative-containing product;Medicinal product categorized by structure;Sulfonylurea-containing product;Sulfur and/or sulfur compound-containing product,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,"Chemically-Induced Disorders;Endocrine System Diseases;Diabetes Mellitus, Type 1;Diabetic Ketoacidosis;Acid-Base Imbalance;Diabetes Complications;Autoimmune Diseases;Acidosis;Disease;Drug-Related Side Effects and Adverse Reactions;Nutritional and Metabolic Diseases;Immune System Diseases;Glucose Metabolism Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Diabetes Mellitus;Metabolic Diseases;Drug Hypersensitivity;Ketosis","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases",Sulfur Compounds;Substances;Organic Chemicals;Amides;Sulfones;Sulfonylurea Compounds;Urea;Substances and Cells (CHEM);Inorganic Chemicals;Glipizide,,Decreased Glycolysis;Pancreatic Islet Activity Alteration;Glucose Metabolism Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Increased Insulin Secretion;Generalized Systemic Effects,Mechanism of Action (MoA);Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Receptor Interactions;Insulin Receptor Agonists,Blood Glucose Regulator;Established Pharmacologic Class (EPC);Sulfonylurea;Chemical Structure,"Sulfonylureas;ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Substances;Organic Chemicals;Amides;Sulfones;Sulfonylurea Compounds;Urea;Substances and Cells (CHEM);Inorganic Chemicals;Sulfur Compounds,,,,,Hepatic Metabolism;Site of Metabolism;Elimination;Pharmacokinetics (PK);Metabolism,
43,8,Concomitant Medications,Generic Name,RxNorm,gabapentin,,,,25480.0,25480.0,25480,False,Medicinal product categorized by disposition;Calcium channel blocker-containing product,Nitrogen and/or nitrogen compound-containing product;Amino acid-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,Analgesics;Therapeutic Uses;Antimanic Agents;Neurotransmitter Agents;Sensory System Agents;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Tranquilizing Agents;Physiological Effects of Drugs;Psychotropic Drugs;Anticonvulsants;Central Nervous System Depressants;Molecular Mechanisms of Pharmacological Action;Anti-Anxiety Agents;Excitatory Amino Acid Antagonists;Excitatory Amino Acid Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Epilepsy;Epilepsies, Partial;Bipolar and Related Disorders;Signs and Symptoms;Phobic Disorders;Mental Disorders;Pain;Peripheral Nervous System Diseases;Neurologic Manifestations;Neuralgia;Pathological Conditions, Signs and Symptoms;Brain Diseases;Neuralgia, Postherpetic;Bipolar Disorder;Disease;Anxiety Disorders;Mood Disorders;Nervous System Diseases;Neuromuscular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases","Hydrocarbons, Alicyclic;Amino Acids;Cyclohexanes;Fatty Acids;Fatty Acids, Volatile;Hydrocarbons, Cyclic;Carbamates;Cycloparaffins;Carboxylic Acids;Polycyclic Compounds;Acids, Carbocyclic;Substances and Cells (CHEM);Acids, Acyclic;Macrocyclic Compounds;gamma-Aminobutyric Acid;Gabapentin;Lipids;Butyrates;Substances;Amines;Organic Chemicals;Hydrocarbons;Amino Acids, Peptides, and Proteins;Aminobutyrates;Cyclohexanecarboxylic Acids",,Disorganized Electrical Activity Alteration;Decreased Disorganized Electrical Activity;Decreased Organized Electrical Activity;Organized Electrical Activity Alteration;Organ System Specific Effects;Decreased Central Nervous System Disorganized Electrical Activity;Nervous System Activity Alteration;Electrical Activity Alteration;Physiologic Effect (PE),Unknown Cellular or Molecular Interaction;Mechanism of Action (MoA),Anti-epileptic Agent;Established Pharmacologic Class (EPC);Nervous System Agent,ANALGESICS;Gabapentinoids;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;OTHER ANALGESICS AND ANTIPYRETICS,Medicinal product categorized by therapeutic role;Anticonvulsant agent,,Anti-epileptic Agent;Central Nervous System Agent;Therapeutic Categories,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTICONVULSANTS;CNS MEDICATIONS,OTHER;VA CLASSES","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTICONVULSANTS;CNS MEDICATIONS,OTHER;VA CLASSES",,,,,,,,
44,9,Concomitant Medications,Generic Name,RxNorm,advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Carboxylic Acids;Substances;Phenylpropionates;Acids, Carbocyclic;Organic Chemicals;Substances and Cells (CHEM)",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;RESPIRATORY SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;Other throat preparations;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;Propionic acid derivatives;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"ANTIRHEUMATICS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;NONSALICYLATE NSAIs,ANTIRHEUMATIC","ANTIRHEUMATICS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;NONSALICYLATE NSAIs,ANTIRHEUMATIC",,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
45,13,Concomitant Medications,Generic Name,RxNorm,Advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Carboxylic Acids;Substances;Phenylpropionates;Acids, Carbocyclic;Organic Chemicals;Substances and Cells (CHEM)",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;RESPIRATORY SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;Other throat preparations;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;Propionic acid derivatives;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"ANTIRHEUMATICS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;NONSALICYLATE NSAIs,ANTIRHEUMATIC","ANTIRHEUMATICS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;NONSALICYLATE NSAIs,ANTIRHEUMATIC",,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
46,31,Concomitant Medications,Generic Name,RxNorm,advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Carboxylic Acids;Substances;Phenylpropionates;Acids, Carbocyclic;Organic Chemicals;Substances and Cells (CHEM)",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;RESPIRATORY SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;Other throat preparations;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;Propionic acid derivatives;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"ANTIRHEUMATICS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;NONSALICYLATE NSAIs,ANTIRHEUMATIC","ANTIRHEUMATICS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;NONSALICYLATE NSAIs,ANTIRHEUMATIC",,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
47,9,Concomitant Medications,Generic Name,RxNorm,Naproxen,Naproxen,7258.0,Naproxen,7258.0,7258.0,7258,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Naphthalene-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antirheumatic Agents;Anti-Inflammatory Agents;Cyclooxygenase Inhibitors;Gout Suppressants;Enzyme Inhibitors;Anti-Inflammatory Agents, Non-Steroidal;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Sensory System Agents;Analgesics, Non-Narcotic;Physiological Effects of Drugs;Molecular Mechanisms of Pharmacological Action;Analgesics","Chemically-Induced Disorders;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Disease;Drug-Related Side Effects and Adverse Reactions;Pregnancy Trimesters;Pregnancy Trimester, Third;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Respiratory Tract Diseases;Common Cold;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Signs and Symptoms;Bone Diseases;Bursitis;Pain;Virus Diseases;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Tooth Diseases;Autoimmune Diseases;Spondylitis, Ankylosing;Back Pain;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Metabolic Diseases;Spondylitis;Disease;RNA Virus Infections;Rheumatic Diseases;Infections;Stomatognathic Diseases;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Respiratory Tract Infections;Toothache;Nervous System Diseases;Joint Diseases;Facial Pain;Headache;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Picornaviridae Infections;Arthritis, Rheumatoid;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Naproxen;Naphthalenes;Hydrocarbons, Cyclic;Polycyclic Compounds;Substances;Organic Chemicals;Substances and Cells (CHEM);Naphthaleneacetic Acids;Hydrocarbons;Polycyclic Aromatic Hydrocarbons;Hydrocarbons, Aromatic",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;Antiinflammatory preparations, non-steroids for topical use;MUSCULO-SKELETAL SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;Antiinflammatory products for vaginal administration;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;Propionic acid derivatives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;ANTIMIGRAINE AGENTS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;ANTIMIGRAINE AGENTS;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC",,,,,,Elimination;Renal Excretion;Pharmacokinetics (PK);Route of Excretion,,
48,22,Concomitant Medications,Generic Name,RxNorm,Naproxen,Aleve,215101.0,Aleve,7258.0,7258.0,7258,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Naphthalene-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Antirheumatic Agents;Anti-Inflammatory Agents;Cyclooxygenase Inhibitors;Gout Suppressants;Enzyme Inhibitors;Anti-Inflammatory Agents, Non-Steroidal;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Sensory System Agents;Analgesics, Non-Narcotic;Physiological Effects of Drugs;Molecular Mechanisms of Pharmacological Action;Analgesics","Chemically-Induced Disorders;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Disease;Drug-Related Side Effects and Adverse Reactions;Pregnancy Trimesters;Pregnancy Trimester, Third;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Respiratory Tract Diseases;Common Cold;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Signs and Symptoms;Bone Diseases;Bursitis;Pain;Virus Diseases;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Tooth Diseases;Autoimmune Diseases;Spondylitis, Ankylosing;Back Pain;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Metabolic Diseases;Spondylitis;Disease;RNA Virus Infections;Rheumatic Diseases;Infections;Stomatognathic Diseases;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Respiratory Tract Infections;Toothache;Nervous System Diseases;Joint Diseases;Facial Pain;Headache;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Picornaviridae Infections;Arthritis, Rheumatoid;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Naproxen;Naphthalenes;Hydrocarbons, Cyclic;Polycyclic Compounds;Substances;Organic Chemicals;Substances and Cells (CHEM);Naphthaleneacetic Acids;Hydrocarbons;Polycyclic Aromatic Hydrocarbons;Hydrocarbons, Aromatic",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;Antiinflammatory preparations, non-steroids for topical use;MUSCULO-SKELETAL SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;Antiinflammatory products for vaginal administration;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER GYNECOLOGICALS;Propionic acid derivatives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;ANTIMIGRAINE AGENTS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;ANTIMIGRAINE AGENTS;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC",,,,,,Elimination;Renal Excretion;Pharmacokinetics (PK);Route of Excretion,,
49,9,Concomitant Medications,Generic Name,RxNorm,Dayquil,DayQuil Cough,1114038.0,DayQuil Cough,,1114038.0,1114038,True,Medicinal product categorized by disposition;Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product,Medicinal product categorized by structure;Ether structure-containing product,Therapeutic Uses;Neurotransmitter Agents;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Antitussive Agents;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Excitatory Amino Acid Antagonists;Excitatory Amino Acid Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders","Opiate Alkaloids;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 4 or More Rings;Phenanthrenes;Hydrocarbons, Cyclic;Polycyclic Compounds;Dextromethorphan;Morphinans;Substances;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Polycyclic Aromatic Hydrocarbons;Heterocyclic Compounds, Bridged-Ring;Alkaloids;Hydrocarbons, Aromatic",,Medullary Respiratory Center Activity Alteration;Organ System Specific Effects;Physiologic Effect (PE);Decreased Medullary Respiratory Drive;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Serotonin Uptake Inhibitors;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Ionotropic Glutamate Receptor Antagonists;Sigma Receptor Interactions;Membrane Transporter Interactions;Symporter Interactions;Ligand-Gated Ion Channel Interactions;Ion Transporter Interactions,Receptor Antagonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Ion Channel or Pump Agent;Receptor Agonist;Nervous System Agent;Established Pharmacologic Class (EPC);Sigma-1 Agonist,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
50,16,Concomitant Medications,Generic Name,RxNorm,Dayquil,,,,,1114038.0,1114038,True,Medicinal product categorized by disposition;Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product,Medicinal product categorized by structure;Ether structure-containing product,Therapeutic Uses;Neurotransmitter Agents;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Antitussive Agents;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Excitatory Amino Acid Antagonists;Excitatory Amino Acid Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders","Opiate Alkaloids;Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 4 or More Rings;Phenanthrenes;Hydrocarbons, Cyclic;Polycyclic Compounds;Dextromethorphan;Morphinans;Substances;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Polycyclic Aromatic Hydrocarbons;Heterocyclic Compounds, Bridged-Ring;Alkaloids;Hydrocarbons, Aromatic",,Medullary Respiratory Center Activity Alteration;Organ System Specific Effects;Physiologic Effect (PE);Decreased Medullary Respiratory Drive;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Serotonin Uptake Inhibitors;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Ionotropic Glutamate Receptor Antagonists;Sigma Receptor Interactions;Membrane Transporter Interactions;Symporter Interactions;Ligand-Gated Ion Channel Interactions;Ion Transporter Interactions,Receptor Antagonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Ion Channel or Pump Agent;Receptor Agonist;Nervous System Agent;Established Pharmacologic Class (EPC);Sigma-1 Agonist,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
51,9,Concomitant Medications,Generic Name,RxNorm,nyquil,Nyquil Cough,702274.0,Nyquil Cough,,1234386.0,1234386,True,Medicinal product categorized by disposition;Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Ether structure-containing product,Histamine Agents;Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Antiemetics;Histamine Antagonists;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Gastrointestinal Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Excitatory Amino Acid Antagonists;Excitatory Amino Acid Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Respiratory Tract Diseases;Sleep Disorders, Intrinsic;Signs and Symptoms;Mental Disorders;Pain;Neurologic Manifestations;Signs and Symptoms, Respiratory;Otorhinolaryngologic Diseases;Dyssomnias;Pathological Conditions, Signs and Symptoms;Respiratory Hypersensitivity;Hypersensitivity;Disease;Infections;Sleep Initiation and Maintenance Disorders;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nervous System Diseases;Nose Diseases;Rhinitis, Allergic;Headache;Cough;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Sleep Wake Disorders;Respiration Disorders","Heterocyclic Compounds, 4 or More Rings;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, Bridged-Ring;Doxylamine;Hydrocarbons, Aromatic;Heterocyclic Compounds, Fused-Ring;Hydrocarbons, Cyclic;Alkaloids;Heterocyclic Compounds;Polycyclic Compounds;Substances and Cells (CHEM);Polycyclic Aromatic Hydrocarbons;Pyridines;Morphinans;Opiate Alkaloids;Substances;Dextromethorphan;Organic Chemicals;Hydrocarbons;Phenanthrenes",,Immunologically Active Molecule Activity Alteration;Medullary Respiratory Center Activity Alteration;Decreased Immunologically Active Molecule Activity;Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Histamine Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Decreased Medullary Respiratory Drive;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Generalized Systemic Effects,Ion Channel Interactions;G-Protein-linked Receptor Interactions;Receptor Interactions;Ionotropic Glutamate Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Histamine H1 Receptor Antagonists;Serotonin Transporter Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Neurotransmitter Transporter Interactions;Sigma-1 Receptor Agonists;Histamine Receptor Antagonists;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Membrane Transporter Interactions;Symporter Interactions;Ligand-Gated Ion Channel Interactions;NMDA Receptor Antagonists;Sigma Receptor Interactions;Histamine Receptor Interactions;Ion Transporter Interactions,Receptor Antagonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Ion Channel or Pump Agent;Antihistamine;Respiratory Agent;Receptor Agonist;Nervous System Agent;Established Pharmacologic Class (EPC);Sigma-1 Agonist,"RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;Aminoalkyl ethers;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",,"RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/ANTITUSSIVE;VA CLASSES",,,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
52,16,Concomitant Medications,Generic Name,RxNorm,Nyquil,,,,,1234386.0,1234386,True,Medicinal product categorized by disposition;Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Ether structure-containing product,Histamine Agents;Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Antiemetics;Histamine Antagonists;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Gastrointestinal Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Excitatory Amino Acid Antagonists;Excitatory Amino Acid Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Respiratory Tract Diseases;Sleep Disorders, Intrinsic;Signs and Symptoms;Mental Disorders;Pain;Neurologic Manifestations;Signs and Symptoms, Respiratory;Otorhinolaryngologic Diseases;Dyssomnias;Pathological Conditions, Signs and Symptoms;Respiratory Hypersensitivity;Hypersensitivity;Disease;Infections;Sleep Initiation and Maintenance Disorders;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nervous System Diseases;Nose Diseases;Rhinitis, Allergic;Headache;Cough;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Sleep Wake Disorders;Respiration Disorders","Heterocyclic Compounds, 4 or More Rings;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, Bridged-Ring;Doxylamine;Hydrocarbons, Aromatic;Heterocyclic Compounds, Fused-Ring;Hydrocarbons, Cyclic;Alkaloids;Heterocyclic Compounds;Polycyclic Compounds;Substances and Cells (CHEM);Polycyclic Aromatic Hydrocarbons;Pyridines;Morphinans;Opiate Alkaloids;Substances;Dextromethorphan;Organic Chemicals;Hydrocarbons;Phenanthrenes",,Immunologically Active Molecule Activity Alteration;Medullary Respiratory Center Activity Alteration;Decreased Immunologically Active Molecule Activity;Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Histamine Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Decreased Medullary Respiratory Drive;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Generalized Systemic Effects,Ion Channel Interactions;G-Protein-linked Receptor Interactions;Receptor Interactions;Ionotropic Glutamate Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Histamine H1 Receptor Antagonists;Serotonin Transporter Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Neurotransmitter Transporter Interactions;Sigma-1 Receptor Agonists;Histamine Receptor Antagonists;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Membrane Transporter Interactions;Symporter Interactions;Ligand-Gated Ion Channel Interactions;NMDA Receptor Antagonists;Sigma Receptor Interactions;Histamine Receptor Interactions;Ion Transporter Interactions,Receptor Antagonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Ion Channel or Pump Agent;Antihistamine;Respiratory Agent;Receptor Agonist;Nervous System Agent;Established Pharmacologic Class (EPC);Sigma-1 Agonist,"RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;Aminoalkyl ethers;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",,"RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/ANTITUSSIVE;VA CLASSES",,,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
53,21,Concomitant Medications,Generic Name,RxNorm,Nyquil,Nyquil Cough,702274.0,Nyquil Cough,,1234386.0,1234386,True,Medicinal product categorized by disposition;Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Ether structure-containing product,Histamine Agents;Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Antiemetics;Histamine Antagonists;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Gastrointestinal Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Excitatory Amino Acid Antagonists;Excitatory Amino Acid Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Respiratory Tract Diseases;Sleep Disorders, Intrinsic;Signs and Symptoms;Mental Disorders;Pain;Neurologic Manifestations;Signs and Symptoms, Respiratory;Otorhinolaryngologic Diseases;Dyssomnias;Pathological Conditions, Signs and Symptoms;Respiratory Hypersensitivity;Hypersensitivity;Disease;Infections;Sleep Initiation and Maintenance Disorders;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nervous System Diseases;Nose Diseases;Rhinitis, Allergic;Headache;Cough;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Sleep Wake Disorders;Respiration Disorders","Heterocyclic Compounds, 4 or More Rings;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, Bridged-Ring;Doxylamine;Hydrocarbons, Aromatic;Heterocyclic Compounds, Fused-Ring;Hydrocarbons, Cyclic;Alkaloids;Heterocyclic Compounds;Polycyclic Compounds;Substances and Cells (CHEM);Polycyclic Aromatic Hydrocarbons;Pyridines;Morphinans;Opiate Alkaloids;Substances;Dextromethorphan;Organic Chemicals;Hydrocarbons;Phenanthrenes",,Immunologically Active Molecule Activity Alteration;Medullary Respiratory Center Activity Alteration;Decreased Immunologically Active Molecule Activity;Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Histamine Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Decreased Medullary Respiratory Drive;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Generalized Systemic Effects,Ion Channel Interactions;G-Protein-linked Receptor Interactions;Receptor Interactions;Ionotropic Glutamate Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Histamine H1 Receptor Antagonists;Serotonin Transporter Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Neurotransmitter Transporter Interactions;Sigma-1 Receptor Agonists;Histamine Receptor Antagonists;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Membrane Transporter Interactions;Symporter Interactions;Ligand-Gated Ion Channel Interactions;NMDA Receptor Antagonists;Sigma Receptor Interactions;Histamine Receptor Interactions;Ion Transporter Interactions,Receptor Antagonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Ion Channel or Pump Agent;Antihistamine;Respiratory Agent;Receptor Agonist;Nervous System Agent;Established Pharmacologic Class (EPC);Sigma-1 Agonist,"RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;Aminoalkyl ethers;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",,"RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/ANTITUSSIVE;VA CLASSES",,,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
54,32,Concomitant Medications,Generic Name,RxNorm,NyQuil,,,,,1234386.0,1234386,True,Medicinal product categorized by disposition;Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Ether structure-containing product,Histamine Agents;Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Antiemetics;Histamine Antagonists;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Gastrointestinal Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Excitatory Amino Acid Antagonists;Excitatory Amino Acid Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Respiratory Tract Diseases;Sleep Disorders, Intrinsic;Signs and Symptoms;Mental Disorders;Pain;Neurologic Manifestations;Signs and Symptoms, Respiratory;Otorhinolaryngologic Diseases;Dyssomnias;Pathological Conditions, Signs and Symptoms;Respiratory Hypersensitivity;Hypersensitivity;Disease;Infections;Sleep Initiation and Maintenance Disorders;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nervous System Diseases;Nose Diseases;Rhinitis, Allergic;Headache;Cough;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Sleep Wake Disorders;Respiration Disorders","Heterocyclic Compounds, 4 or More Rings;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, Bridged-Ring;Doxylamine;Hydrocarbons, Aromatic;Heterocyclic Compounds, Fused-Ring;Hydrocarbons, Cyclic;Alkaloids;Heterocyclic Compounds;Polycyclic Compounds;Substances and Cells (CHEM);Polycyclic Aromatic Hydrocarbons;Pyridines;Morphinans;Opiate Alkaloids;Substances;Dextromethorphan;Organic Chemicals;Hydrocarbons;Phenanthrenes",,Immunologically Active Molecule Activity Alteration;Medullary Respiratory Center Activity Alteration;Decreased Immunologically Active Molecule Activity;Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Histamine Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Decreased Medullary Respiratory Drive;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Generalized Systemic Effects,Ion Channel Interactions;G-Protein-linked Receptor Interactions;Receptor Interactions;Ionotropic Glutamate Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Histamine H1 Receptor Antagonists;Serotonin Transporter Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Neurotransmitter Transporter Interactions;Sigma-1 Receptor Agonists;Histamine Receptor Antagonists;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Membrane Transporter Interactions;Symporter Interactions;Ligand-Gated Ion Channel Interactions;NMDA Receptor Antagonists;Sigma Receptor Interactions;Histamine Receptor Interactions;Ion Transporter Interactions,Receptor Antagonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Ion Channel or Pump Agent;Antihistamine;Respiratory Agent;Receptor Agonist;Nervous System Agent;Established Pharmacologic Class (EPC);Sigma-1 Agonist,"RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;Aminoalkyl ethers;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",,"RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/ANTITUSSIVE;VA CLASSES",,,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
55,10,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Amino Acids;Carboxylic Acids;Lysine;Substances;Phenylpropionates;Amino Acids, Basic;Amino Acids, Diamino;Acids, Carbocyclic;Substances and Cells (CHEM);Organic Chemicals;Amino Acids, Essential;Amino Acids, Peptides, and Proteins",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;CARDIOVASCULAR SYSTEM;NERVOUS SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);OPIOIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Other throat preparations;Propionic acid derivatives;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANALGESICS;RESPIRATORY SYSTEM;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC",CSA SCHEDULE;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
56,12,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Amino Acids;Carboxylic Acids;Lysine;Substances;Phenylpropionates;Amino Acids, Basic;Amino Acids, Diamino;Acids, Carbocyclic;Substances and Cells (CHEM);Organic Chemicals;Amino Acids, Essential;Amino Acids, Peptides, and Proteins",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;CARDIOVASCULAR SYSTEM;NERVOUS SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);OPIOIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Other throat preparations;Propionic acid derivatives;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANALGESICS;RESPIRATORY SYSTEM;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC",CSA SCHEDULE;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
57,19,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Amino Acids;Carboxylic Acids;Lysine;Substances;Phenylpropionates;Amino Acids, Basic;Amino Acids, Diamino;Acids, Carbocyclic;Substances and Cells (CHEM);Organic Chemicals;Amino Acids, Essential;Amino Acids, Peptides, and Proteins",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;CARDIOVASCULAR SYSTEM;NERVOUS SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);OPIOIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Other throat preparations;Propionic acid derivatives;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANALGESICS;RESPIRATORY SYSTEM;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC",CSA SCHEDULE;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
58,20,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Amino Acids;Carboxylic Acids;Lysine;Substances;Phenylpropionates;Amino Acids, Basic;Amino Acids, Diamino;Acids, Carbocyclic;Substances and Cells (CHEM);Organic Chemicals;Amino Acids, Essential;Amino Acids, Peptides, and Proteins",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;CARDIOVASCULAR SYSTEM;NERVOUS SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);OPIOIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Other throat preparations;Propionic acid derivatives;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANALGESICS;RESPIRATORY SYSTEM;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC",CSA SCHEDULE;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
59,21,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Amino Acids;Carboxylic Acids;Lysine;Substances;Phenylpropionates;Amino Acids, Basic;Amino Acids, Diamino;Acids, Carbocyclic;Substances and Cells (CHEM);Organic Chemicals;Amino Acids, Essential;Amino Acids, Peptides, and Proteins",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;CARDIOVASCULAR SYSTEM;NERVOUS SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);OPIOIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Other throat preparations;Propionic acid derivatives;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANALGESICS;RESPIRATORY SYSTEM;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC",CSA SCHEDULE;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
60,32,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Amino Acids;Carboxylic Acids;Lysine;Substances;Phenylpropionates;Amino Acids, Basic;Amino Acids, Diamino;Acids, Carbocyclic;Substances and Cells (CHEM);Organic Chemicals;Amino Acids, Essential;Amino Acids, Peptides, and Proteins",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;CARDIOVASCULAR SYSTEM;NERVOUS SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);OPIOIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Other throat preparations;Propionic acid derivatives;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANALGESICS;RESPIRATORY SYSTEM;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC",CSA SCHEDULE;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
61,42,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,Medicinal product categorized by disposition;Enzyme inhibitor-containing product;COX-2 inhibitor-containing product,Organic acid and/or organic acid derivative-containing product;Medicinal product categorized by structure;Propionic acid and/or propionic acid derivative-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Antirheumatic Agents;Cyclooxygenase Inhibitors;Enzyme Inhibitors;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Physiological Effects of Drugs;Analgesics;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Respiratory Tract Diseases;Pregnancy Trimesters;Pregnancy Trimester, Third;Pregnancy, Abdominal;Otorhinolaryngologic Diseases;Bronchial Hyperreactivity;Pregnancy Complications;Bronchial Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pregnancy, Ectopic;Reproductive Physiological Phenomena","Spondylarthritis;Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Bone Diseases;Signs and Symptoms;Menorrhagia;Bursitis;Pain;Axial Spondyloarthritis;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Spondylitis, Ankylosing;Spondylarthropathies;Ankylosis;Inflammation;Skin and Connective Tissue Diseases;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Pain, Postoperative;Metabolic Diseases;Postoperative Complications;Female Urogenital Diseases and Pregnancy Complications;Spondylitis;Disease;Rheumatic Diseases;Infections;Dysmenorrhea;Pelvic Pain;Spinal Diseases;Gout;Bone Diseases, Infectious;Menstruation Disturbances;Genital Diseases, Female;Hemorrhage;Nervous System Diseases;Genital Diseases;Joint Diseases;Uterine Hemorrhage;Premenstrual Syndrome;Immune System Diseases;Arthritis, Juvenile;Metabolism, Inborn Errors;Female Urogenital Diseases;Arthritis, Rheumatoid;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Ibuprofen;Amino Acids;Carboxylic Acids;Lysine;Substances;Phenylpropionates;Amino Acids, Basic;Amino Acids, Diamino;Acids, Carbocyclic;Substances and Cells (CHEM);Organic Chemicals;Amino Acids, Essential;Amino Acids, Peptides, and Proteins",,Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Eicosanoid Production;Decreased Prostaglandin Production;Decreased Thromboxane Production;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Interaction;Enzyme Inhibitor;Established Pharmacologic Class (EPC);Nonsteroidal Anti-inflammatory Drug,"Antiinflammatory preparations, non-steroids for topical use;Other cardiac preparations;MUSCULO-SKELETAL SYSTEM;OTHER CARDIAC PREPARATIONS;Antiinflammatory products for vaginal administration;CARDIOVASCULAR SYSTEM;NERVOUS SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);OPIOIDS;GENITO URINARY SYSTEM AND SEX HORMONES;Other throat preparations;Propionic acid derivatives;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANALGESICS;RESPIRATORY SYSTEM;Opioids in combination with non-opioid analgesics;THROAT PREPARATIONS;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS",,"Neurologic Manifestations;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIRHEUMATICS;COLD REMEDIES,COMBINATIONS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;MUSCULOSKELETAL MEDICATIONS;NONSALICYLATE NSAIs,ANTIRHEUMATIC",CSA SCHEDULE;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
62,10,Concomitant Medications,Generic Name,RxNorm,tessalon perles,Tessalon Perles,220224.0,Tessalon Perles,220224.0,220224.0,220224,False,,Nitrogen and/or nitrogen compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Therapeutic Uses;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Respiratory System Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Respiratory;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders","Substances;Alkanes;Butanes;Amines;Organic Chemicals;Hydrocarbons, Acyclic;Substances and Cells (CHEM);Hydrocarbons;Butylamines",,Tracheobronchial Stretch Receptor Alteration;Organ System Specific Effects;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Sodium-Potassium Exchanging ATPase Interactions;Mechanism of Action (MoA);Antiporter Interactions;Receptor Interactions;Membrane Transporter Interactions;Ion Transporter Interactions,Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),"RESPIRATORY SYSTEM;Other cough suppressants;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",Respiratory System Agent;Antitussive Agent;Therapeutic Categories,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,,,,,,,,
63,11,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine,,,,,2479830.0,2479830,True,,Recombinant deoxyribonucleic acid-containing product;Medicinal product categorized by structure,,,,Vaccines;Ad26COVS1;Complex Mixtures;Viral Vaccines;Substances;Biological Products;Substances and Cells (CHEM);COVID-19 Vaccines,,,,,,,,,IMMUNOLOGICAL AGENTS;VA CLASSES;VACCINES,,,,,,,,,
64,21,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine,,,,,2479830.0,2479830,True,,Recombinant deoxyribonucleic acid-containing product;Medicinal product categorized by structure,,,,Vaccines;Ad26COVS1;Complex Mixtures;Viral Vaccines;Substances;Biological Products;Substances and Cells (CHEM);COVID-19 Vaccines,,,,,,,,,IMMUNOLOGICAL AGENTS;VA CLASSES;VACCINES,,,,,,,,,
65,14,Concomitant Medications,Generic Name,RxNorm,sudafed,Phenylephrine Hydrochloride 10 MG Oral Tablet [Sudafed PE],1052767.0,Phenylephrine Hydrochloride 10 MG Oral Tablet [Sudafed PE],203302.0,203302.0,203302,False,Alpha adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Medicinal product categorized by disposition,Alcohol-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Bronchodilator Agents;Physiological Effects of Drugs;Nasal Decongestants;Respiratory System Agents;Cardiovascular Agents;Anti-Asthmatic Agents;Vasoconstrictor Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Lung Diseases;Sinusitis;Respiratory Tract Diseases;Common Cold;Virus Diseases;Otorhinolaryngologic Diseases;Bronchial Diseases;Paranasal Sinus Diseases;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;RNA Virus Infections;Infections;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nose Diseases;Rhinitis, Allergic;Immune System Diseases;Picornaviridae Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Propanolamines;Alcohols;Pseudoephedrine;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Propanols;Ethylamines;Amino Alcohols,,Vasoconstriction;Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Bronchodilation;Smooth Muscle Tone Alteration;Organ System Specific Effects;Cardiovascular Activity Alteration;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Vascular Alterations;Vascular Tone Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic Receptor Interactions;Adrenergic alpha-Agonists;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;Receptor Agonist;alpha-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics;RESPIRATORY SYSTEM;Anatomical Therapeutic Chemical (ATC1-4),,,,"RESPIRATORY TRACT MEDICATIONS;VA CLASSES;DECONGESTANTS,SYSTEMIC","RESPIRATORY TRACT MEDICATIONS;VA CLASSES;DECONGESTANTS,SYSTEMIC",,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
66,16,Concomitant Medications,Generic Name,RxNorm,Sudafed,,,,203302.0,203302.0,203302,False,Alpha adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Medicinal product categorized by disposition,Alcohol-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Bronchodilator Agents;Physiological Effects of Drugs;Nasal Decongestants;Respiratory System Agents;Cardiovascular Agents;Anti-Asthmatic Agents;Vasoconstrictor Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Lung Diseases;Sinusitis;Respiratory Tract Diseases;Common Cold;Virus Diseases;Otorhinolaryngologic Diseases;Bronchial Diseases;Paranasal Sinus Diseases;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;RNA Virus Infections;Infections;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nose Diseases;Rhinitis, Allergic;Immune System Diseases;Picornaviridae Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Propanolamines;Alcohols;Pseudoephedrine;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Propanols;Ethylamines;Amino Alcohols,,Vasoconstriction;Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Bronchodilation;Smooth Muscle Tone Alteration;Organ System Specific Effects;Cardiovascular Activity Alteration;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Vascular Alterations;Vascular Tone Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic Receptor Interactions;Adrenergic alpha-Agonists;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;Receptor Agonist;alpha-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics;RESPIRATORY SYSTEM;Anatomical Therapeutic Chemical (ATC1-4),,,,"RESPIRATORY TRACT MEDICATIONS;VA CLASSES;DECONGESTANTS,SYSTEMIC","RESPIRATORY TRACT MEDICATIONS;VA CLASSES;DECONGESTANTS,SYSTEMIC",,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
67,26,Concomitant Medications,Generic Name,RxNorm,Sudafed,,,,203302.0,203302.0,203302,False,Alpha adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Medicinal product categorized by disposition,Alcohol-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Bronchodilator Agents;Physiological Effects of Drugs;Nasal Decongestants;Respiratory System Agents;Cardiovascular Agents;Anti-Asthmatic Agents;Vasoconstrictor Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Lung Diseases;Sinusitis;Respiratory Tract Diseases;Common Cold;Virus Diseases;Otorhinolaryngologic Diseases;Bronchial Diseases;Paranasal Sinus Diseases;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;RNA Virus Infections;Infections;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nose Diseases;Rhinitis, Allergic;Immune System Diseases;Picornaviridae Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Propanolamines;Alcohols;Pseudoephedrine;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Propanols;Ethylamines;Amino Alcohols,,Vasoconstriction;Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Bronchodilation;Smooth Muscle Tone Alteration;Organ System Specific Effects;Cardiovascular Activity Alteration;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Vascular Alterations;Vascular Tone Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic Receptor Interactions;Adrenergic alpha-Agonists;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;Receptor Agonist;alpha-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics;RESPIRATORY SYSTEM;Anatomical Therapeutic Chemical (ATC1-4),,,,"RESPIRATORY TRACT MEDICATIONS;VA CLASSES;DECONGESTANTS,SYSTEMIC","RESPIRATORY TRACT MEDICATIONS;VA CLASSES;DECONGESTANTS,SYSTEMIC",,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
68,36,Concomitant Medications,Generic Name,RxNorm,sudafed,12 HR Pseudoephedrine Hydrochloride 120 MG Extended Release Oral Tablet [Sudafed],1049668.0,12 HR Pseudoephedrine Hydrochloride 120 MG Extended Release Oral Tablet [Sudafed],203302.0,203302.0,203302,False,Alpha adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Medicinal product categorized by disposition,Alcohol-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Bronchodilator Agents;Physiological Effects of Drugs;Nasal Decongestants;Respiratory System Agents;Cardiovascular Agents;Anti-Asthmatic Agents;Vasoconstrictor Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Lung Diseases;Sinusitis;Respiratory Tract Diseases;Common Cold;Virus Diseases;Otorhinolaryngologic Diseases;Bronchial Diseases;Paranasal Sinus Diseases;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;RNA Virus Infections;Infections;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nose Diseases;Rhinitis, Allergic;Immune System Diseases;Picornaviridae Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Propanolamines;Alcohols;Pseudoephedrine;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Propanols;Ethylamines;Amino Alcohols,,Vasoconstriction;Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Bronchodilation;Smooth Muscle Tone Alteration;Organ System Specific Effects;Cardiovascular Activity Alteration;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Vascular Alterations;Vascular Tone Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic Receptor Interactions;Adrenergic alpha-Agonists;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;Receptor Agonist;alpha-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics;RESPIRATORY SYSTEM;Anatomical Therapeutic Chemical (ATC1-4),,,,"RESPIRATORY TRACT MEDICATIONS;VA CLASSES;DECONGESTANTS,SYSTEMIC","RESPIRATORY TRACT MEDICATIONS;VA CLASSES;DECONGESTANTS,SYSTEMIC",,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
69,14,Concomitant Medications,Generic Name,RxNorm,Excedrine Migraine,,,,,209468.0,209468,True,Hydrolase inhibitor-containing product;Phosphodiesterase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition;Platelet aggregation inhibitor-containing product,Alkaloid-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Salicylate-containing product;Purine and/or purine derivative-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Phenol structure-containing product;Methyl xanthine-containing product;Organic acid and/or organic acid derivative-containing product,"Therapeutic Uses;Purinergic P1 Receptor Antagonists;Neurotransmitter Agents;Cardiovascular Agents;Phosphodiesterase Inhibitors;Anti-Inflammatory Agents;Enzyme Inhibitors;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Purinergic Agents;Central Nervous System Stimulants;Fibrinolytic Agents;Fibrin Modulating Agents;Anti-Inflammatory Agents, Non-Steroidal;Purinergic Antagonists;Analgesics, Non-Narcotic;Analgesics;Antipyretics;Antirheumatic Agents;Cyclooxygenase Inhibitors;Platelet Aggregation Inhibitors;Hematologic Agents;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Polyps;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Pregnancy Trimesters;Reproductive Physiological Phenomena;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Nutritional and Metabolic Diseases;Pregnancy Trimester, Third;Child;Signs and Symptoms;Varicella Zoster Virus Infection;Anemia;Melena;Hemorrhagic Disorders;Virus Diseases;Gastrointestinal Diseases;Digestive System Diseases;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Nasal Polyps;Age Groups;Gastrointestinal Hemorrhage;Pathological Conditions, Signs and Symptoms;Metabolic Diseases;DNA Virus Infections;Hematemesis;Chemically-Induced Disorders;Infant;Anemia, Hemolytic, Congenital;Vomiting;Disease;Blood Platelet Disorders;Chickenpox;Infections;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Hemorrhage;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Herpesviridae Infections;Child, Preschool;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Blood Coagulation Disorders;Hematologic Diseases;Liver Diseases;Pathologic Processes;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Fatigue;Osteoarthritis;Arthritis;Connective Tissue Diseases;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Signs and Symptoms;Pain;Musculoskeletal Diseases;Neurologic Manifestations;Signs and Symptoms, Respiratory;Autoimmune Diseases;Streptococcal Infections;Inflammation;Skin and Connective Tissue Diseases;Bacterial Infections;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Metabolic Diseases;Apnea;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Disease;Rheumatic Fever;Rheumatic Diseases;Infections;Gout;Nervous System Diseases;Joint Diseases;Immune System Diseases;Metabolism, Inborn Errors;Arthritis, Rheumatoid;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Respiration Disorders;Purine-Pyrimidine Metabolism, Inborn Errors","Phenols;Caffeine;Purinones;Hydrocarbons, Aromatic;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Xanthines;Hydrocarbons, Cyclic;Purines;Acetanilides;Hydroxy Acids;Alkaloids;Heterocyclic Compounds;Carboxylic Acids;Acetaminophen;Acids, Carbocyclic;Benzoates;Substances and Cells (CHEM);Amides;Hydroxybenzoates;Benzene Derivatives;Salicylates;Substances;Aspirin;Amines;Organic Chemicals;Hydrocarbons;Aniline Compounds;Anilides",,Hematologic Activity Alteration;Smooth Muscle Tone Alteration;Increased Central Nervous System Organized Electrical Activity;Organ System Specific Effects;Endocrine Activity Alteration;Nervous System Activity Alteration;Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Hemostasis Alteration;Decreased Collecting Duct Water Permeability;Decreased Thromboxane Production;Platelet Aggregation Alteration;Immunologic Activity Alteration;Renal/Urological Activity Alteration;Hypothalamic Endocrine Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Prostaglandin Production;Generalized Systemic Effects;Decreased Eicosanoid Production;Coagulation Activity Alteration;Decreased Platelet Activating Factor Production;Organized Electrical Activity Alteration;Decreased Immunologically Active Molecule Production;Bronchial Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Immunologically Active Molecule Production Alteration;Central Nervous System Stimulation;Bronchodilation;Increased Organized Electrical Activity;Decreased Lipid Derived Immunologically Active Molecule Production;Hemic/Lymphatic Activity Alteration;Decreased Coagulation Activity;Central Nervous System Activity Alteration;Collecting Duct Water Permeability Alteration;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Peripheral Nervous System Activity Alteration;Decreased Immunologic Activity;Electrical Activity Alteration;Decreased Platelet Aggregation,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Prostaglandin Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions;Enzyme Interactions,Enzyme Inhibitor;Enzyme Interaction;Platelet Aggregation Inhibitor;Central Nervous System Stimulant;Hematology Agent;Methylxanthine;Chemical Structure;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC);Nervous System Agent,"PSYCHOANALEPTICS;ANTITHROMBOTIC AGENTS;ANALGESICS;STOMATOLOGICAL PREPARATIONS;Anilides;Other agents for local oral treatment;Salicylic acid and derivatives;BLOOD AND BLOOD FORMING ORGANS;PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS;ALIMENTARY TRACT AND METABOLISM;Platelet aggregation inhibitors excl. heparin;DERMATOLOGICALS;Other dermatologicals;OTHER DERMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Xanthine derivatives;NERVOUS SYSTEM;OTHER ANALGESICS AND ANTIPYRETICS",,"Ischemia;Stroke;Infarction;Body Temperature Changes;Cardiovascular Diseases;Vascular Diseases;Signs and Symptoms;Pain;Myocardial Ischemia;Neurologic Manifestations;Hypertension;Pregnancy Complications;Ischemic Attack, Transient;Fever;Pathological Conditions, Signs and Symptoms;Hypertension, Pregnancy-Induced;Brain Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Myocardial Infarction;Pre-Eclampsia;Brain Infarction;Heart Diseases;Cerebral Infarction;Nervous System Diseases;Necrosis;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Pathologic Processes;Brain Ischemia;Cerebrovascular Disorders",,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;NON-OPIOID ANALGESICS;ANALGESICS;VA CLASSES,,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Xanthines;Substances;Substances and Cells (CHEM);Purines;Purinones;Alkaloids",,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
70,15,Concomitant Medications,Generic Name,RxNorm,Fosinopril,Fosinopril Oral Tablet [Monopril],367691.0,Fosinopril Oral Tablet [Monopril],50166.0,50166.0,50166,False,Hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Enzyme inhibitor-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Amino acid derivative-containing product;Medicinal product categorized by structure,Therapeutic Uses;Angiotensin-Converting Enzyme Inhibitors;Enzyme Inhibitors;MeSH Pharmacologic Actions (MESHPA);Antihypertensive Agents;Cardiovascular Agents;Molecular Mechanisms of Pharmacological Action;Protease Inhibitors,"Endocrine System Diseases;Angioedema;Skin Diseases, Vascular;Reproduction;Cardiovascular Diseases;Vascular Diseases;Urticaria;Hypotension;Pregnancy;Skin and Connective Tissue Diseases;Chemically-Induced Disorders;Hypersensitivity;Disease;Adrenocortical Hyperfunction;Drug Hypersensitivity;Life Phases, Behavior Mechanisms and Physiologic States;Drug-Related Side Effects and Adverse Reactions;Hyperaldosteronism;Immune System Diseases;Adrenal Gland Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Reproductive Physiological Phenomena;Skin Diseases","Endocrine System Diseases;Male Urogenital Diseases;Diabetes Complications;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Vascular Diseases;Diabetic Nephropathies;Urologic Diseases;Hypertension;Ventricular Dysfunction, Left;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Heart Diseases;Heart Failure;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction","Amino Acids;Phosphorus Acids;Inorganic Chemicals;Imino Acids;Acids, Noncarboxylic;Imines;Fosinopril;Organophosphorus Compounds;Carboxylic Acids;Substances and Cells (CHEM);Acids, Acyclic;Acids;Phosphorus Compounds;Amino Acids, Cyclic;Proline;Substances;Organic Chemicals;Amino Acids, Peptides, and Proteins;Phosphinic Acids",,Immunologically Active Molecule Degradation Alteration;Hematologic Activity Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Increased Renal Na+ Excretion;Physiologic Effect (PE);Blood & Lymphatic Fluid Function Alteration;Renal Ion Transport Alteration;Decreased Renal Ion Excretion;Decreased Renal K+ Excretion;Decreased Immunologically Active Molecule Degradation;Decreased Blood Pressure;Immunologic Activity Alteration;Renal Arterial Vasodilation;Renal/Urological Activity Alteration;Generalized Systemic Effects;Arterial Vasodilation;Vasodilation;Cardiovascular Activity Alteration;Decreased Bradykinin Degradation;Vascular Tone Alteration;Decreased Intravascular Volume;Hemic/Lymphatic Activity Alteration;Adrenal Cortical Activity Alteration;Decreased Kinin Degradation;Blood Pressure Alteration;Intravascular Volume Alteration;Decreased Mineralocorticoid Secretion;Decreased Immunologic Activity;Vascular Alterations;Increased Renal Ion Excretion,Angiotensin-converting Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Inhibitors;Protease Inhibitors;Enzyme Interactions,Angiotensin Converting Enzyme Inhibitor;Cardiovascular Agent;Enzyme Inhibitor;Enzyme Interaction;Protease Inhibitor;Anti-infective;Antimicrobial;Established Pharmacologic Class (EPC),"ACE INHIBITORS, PLAIN;ACE inhibitors, plain;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM",,"Endocrine System Diseases;Male Urogenital Diseases;Diabetes Complications;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Diabetic Nephropathies;Urologic Diseases;Pathological Conditions, Anatomical;Ventricular Dysfunction, Left;Pathological Conditions, Signs and Symptoms;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Hypertrophy, Left Ventricular;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Hypertrophy;Heart Diseases;Cardiomegaly;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ventricular Dysfunction",,ANTIHYPERTENSIVE COMBINATIONS;ACE INHIBITORS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,ACE INHIBITORS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,,,,Angiotensin-converting Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Inhibitors;Protease Inhibitors;Enzyme Interactions,,,
71,15,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine (Pfizer),,,,,2468230.0,2468230,True,,,,,,"mRNA Vaccines;Vaccines;Complex Mixtures;Viral Vaccines;Substances;Recombinant Proteins;BNT162 Vaccine;Biological Products;Proteins;Vaccines, Synthetic;Substances and Cells (CHEM);Biological Factors;Amino Acids, Peptides, and Proteins;COVID-19 Vaccines;Antigens;Nucleic Acid-Based Vaccines",,,,,,,,,IMMUNOLOGICAL AGENTS;VA CLASSES;VACCINES,IMMUNOLOGICAL AGENTS;VA CLASSES;VACCINES,,,,,,,,
72,18,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine (Pfizer),,,,,2468230.0,2468230,True,,,,,,"mRNA Vaccines;Vaccines;Complex Mixtures;Viral Vaccines;Substances;Recombinant Proteins;BNT162 Vaccine;Biological Products;Proteins;Vaccines, Synthetic;Substances and Cells (CHEM);Biological Factors;Amino Acids, Peptides, and Proteins;COVID-19 Vaccines;Antigens;Nucleic Acid-Based Vaccines",,,,,,,,,IMMUNOLOGICAL AGENTS;VA CLASSES;VACCINES,IMMUNOLOGICAL AGENTS;VA CLASSES;VACCINES,,,,,,,,
73,16,Concomitant Medications,Generic Name,RxNorm,Zyrtec,ZyrTEC,58930.0,ZyrTEC,58930.0,58930.0,58930,False,Medicinal product categorized by disposition;Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product,Piperazine and/or piperazine derivative-containing product;Medicinal product categorized by structure,"Histamine Agents;Histamine H1 Antagonists, Non-Sedating;Therapeutic Uses;Neurotransmitter Agents;Anti-Allergic Agents;MeSH Pharmacologic Actions (MESHPA);Histamine H1 Antagonists;Physiological Effects of Drugs;Molecular Mechanisms of Pharmacological Action;Histamine Antagonists","Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Respiratory Tract Infections;Respiratory Hypersensitivity;Rhinitis;Nose Diseases;Skin Diseases, Vascular;Hypersensitivity;Disease;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Rhinitis, Allergic;Immune System Diseases;Skin and Connective Tissue Diseases;Infections;Urticaria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Rhinitis, Allergic, Perennial;Skin Diseases","Heterocyclic Compounds;Hydroxyzine;Substances;Cetirizine;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Piperazines",,Immunologically Active Molecule Activity Alteration;Decreased Immunologically Active Molecule Activity;Organ System Specific Effects;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Histamine Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Decreased Immunologically Active Biogenic Amine Activity;Decreased Histamine Activity;Generalized Systemic Effects,Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Antagonists;Receptor Interactions;Histamine Receptor Interactions;Histamine H1 Receptor Antagonists,Histamine-1 Receptor Antagonist;Receptor Interaction;Receptor Antagonist;Established Pharmacologic Class (EPC),Other antiallergics;RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;SENSORY ORGANS;DECONGESTANTS AND ANTIALLERGICS;OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);Piperazine derivatives,,,,"ANTIHISTAMINES;ANTIHISTAMINES,PIPERAZINE;VA CLASSES","ANTIHISTAMINES;ANTIHISTAMINES,PIPERAZINE;VA CLASSES",,,,,,,,
74,23,Concomitant Medications,Generic Name,RxNorm,zyrtec,Zyrtec,58930.0,Zyrtec,58930.0,58930.0,58930,False,Medicinal product categorized by disposition;Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product,Piperazine and/or piperazine derivative-containing product;Medicinal product categorized by structure,"Histamine Agents;Histamine H1 Antagonists, Non-Sedating;Therapeutic Uses;Neurotransmitter Agents;Anti-Allergic Agents;MeSH Pharmacologic Actions (MESHPA);Histamine H1 Antagonists;Physiological Effects of Drugs;Molecular Mechanisms of Pharmacological Action;Histamine Antagonists","Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Respiratory Tract Infections;Respiratory Hypersensitivity;Rhinitis;Nose Diseases;Skin Diseases, Vascular;Hypersensitivity;Disease;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Rhinitis, Allergic;Immune System Diseases;Skin and Connective Tissue Diseases;Infections;Urticaria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Rhinitis, Allergic, Perennial;Skin Diseases","Heterocyclic Compounds;Hydroxyzine;Substances;Cetirizine;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Piperazines",,Immunologically Active Molecule Activity Alteration;Decreased Immunologically Active Molecule Activity;Organ System Specific Effects;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Histamine Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Decreased Immunologically Active Biogenic Amine Activity;Decreased Histamine Activity;Generalized Systemic Effects,Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Antagonists;Receptor Interactions;Histamine Receptor Interactions;Histamine H1 Receptor Antagonists,Histamine-1 Receptor Antagonist;Receptor Interaction;Receptor Antagonist;Established Pharmacologic Class (EPC),Other antiallergics;RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;SENSORY ORGANS;DECONGESTANTS AND ANTIALLERGICS;OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);Piperazine derivatives,,,,"ANTIHISTAMINES;ANTIHISTAMINES,PIPERAZINE;VA CLASSES","ANTIHISTAMINES;ANTIHISTAMINES,PIPERAZINE;VA CLASSES",,,,,,,,
75,38,Concomitant Medications,Generic Name,RxNorm,Zyrtec,,,,58930.0,58930.0,58930,False,Medicinal product categorized by disposition;Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product,Piperazine and/or piperazine derivative-containing product;Medicinal product categorized by structure,"Histamine Agents;Histamine H1 Antagonists, Non-Sedating;Therapeutic Uses;Neurotransmitter Agents;Anti-Allergic Agents;MeSH Pharmacologic Actions (MESHPA);Histamine H1 Antagonists;Physiological Effects of Drugs;Molecular Mechanisms of Pharmacological Action;Histamine Antagonists","Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Respiratory Tract Infections;Respiratory Hypersensitivity;Rhinitis;Nose Diseases;Skin Diseases, Vascular;Hypersensitivity;Disease;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Rhinitis, Allergic;Immune System Diseases;Skin and Connective Tissue Diseases;Infections;Urticaria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Rhinitis, Allergic, Perennial;Skin Diseases","Heterocyclic Compounds;Hydroxyzine;Substances;Cetirizine;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Piperazines",,Immunologically Active Molecule Activity Alteration;Decreased Immunologically Active Molecule Activity;Organ System Specific Effects;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Histamine Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Decreased Immunologically Active Biogenic Amine Activity;Decreased Histamine Activity;Generalized Systemic Effects,Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Antagonists;Receptor Interactions;Histamine Receptor Interactions;Histamine H1 Receptor Antagonists,Histamine-1 Receptor Antagonist;Receptor Interaction;Receptor Antagonist;Established Pharmacologic Class (EPC),Other antiallergics;RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;SENSORY ORGANS;DECONGESTANTS AND ANTIALLERGICS;OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);Piperazine derivatives,,,,"ANTIHISTAMINES;ANTIHISTAMINES,PIPERAZINE;VA CLASSES","ANTIHISTAMINES;ANTIHISTAMINES,PIPERAZINE;VA CLASSES",,,,,,,,
76,16,Concomitant Medications,Generic Name,RxNorm,Multivitamin,,,,,1234482.0,1234482,True,Medicinal product categorized by disposition;Hormone-containing product;Calcium regulating hormone-containing product,Alcohol-containing product;Organic acid and/or organic acid derivative-containing product;Retinoid-containing product;Nitrogen and/or nitrogen compound-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Metal and/or metallic compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Thiazole-containing product;Carbohydrate-containing product;Medicinal product categorized by structure;Azole-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Sulfur and/or sulfur compound-containing product;Vitamin A and/or vitamin A derivative-containing product;Terpene-containing product;Vitamin D and/or vitamin D derivative-containing product;Fluorine and/or fluorine compound-containing product;Sodium and/or sodium compound-containing product;Steroid-containing product,Therapeutic Uses;Cardiovascular Agents;Vitamins;Hypolipidemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Antimetabolites;Vitamin B Complex;Micronutrients;Radiation-Sensitizing Agents;Bone Density Conservation Agents;Cariostatic Agents;Lipid Regulating Agents;Photosensitizing Agents;Vasodilator Agents;Antioxidants;Dermatologic Agents;Protective Agents;Calcium-Regulating Hormones and Agents;Molecular Mechanisms of Pharmacological Action,"Chemically-Induced Disorders;Intestinal Diseases;Gastrointestinal Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemorrhage;Drug Hypersensitivity;Digestive System Diseases;Disease;Drug-Related Side Effects and Adverse Reactions;Duodenal Diseases;Peptic Ulcer;Cardiovascular Diseases;Stomach Diseases;Vascular Diseases;Pathological Conditions, Signs and Symptoms;Liver Diseases;Pathologic Processes;Hypotension","Brain Diseases, Metabolic;Dry Eye Syndromes;Diabetes Complications;Rickets;Inflammatory Bowel Diseases;Common Cold;Nutritional and Metabolic Diseases;Phosphorus Metabolism Disorders;Signs and Symptoms;Mental Disorders;Demyelinating Autoimmune Diseases, CNS;Vitamin E Deficiency;Chronic Disease;Neurotoxicity Syndromes;Substance-Related Disorders;Neurologic Manifestations;Digestive System Diseases;Conjunctival Diseases;Metabolic Diseases;Kidney Diseases;Movement Disorders;Alcohol-Related Disorders;Amino Acid Metabolism, Inborn Errors;Rickets, Hypophosphatemic;Gastroenteritis;Anemia, Macrocytic;Night Blindness;Vitamin D Deficiency;Methemoglobinemia;Hypercholesterolemia;Anemia, Hemolytic;Peripheral Vascular Diseases;Metal Metabolism, Inborn Errors;Nervous System Diseases;Hemostatic Disorders;Psoriasis;Female Urogenital Diseases;Neuromuscular Diseases;Dementia;Central Nervous System Diseases;Lacrimal Apparatus Diseases;Photosensitivity Disorders;Lung Diseases;Calcium Metabolism Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Poisoning;Hemorrhagic Disorders;Respiratory Tract Neoplasms;Urologic Diseases;Hypertriglyceridemia;Hypoparathyroidism;Wernicke Encephalopathy;Diabetes Mellitus;Dyskinesia, Drug-Induced;Lipid Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Vitamin B 12 Deficiency;Anemia, Megaloblastic;Renal Insufficiency, Chronic;Neurodegenerative Diseases;Tyrosinemias;Anemia, Pernicious;Bone Diseases, Metabolic;Kidney Failure, Chronic;Respiratory Tract Infections;Drug-Related Side Effects and Adverse Reactions;Alcoholic Neuropathy;Metabolism, Inborn Errors;Renal Tubular Transport, Inborn Errors;Pellagra;Skin Diseases;Endocrine System Diseases;Autoimmune Diseases of the Nervous System;Vitamin A Deficiency;Skin Diseases, Papulosquamous;Sensation Disorders;Vascular Diseases;Bone Diseases;Brain Diseases, Metabolic, Inborn;Ascorbic Acid Deficiency;Dermatitis;Peripheral Nervous System Diseases;Virus Diseases;Gastrointestinal Diseases;Musculoskeletal Diseases;Eye Diseases;Alzheimer Disease;Wounds and Injuries;Dyskinesias;Skin and Connective Tissue Diseases;Disease Attributes;Pathological Conditions, Signs and Symptoms;Parathyroid Diseases;Brain Diseases;Neurocognitive Disorders;Vitamin B 6 Deficiency;Alcohol-Induced Disorders;Wounds, Penetrating;Dyslipidemias;Hemic and Lymphatic Diseases;Neoplasms by Site;Alcohol-Induced Disorders, Nervous System;Diabetic Neuropathies;Hyperlipidemias;Thiamine Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Lung Neoplasms;Malnutrition;Pathologic Processes;Genetic Diseases, Inborn;Vitamin B Deficiency;Leukoencephalopathies;Male Urogenital Diseases;Hypophosphatemia;Renal Insufficiency;Multiple Sclerosis;Respiratory Tract Diseases;Tauopathies;Neoplasms;Anemia;Nutrition Disorders;Deficiency Diseases;Osteoporosis;Autoimmune Diseases;Beriberi;Glucose Metabolism Disorders;Crohn Disease;Avitaminosis;Chemically-Induced Disorders;Skin Neoplasms;Intestinal Diseases;Thoracic Neoplasms;Disease;RNA Virus Infections;Infections;Hypophosphatemia, Familial;Scurvy;Demyelinating Diseases;Polyneuropathies;Familial Hypophosphatemic Rickets;Immune System Diseases;Xerophthalmia;Picornaviridae Infections;Riboflavin Deficiency;Urogenital Diseases;Hematologic Diseases;Vision Disorders","Fluorine Compounds;Hydrocarbons, Alicyclic;Cyclohexenes;Ions;Cholestanes;Specialty Uses of Chemicals;Biological Factors;Vitamin D;Heterocyclic Compounds, 2-Ring;Sterols;Corrinoids;Heterocyclic Compounds;Sodium Fluoride;Electrolytes;Polycyclic Compounds;Thiazoles;Picolines;Polyenes;Diterpenes;Fluorides;Lipids;Fused-Ring Compounds;Secosteroids;Heterocyclic Compounds, 4 or More Rings;Cyclohexanes;Heterocyclic Compounds, 1-Ring;Membrane Lipids;Carotenoids;Vitamin E;Benzopyrans;Cycloparaffins;Steroids;Anions;Niacin;Cholecalciferol;Enzymes and Coenzymes;Pteridines;Hydrofluoric Acid;Ascorbic Acid;Substances and Cells (CHEM);Biomedical and Dental Materials;Azoles;Acids;Riboflavin;Vitamin A;Tetrapyrroles;Nicotinic Acids;Vitamin B 6;Pyrans;Inorganic Chemicals;Heterocyclic Compounds, 3-Ring;Carboxylic Acids;Macrocyclic Compounds;Thiamine;Pyridines;Sodium Compounds;Substances;Alkenes;Protective Agents;Flavins;Terpenes;Vitamin B 12;Pyrroles;Sulfur Compounds;Pigments, Biological;Heterocyclic Compounds, Fused-Ring;Pyrimidines;Hydrocarbons, Cyclic;Acids, Noncarboxylic;Hydrocarbons, Acyclic;Retinoids;Cholestenes;Hydroxy Acids;Coenzymes;Cariostatic Agents;Acids, Acyclic;Carbohydrates;Acids, Heterocyclic;Sugar Acids;Organic Chemicals;Hydrocarbons;Chemical Actions and Uses",,Cholesterol Metabolism Alteration;Organ System Specific Effects;Physiologic Effect (PE);Bone Formation Stimulation;Carbohydrate Metabolism Alteration;Renal Ion Transport Alteration;Decreased Renal Ion Excretion;Small Intestine Fluid/Electrolyte Alteration;Decreased Renal Ca++ Excretion;Decreased Cholesterol Synthesis;Bone Formation Alteration;Renal/Urological Activity Alteration;Cellular Activity Alteration;Metabolic Activity Alteration;Vitamin Uptake and Modification Alteration;Generalized Systemic Effects;Digestive/GI System Activity Alteration;Bone Alteration;Sterol Metabolism Alteration;Glucose Metabolism Alteration;Small Intestine Fluid/Electrolyte Absorption Alteration;Cholesterol Synthesis Alteration;Lipid Metabolism Alteration;Musculoskeletal Activity Alteration;Stimulation Small Intestine Fluid/Electrolyte Absorption;Decreased Vitamin Uptake and Modification,Mechanism of Action (MoA);Oxidation-Reduction Activity;Reduction Activity;Free Radical Scavenging Activity;Unknown Cellular or Molecular Interaction;Physiochemical Activity;Enzyme Interactions,Hormone;Vitamin D;Nicotinic Acid;Vitamin A;Vitamin C;Established Pharmacologic Class (EPC);Chemical Structure;Vitamin B12;Vitamin or Mineral,"Caries prophylactic agents;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;Other plain vitamin preparations;LIPID MODIFYING AGENTS, PLAIN;OPHTHALMOLOGICALS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;CARDIOVASCULAR SYSTEM;Nicotinic acid and derivatives;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;Vitamin B1, plain;BLOOD AND BLOOD FORMING ORGANS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;DERMATOLOGICALS;Organic acids;Retinoids for topical use in acne;Anatomical Therapeutic Chemical (ATC1-4);ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;OTHER PLAIN VITAMIN PREPARATIONS;GENITO URINARY SYSTEM AND SEX HORMONES;VITAMINS;Fluoride;LIPID MODIFYING AGENTS;Ascorbic acid (vitamin C), plain;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Vitamin D and analogues;VITAMIN B12 AND FOLIC ACID;Vitamin B12 (cyanocobalamin and analogues);NASAL PREPARATIONS;Other nasal preparations;STOMATOLOGICAL PREPARATIONS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;RESPIRATORY SYSTEM;SENSORY ORGANS;MINERAL SUPPLEMENTS;PERIPHERAL VASODILATORS;ANTIANEMIC PREPARATIONS;Vitamin A, plain",,"Vitamin A Deficiency;Lung Diseases;Tauopathies;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Thoracic Injuries;Cardiovascular Diseases;Anemia;Poisoning;Signs and Symptoms;Dental Plaque;Mental Disorders;Bronchopulmonary Dysplasia;Vitamin E Deficiency;Nutrition Disorders;Deficiency Diseases;Neurotoxicity Syndromes;Coronary Disease;Myocardial Ischemia;Mouth Diseases;Tooth Diseases;Neurologic Manifestations;Lung Injury;Alzheimer Disease;Infant, Newborn, Diseases;Wounds and Injuries;Dyskinesias;Pathological Conditions, Signs and Symptoms;Brain Diseases;Coronary Artery Disease;Dyskinesia, Drug-Induced;Avitaminosis;Infant, Premature, Diseases;Chemically-Induced Disorders;Neurocognitive Disorders;Vitamin B 12 Deficiency;Movement Disorders;Vitamin B 6 Deficiency;Periodontal Diseases;Disease;Neurodegenerative Diseases;Tooth Demineralization;Arteriosclerosis;Vascular Diseases;Arterial Occlusive Diseases;Stomatognathic Diseases;Hemic and Lymphatic Diseases;Malnutrition;Anemia, Hemolytic;Heart Diseases;Ventilator-Induced Lung Injury;Nervous System Diseases;Drug-Related Side Effects and Adverse Reactions;Tooth Loss;Riboflavin Deficiency;Dementia;Dental Caries;Dental Deposits;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Hematologic Diseases;Vitamin B Deficiency",,,,,"Tetrapyrroles;Hydrocarbons, Alicyclic;Nicotinic Acids;Heterocyclic Compounds, 4 or More Rings;Cyclohexenes;Cyclohexanes;Terpenes;Heterocyclic Compounds, 1-Ring;Vitamin B 12;Biological Factors;Pyrroles;Carotenoids;Pigments, Biological;Heterocyclic Compounds, Fused-Ring;Vitamin D;Hydrocarbons, Cyclic;Cycloparaffins;Steroids;Hydrocarbons, Acyclic;Corrinoids;Retinoids;Hydroxy Acids;Heterocyclic Compounds;Carboxylic Acids;Polycyclic Compounds;Ascorbic Acid;Polyenes;Substances and Cells (CHEM);Azoles;Macrocyclic Compounds;Acids, Acyclic;Diterpenes;Pyridines;Carbohydrates;Acids, Heterocyclic;Substances;Alkenes;Sugar Acids;Organic Chemicals;Hydrocarbons;Fused-Ring Compounds;Secosteroids;Vitamin A",,"Intestinal Diseases;Gastrointestinal Diseases;Malabsorption Syndromes;Digestive System Diseases;Disease;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Metabolic Diseases",,,,"Hyperoxaluria;Male Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Flatulence;Female Urogenital Diseases and Pregnancy Complications;Signs and Symptoms, Digestive;Kidney Diseases;Urologic Diseases;Disease;Skin Manifestations;Female Urogenital Diseases;Diarrhea;Signs and Symptoms;Urogenital Diseases;Pathological Conditions, Signs and Symptoms;Flushing"
77,18,Concomitant Medications,Generic Name,RxNorm,multivitamin,,,,,1234482.0,1234482,True,Medicinal product categorized by disposition;Hormone-containing product;Calcium regulating hormone-containing product,Alcohol-containing product;Organic acid and/or organic acid derivative-containing product;Retinoid-containing product;Nitrogen and/or nitrogen compound-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Metal and/or metallic compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Thiazole-containing product;Carbohydrate-containing product;Medicinal product categorized by structure;Azole-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Sulfur and/or sulfur compound-containing product;Vitamin A and/or vitamin A derivative-containing product;Terpene-containing product;Vitamin D and/or vitamin D derivative-containing product;Fluorine and/or fluorine compound-containing product;Sodium and/or sodium compound-containing product;Steroid-containing product,Therapeutic Uses;Cardiovascular Agents;Vitamins;Hypolipidemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Antimetabolites;Vitamin B Complex;Micronutrients;Radiation-Sensitizing Agents;Bone Density Conservation Agents;Cariostatic Agents;Lipid Regulating Agents;Photosensitizing Agents;Vasodilator Agents;Antioxidants;Dermatologic Agents;Protective Agents;Calcium-Regulating Hormones and Agents;Molecular Mechanisms of Pharmacological Action,"Chemically-Induced Disorders;Intestinal Diseases;Gastrointestinal Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemorrhage;Drug Hypersensitivity;Digestive System Diseases;Disease;Drug-Related Side Effects and Adverse Reactions;Duodenal Diseases;Peptic Ulcer;Cardiovascular Diseases;Stomach Diseases;Vascular Diseases;Pathological Conditions, Signs and Symptoms;Liver Diseases;Pathologic Processes;Hypotension","Brain Diseases, Metabolic;Dry Eye Syndromes;Diabetes Complications;Rickets;Inflammatory Bowel Diseases;Common Cold;Nutritional and Metabolic Diseases;Phosphorus Metabolism Disorders;Signs and Symptoms;Mental Disorders;Demyelinating Autoimmune Diseases, CNS;Vitamin E Deficiency;Chronic Disease;Neurotoxicity Syndromes;Substance-Related Disorders;Neurologic Manifestations;Digestive System Diseases;Conjunctival Diseases;Metabolic Diseases;Kidney Diseases;Movement Disorders;Alcohol-Related Disorders;Amino Acid Metabolism, Inborn Errors;Rickets, Hypophosphatemic;Gastroenteritis;Anemia, Macrocytic;Night Blindness;Vitamin D Deficiency;Methemoglobinemia;Hypercholesterolemia;Anemia, Hemolytic;Peripheral Vascular Diseases;Metal Metabolism, Inborn Errors;Nervous System Diseases;Hemostatic Disorders;Psoriasis;Female Urogenital Diseases;Neuromuscular Diseases;Dementia;Central Nervous System Diseases;Lacrimal Apparatus Diseases;Photosensitivity Disorders;Lung Diseases;Calcium Metabolism Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Poisoning;Hemorrhagic Disorders;Respiratory Tract Neoplasms;Urologic Diseases;Hypertriglyceridemia;Hypoparathyroidism;Wernicke Encephalopathy;Diabetes Mellitus;Dyskinesia, Drug-Induced;Lipid Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Vitamin B 12 Deficiency;Anemia, Megaloblastic;Renal Insufficiency, Chronic;Neurodegenerative Diseases;Tyrosinemias;Anemia, Pernicious;Bone Diseases, Metabolic;Kidney Failure, Chronic;Respiratory Tract Infections;Drug-Related Side Effects and Adverse Reactions;Alcoholic Neuropathy;Metabolism, Inborn Errors;Renal Tubular Transport, Inborn Errors;Pellagra;Skin Diseases;Endocrine System Diseases;Autoimmune Diseases of the Nervous System;Vitamin A Deficiency;Skin Diseases, Papulosquamous;Sensation Disorders;Vascular Diseases;Bone Diseases;Brain Diseases, Metabolic, Inborn;Ascorbic Acid Deficiency;Dermatitis;Peripheral Nervous System Diseases;Virus Diseases;Gastrointestinal Diseases;Musculoskeletal Diseases;Eye Diseases;Alzheimer Disease;Wounds and Injuries;Dyskinesias;Skin and Connective Tissue Diseases;Disease Attributes;Pathological Conditions, Signs and Symptoms;Parathyroid Diseases;Brain Diseases;Neurocognitive Disorders;Vitamin B 6 Deficiency;Alcohol-Induced Disorders;Wounds, Penetrating;Dyslipidemias;Hemic and Lymphatic Diseases;Neoplasms by Site;Alcohol-Induced Disorders, Nervous System;Diabetic Neuropathies;Hyperlipidemias;Thiamine Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Lung Neoplasms;Malnutrition;Pathologic Processes;Genetic Diseases, Inborn;Vitamin B Deficiency;Leukoencephalopathies;Male Urogenital Diseases;Hypophosphatemia;Renal Insufficiency;Multiple Sclerosis;Respiratory Tract Diseases;Tauopathies;Neoplasms;Anemia;Nutrition Disorders;Deficiency Diseases;Osteoporosis;Autoimmune Diseases;Beriberi;Glucose Metabolism Disorders;Crohn Disease;Avitaminosis;Chemically-Induced Disorders;Skin Neoplasms;Intestinal Diseases;Thoracic Neoplasms;Disease;RNA Virus Infections;Infections;Hypophosphatemia, Familial;Scurvy;Demyelinating Diseases;Polyneuropathies;Familial Hypophosphatemic Rickets;Immune System Diseases;Xerophthalmia;Picornaviridae Infections;Riboflavin Deficiency;Urogenital Diseases;Hematologic Diseases;Vision Disorders","Fluorine Compounds;Hydrocarbons, Alicyclic;Cyclohexenes;Ions;Cholestanes;Specialty Uses of Chemicals;Biological Factors;Vitamin D;Heterocyclic Compounds, 2-Ring;Sterols;Corrinoids;Heterocyclic Compounds;Sodium Fluoride;Electrolytes;Polycyclic Compounds;Thiazoles;Picolines;Polyenes;Diterpenes;Fluorides;Lipids;Fused-Ring Compounds;Secosteroids;Heterocyclic Compounds, 4 or More Rings;Cyclohexanes;Heterocyclic Compounds, 1-Ring;Membrane Lipids;Carotenoids;Vitamin E;Benzopyrans;Cycloparaffins;Steroids;Anions;Niacin;Cholecalciferol;Enzymes and Coenzymes;Pteridines;Hydrofluoric Acid;Ascorbic Acid;Substances and Cells (CHEM);Biomedical and Dental Materials;Azoles;Acids;Riboflavin;Vitamin A;Tetrapyrroles;Nicotinic Acids;Vitamin B 6;Pyrans;Inorganic Chemicals;Heterocyclic Compounds, 3-Ring;Carboxylic Acids;Macrocyclic Compounds;Thiamine;Pyridines;Sodium Compounds;Substances;Alkenes;Protective Agents;Flavins;Terpenes;Vitamin B 12;Pyrroles;Sulfur Compounds;Pigments, Biological;Heterocyclic Compounds, Fused-Ring;Pyrimidines;Hydrocarbons, Cyclic;Acids, Noncarboxylic;Hydrocarbons, Acyclic;Retinoids;Cholestenes;Hydroxy Acids;Coenzymes;Cariostatic Agents;Acids, Acyclic;Carbohydrates;Acids, Heterocyclic;Sugar Acids;Organic Chemicals;Hydrocarbons;Chemical Actions and Uses",,Cholesterol Metabolism Alteration;Organ System Specific Effects;Physiologic Effect (PE);Bone Formation Stimulation;Carbohydrate Metabolism Alteration;Renal Ion Transport Alteration;Decreased Renal Ion Excretion;Small Intestine Fluid/Electrolyte Alteration;Decreased Renal Ca++ Excretion;Decreased Cholesterol Synthesis;Bone Formation Alteration;Renal/Urological Activity Alteration;Cellular Activity Alteration;Metabolic Activity Alteration;Vitamin Uptake and Modification Alteration;Generalized Systemic Effects;Digestive/GI System Activity Alteration;Bone Alteration;Sterol Metabolism Alteration;Glucose Metabolism Alteration;Small Intestine Fluid/Electrolyte Absorption Alteration;Cholesterol Synthesis Alteration;Lipid Metabolism Alteration;Musculoskeletal Activity Alteration;Stimulation Small Intestine Fluid/Electrolyte Absorption;Decreased Vitamin Uptake and Modification,Mechanism of Action (MoA);Oxidation-Reduction Activity;Reduction Activity;Free Radical Scavenging Activity;Unknown Cellular or Molecular Interaction;Physiochemical Activity;Enzyme Interactions,Hormone;Vitamin D;Nicotinic Acid;Vitamin A;Vitamin C;Established Pharmacologic Class (EPC);Chemical Structure;Vitamin B12;Vitamin or Mineral,"Caries prophylactic agents;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;Other plain vitamin preparations;LIPID MODIFYING AGENTS, PLAIN;OPHTHALMOLOGICALS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;CARDIOVASCULAR SYSTEM;Nicotinic acid and derivatives;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;Vitamin B1, plain;BLOOD AND BLOOD FORMING ORGANS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;DERMATOLOGICALS;Organic acids;Retinoids for topical use in acne;Anatomical Therapeutic Chemical (ATC1-4);ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;OTHER PLAIN VITAMIN PREPARATIONS;GENITO URINARY SYSTEM AND SEX HORMONES;VITAMINS;Fluoride;LIPID MODIFYING AGENTS;Ascorbic acid (vitamin C), plain;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Vitamin D and analogues;VITAMIN B12 AND FOLIC ACID;Vitamin B12 (cyanocobalamin and analogues);NASAL PREPARATIONS;Other nasal preparations;STOMATOLOGICAL PREPARATIONS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;RESPIRATORY SYSTEM;SENSORY ORGANS;MINERAL SUPPLEMENTS;PERIPHERAL VASODILATORS;ANTIANEMIC PREPARATIONS;Vitamin A, plain",,"Vitamin A Deficiency;Lung Diseases;Tauopathies;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Thoracic Injuries;Cardiovascular Diseases;Anemia;Poisoning;Signs and Symptoms;Dental Plaque;Mental Disorders;Bronchopulmonary Dysplasia;Vitamin E Deficiency;Nutrition Disorders;Deficiency Diseases;Neurotoxicity Syndromes;Coronary Disease;Myocardial Ischemia;Mouth Diseases;Tooth Diseases;Neurologic Manifestations;Lung Injury;Alzheimer Disease;Infant, Newborn, Diseases;Wounds and Injuries;Dyskinesias;Pathological Conditions, Signs and Symptoms;Brain Diseases;Coronary Artery Disease;Dyskinesia, Drug-Induced;Avitaminosis;Infant, Premature, Diseases;Chemically-Induced Disorders;Neurocognitive Disorders;Vitamin B 12 Deficiency;Movement Disorders;Vitamin B 6 Deficiency;Periodontal Diseases;Disease;Neurodegenerative Diseases;Tooth Demineralization;Arteriosclerosis;Vascular Diseases;Arterial Occlusive Diseases;Stomatognathic Diseases;Hemic and Lymphatic Diseases;Malnutrition;Anemia, Hemolytic;Heart Diseases;Ventilator-Induced Lung Injury;Nervous System Diseases;Drug-Related Side Effects and Adverse Reactions;Tooth Loss;Riboflavin Deficiency;Dementia;Dental Caries;Dental Deposits;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Hematologic Diseases;Vitamin B Deficiency",,,,,"Tetrapyrroles;Hydrocarbons, Alicyclic;Nicotinic Acids;Heterocyclic Compounds, 4 or More Rings;Cyclohexenes;Cyclohexanes;Terpenes;Heterocyclic Compounds, 1-Ring;Vitamin B 12;Biological Factors;Pyrroles;Carotenoids;Pigments, Biological;Heterocyclic Compounds, Fused-Ring;Vitamin D;Hydrocarbons, Cyclic;Cycloparaffins;Steroids;Hydrocarbons, Acyclic;Corrinoids;Retinoids;Hydroxy Acids;Heterocyclic Compounds;Carboxylic Acids;Polycyclic Compounds;Ascorbic Acid;Polyenes;Substances and Cells (CHEM);Azoles;Macrocyclic Compounds;Acids, Acyclic;Diterpenes;Pyridines;Carbohydrates;Acids, Heterocyclic;Substances;Alkenes;Sugar Acids;Organic Chemicals;Hydrocarbons;Fused-Ring Compounds;Secosteroids;Vitamin A",,"Intestinal Diseases;Gastrointestinal Diseases;Malabsorption Syndromes;Digestive System Diseases;Disease;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Metabolic Diseases",,,,"Hyperoxaluria;Male Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Flatulence;Female Urogenital Diseases and Pregnancy Complications;Signs and Symptoms, Digestive;Kidney Diseases;Urologic Diseases;Disease;Skin Manifestations;Female Urogenital Diseases;Diarrhea;Signs and Symptoms;Urogenital Diseases;Pathological Conditions, Signs and Symptoms;Flushing"
78,43,Concomitant Medications,Generic Name,RxNorm,Multivitamin,,,,,1234482.0,1234482,True,Medicinal product categorized by disposition;Hormone-containing product;Calcium regulating hormone-containing product,Alcohol-containing product;Organic acid and/or organic acid derivative-containing product;Retinoid-containing product;Nitrogen and/or nitrogen compound-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Metal and/or metallic compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Thiazole-containing product;Carbohydrate-containing product;Medicinal product categorized by structure;Azole-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Sulfur and/or sulfur compound-containing product;Vitamin A and/or vitamin A derivative-containing product;Terpene-containing product;Vitamin D and/or vitamin D derivative-containing product;Fluorine and/or fluorine compound-containing product;Sodium and/or sodium compound-containing product;Steroid-containing product,Therapeutic Uses;Cardiovascular Agents;Vitamins;Hypolipidemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Antimetabolites;Vitamin B Complex;Micronutrients;Radiation-Sensitizing Agents;Bone Density Conservation Agents;Cariostatic Agents;Lipid Regulating Agents;Photosensitizing Agents;Vasodilator Agents;Antioxidants;Dermatologic Agents;Protective Agents;Calcium-Regulating Hormones and Agents;Molecular Mechanisms of Pharmacological Action,"Chemically-Induced Disorders;Intestinal Diseases;Gastrointestinal Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemorrhage;Drug Hypersensitivity;Digestive System Diseases;Disease;Drug-Related Side Effects and Adverse Reactions;Duodenal Diseases;Peptic Ulcer;Cardiovascular Diseases;Stomach Diseases;Vascular Diseases;Pathological Conditions, Signs and Symptoms;Liver Diseases;Pathologic Processes;Hypotension","Brain Diseases, Metabolic;Dry Eye Syndromes;Diabetes Complications;Rickets;Inflammatory Bowel Diseases;Common Cold;Nutritional and Metabolic Diseases;Phosphorus Metabolism Disorders;Signs and Symptoms;Mental Disorders;Demyelinating Autoimmune Diseases, CNS;Vitamin E Deficiency;Chronic Disease;Neurotoxicity Syndromes;Substance-Related Disorders;Neurologic Manifestations;Digestive System Diseases;Conjunctival Diseases;Metabolic Diseases;Kidney Diseases;Movement Disorders;Alcohol-Related Disorders;Amino Acid Metabolism, Inborn Errors;Rickets, Hypophosphatemic;Gastroenteritis;Anemia, Macrocytic;Night Blindness;Vitamin D Deficiency;Methemoglobinemia;Hypercholesterolemia;Anemia, Hemolytic;Peripheral Vascular Diseases;Metal Metabolism, Inborn Errors;Nervous System Diseases;Hemostatic Disorders;Psoriasis;Female Urogenital Diseases;Neuromuscular Diseases;Dementia;Central Nervous System Diseases;Lacrimal Apparatus Diseases;Photosensitivity Disorders;Lung Diseases;Calcium Metabolism Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Poisoning;Hemorrhagic Disorders;Respiratory Tract Neoplasms;Urologic Diseases;Hypertriglyceridemia;Hypoparathyroidism;Wernicke Encephalopathy;Diabetes Mellitus;Dyskinesia, Drug-Induced;Lipid Metabolism Disorders;Female Urogenital Diseases and Pregnancy Complications;Vitamin B 12 Deficiency;Anemia, Megaloblastic;Renal Insufficiency, Chronic;Neurodegenerative Diseases;Tyrosinemias;Anemia, Pernicious;Bone Diseases, Metabolic;Kidney Failure, Chronic;Respiratory Tract Infections;Drug-Related Side Effects and Adverse Reactions;Alcoholic Neuropathy;Metabolism, Inborn Errors;Renal Tubular Transport, Inborn Errors;Pellagra;Skin Diseases;Endocrine System Diseases;Autoimmune Diseases of the Nervous System;Vitamin A Deficiency;Skin Diseases, Papulosquamous;Sensation Disorders;Vascular Diseases;Bone Diseases;Brain Diseases, Metabolic, Inborn;Ascorbic Acid Deficiency;Dermatitis;Peripheral Nervous System Diseases;Virus Diseases;Gastrointestinal Diseases;Musculoskeletal Diseases;Eye Diseases;Alzheimer Disease;Wounds and Injuries;Dyskinesias;Skin and Connective Tissue Diseases;Disease Attributes;Pathological Conditions, Signs and Symptoms;Parathyroid Diseases;Brain Diseases;Neurocognitive Disorders;Vitamin B 6 Deficiency;Alcohol-Induced Disorders;Wounds, Penetrating;Dyslipidemias;Hemic and Lymphatic Diseases;Neoplasms by Site;Alcohol-Induced Disorders, Nervous System;Diabetic Neuropathies;Hyperlipidemias;Thiamine Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Lung Neoplasms;Malnutrition;Pathologic Processes;Genetic Diseases, Inborn;Vitamin B Deficiency;Leukoencephalopathies;Male Urogenital Diseases;Hypophosphatemia;Renal Insufficiency;Multiple Sclerosis;Respiratory Tract Diseases;Tauopathies;Neoplasms;Anemia;Nutrition Disorders;Deficiency Diseases;Osteoporosis;Autoimmune Diseases;Beriberi;Glucose Metabolism Disorders;Crohn Disease;Avitaminosis;Chemically-Induced Disorders;Skin Neoplasms;Intestinal Diseases;Thoracic Neoplasms;Disease;RNA Virus Infections;Infections;Hypophosphatemia, Familial;Scurvy;Demyelinating Diseases;Polyneuropathies;Familial Hypophosphatemic Rickets;Immune System Diseases;Xerophthalmia;Picornaviridae Infections;Riboflavin Deficiency;Urogenital Diseases;Hematologic Diseases;Vision Disorders","Fluorine Compounds;Hydrocarbons, Alicyclic;Cyclohexenes;Ions;Cholestanes;Specialty Uses of Chemicals;Biological Factors;Vitamin D;Heterocyclic Compounds, 2-Ring;Sterols;Corrinoids;Heterocyclic Compounds;Sodium Fluoride;Electrolytes;Polycyclic Compounds;Thiazoles;Picolines;Polyenes;Diterpenes;Fluorides;Lipids;Fused-Ring Compounds;Secosteroids;Heterocyclic Compounds, 4 or More Rings;Cyclohexanes;Heterocyclic Compounds, 1-Ring;Membrane Lipids;Carotenoids;Vitamin E;Benzopyrans;Cycloparaffins;Steroids;Anions;Niacin;Cholecalciferol;Enzymes and Coenzymes;Pteridines;Hydrofluoric Acid;Ascorbic Acid;Substances and Cells (CHEM);Biomedical and Dental Materials;Azoles;Acids;Riboflavin;Vitamin A;Tetrapyrroles;Nicotinic Acids;Vitamin B 6;Pyrans;Inorganic Chemicals;Heterocyclic Compounds, 3-Ring;Carboxylic Acids;Macrocyclic Compounds;Thiamine;Pyridines;Sodium Compounds;Substances;Alkenes;Protective Agents;Flavins;Terpenes;Vitamin B 12;Pyrroles;Sulfur Compounds;Pigments, Biological;Heterocyclic Compounds, Fused-Ring;Pyrimidines;Hydrocarbons, Cyclic;Acids, Noncarboxylic;Hydrocarbons, Acyclic;Retinoids;Cholestenes;Hydroxy Acids;Coenzymes;Cariostatic Agents;Acids, Acyclic;Carbohydrates;Acids, Heterocyclic;Sugar Acids;Organic Chemicals;Hydrocarbons;Chemical Actions and Uses",,Cholesterol Metabolism Alteration;Organ System Specific Effects;Physiologic Effect (PE);Bone Formation Stimulation;Carbohydrate Metabolism Alteration;Renal Ion Transport Alteration;Decreased Renal Ion Excretion;Small Intestine Fluid/Electrolyte Alteration;Decreased Renal Ca++ Excretion;Decreased Cholesterol Synthesis;Bone Formation Alteration;Renal/Urological Activity Alteration;Cellular Activity Alteration;Metabolic Activity Alteration;Vitamin Uptake and Modification Alteration;Generalized Systemic Effects;Digestive/GI System Activity Alteration;Bone Alteration;Sterol Metabolism Alteration;Glucose Metabolism Alteration;Small Intestine Fluid/Electrolyte Absorption Alteration;Cholesterol Synthesis Alteration;Lipid Metabolism Alteration;Musculoskeletal Activity Alteration;Stimulation Small Intestine Fluid/Electrolyte Absorption;Decreased Vitamin Uptake and Modification,Mechanism of Action (MoA);Oxidation-Reduction Activity;Reduction Activity;Free Radical Scavenging Activity;Unknown Cellular or Molecular Interaction;Physiochemical Activity;Enzyme Interactions,Hormone;Vitamin D;Nicotinic Acid;Vitamin A;Vitamin C;Established Pharmacologic Class (EPC);Chemical Structure;Vitamin B12;Vitamin or Mineral,"Caries prophylactic agents;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;OTHER OPHTHALMOLOGICALS;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;Other plain vitamin preparations;LIPID MODIFYING AGENTS, PLAIN;OPHTHALMOLOGICALS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;CARDIOVASCULAR SYSTEM;Nicotinic acid and derivatives;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;Vitamin B1, plain;BLOOD AND BLOOD FORMING ORGANS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;DERMATOLOGICALS;Organic acids;Retinoids for topical use in acne;Anatomical Therapeutic Chemical (ATC1-4);ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;OTHER PLAIN VITAMIN PREPARATIONS;GENITO URINARY SYSTEM AND SEX HORMONES;VITAMINS;Fluoride;LIPID MODIFYING AGENTS;Ascorbic acid (vitamin C), plain;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Vitamin D and analogues;VITAMIN B12 AND FOLIC ACID;Vitamin B12 (cyanocobalamin and analogues);NASAL PREPARATIONS;Other nasal preparations;STOMATOLOGICAL PREPARATIONS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;RESPIRATORY SYSTEM;SENSORY ORGANS;MINERAL SUPPLEMENTS;PERIPHERAL VASODILATORS;ANTIANEMIC PREPARATIONS;Vitamin A, plain",,"Vitamin A Deficiency;Lung Diseases;Tauopathies;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Thoracic Injuries;Cardiovascular Diseases;Anemia;Poisoning;Signs and Symptoms;Dental Plaque;Mental Disorders;Bronchopulmonary Dysplasia;Vitamin E Deficiency;Nutrition Disorders;Deficiency Diseases;Neurotoxicity Syndromes;Coronary Disease;Myocardial Ischemia;Mouth Diseases;Tooth Diseases;Neurologic Manifestations;Lung Injury;Alzheimer Disease;Infant, Newborn, Diseases;Wounds and Injuries;Dyskinesias;Pathological Conditions, Signs and Symptoms;Brain Diseases;Coronary Artery Disease;Dyskinesia, Drug-Induced;Avitaminosis;Infant, Premature, Diseases;Chemically-Induced Disorders;Neurocognitive Disorders;Vitamin B 12 Deficiency;Movement Disorders;Vitamin B 6 Deficiency;Periodontal Diseases;Disease;Neurodegenerative Diseases;Tooth Demineralization;Arteriosclerosis;Vascular Diseases;Arterial Occlusive Diseases;Stomatognathic Diseases;Hemic and Lymphatic Diseases;Malnutrition;Anemia, Hemolytic;Heart Diseases;Ventilator-Induced Lung Injury;Nervous System Diseases;Drug-Related Side Effects and Adverse Reactions;Tooth Loss;Riboflavin Deficiency;Dementia;Dental Caries;Dental Deposits;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Hematologic Diseases;Vitamin B Deficiency",,,,,"Tetrapyrroles;Hydrocarbons, Alicyclic;Nicotinic Acids;Heterocyclic Compounds, 4 or More Rings;Cyclohexenes;Cyclohexanes;Terpenes;Heterocyclic Compounds, 1-Ring;Vitamin B 12;Biological Factors;Pyrroles;Carotenoids;Pigments, Biological;Heterocyclic Compounds, Fused-Ring;Vitamin D;Hydrocarbons, Cyclic;Cycloparaffins;Steroids;Hydrocarbons, Acyclic;Corrinoids;Retinoids;Hydroxy Acids;Heterocyclic Compounds;Carboxylic Acids;Polycyclic Compounds;Ascorbic Acid;Polyenes;Substances and Cells (CHEM);Azoles;Macrocyclic Compounds;Acids, Acyclic;Diterpenes;Pyridines;Carbohydrates;Acids, Heterocyclic;Substances;Alkenes;Sugar Acids;Organic Chemicals;Hydrocarbons;Fused-Ring Compounds;Secosteroids;Vitamin A",,"Intestinal Diseases;Gastrointestinal Diseases;Malabsorption Syndromes;Digestive System Diseases;Disease;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Metabolic Diseases",,,,"Hyperoxaluria;Male Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Flatulence;Female Urogenital Diseases and Pregnancy Complications;Signs and Symptoms, Digestive;Kidney Diseases;Urologic Diseases;Disease;Skin Manifestations;Female Urogenital Diseases;Diarrhea;Signs and Symptoms;Urogenital Diseases;Pathological Conditions, Signs and Symptoms;Flushing"
79,17,Concomitant Medications,Generic Name,RxNorm,Aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,Medicinal product categorized by disposition;Platelet aggregation inhibitor-containing product,Carboxylic acid and/or carboxylic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Salicylate-containing product,"Therapeutic Uses;Hypnotics and Sedatives;Cardiovascular Agents;Anti-Inflammatory Agents;Enzyme Inhibitors;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Fibrinolytic Agents;Fibrin Modulating Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Analgesics;Antipyretics;Antirheumatic Agents;Cyclooxygenase Inhibitors;Platelet Aggregation Inhibitors;Hematologic Agents;Central Nervous System Depressants;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Polyps;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Pregnancy Trimesters;Reproductive Physiological Phenomena;Child;Pregnancy Trimester, Third;Signs and Symptoms;Varicella Zoster Virus Infection;Melena;Hemorrhagic Disorders;Virus Diseases;Gastrointestinal Diseases;Digestive System Diseases;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Adolescent;Bronchial Diseases;Nasal Polyps;Age Groups;Gastrointestinal Hemorrhage;Pathological Conditions, Signs and Symptoms;DNA Virus Infections;Hematemesis;Chemically-Induced Disorders;Infant;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Vomiting;Disease;Blood Platelet Disorders;Hypersensitivity;Chickenpox;Infections;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Hemorrhage;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Immune System Diseases;Herpesviridae Infections;Child, Preschool;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Blood Coagulation Disorders;Hematologic Diseases;Pathologic Processes","Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Signs and Symptoms;Pain;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Streptococcal Infections;Inflammation;Skin and Connective Tissue Diseases;Bacterial Infections;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Metabolic Diseases;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Disease;Rheumatic Fever;Rheumatic Diseases;Infections;Gout;Nervous System Diseases;Joint Diseases;Immune System Diseases;Metabolism, Inborn Errors;Arthritis, Rheumatoid;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Phenols;Carboxylic Acids;Hydrocarbons, Cyclic;Aspirin;Substances;Acids, Carbocyclic;Benzoates;Hydroxybenzoates;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Benzene Derivatives;Salicylates;Hydroxy Acids;Hydrocarbons, Aromatic",,Hematologic Activity Alteration;Organ System Specific Effects;Physiologic Effect (PE);Hemostasis Alteration;Decreased Thromboxane Production;Platelet Aggregation Alteration;Immunologic Activity Alteration;Decreased Prostaglandin Production;Coagulation Activity Alteration;Decreased Eicosanoid Production;Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Hemic/Lymphatic Activity Alteration;Decreased Coagulation Activity;Decreased Immunologic Activity;Decreased Platelet Aggregation,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Inhibitor;Enzyme Interaction;Platelet Aggregation Inhibitor;Hematology Agent;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC),OPIOIDS;ANTITHROMBOTIC AGENTS;ANALGESICS;STOMATOLOGICAL PREPARATIONS;Salicylic acid and derivatives;Other agents for local oral treatment;BLOOD AND BLOOD FORMING ORGANS;Opioids in combination with non-opioid analgesics;ALIMENTARY TRACT AND METABOLISM;Platelet aggregation inhibitors excl. heparin;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;OTHER ANALGESICS AND ANTIPYRETICS,,"Ischemia;Stroke;Infarction;Cardiovascular Diseases;Vascular Diseases;Signs and Symptoms;Pain;Myocardial Ischemia;Neurologic Manifestations;Hypertension;Pregnancy Complications;Ischemic Attack, Transient;Pathological Conditions, Signs and Symptoms;Hypertension, Pregnancy-Induced;Brain Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Myocardial Infarction;Pre-Eclampsia;Brain Infarction;Heart Diseases;Cerebral Infarction;Nervous System Diseases;Necrosis;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Pathologic Processes;Brain Ischemia;Cerebrovascular Disorders",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANALGESICS;VA CLASSES;SODIUM BICARBONATE CONTAINING ANTACIDS;RESPIRATORY TRACT MEDICATIONS;PLATELET AGGREGATION INHIBITORS;COLD REMEDIES,COMBINATIONS;NON-OPIOID ANALGESICS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;OPIOID ANALGESICS;GASTROINTESTINAL MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;SKELETAL MUSCLE RELAXANTS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANALGESICS;VA CLASSES;SODIUM BICARBONATE CONTAINING ANTACIDS;RESPIRATORY TRACT MEDICATIONS;PLATELET AGGREGATION INHIBITORS;COLD REMEDIES,COMBINATIONS;NON-OPIOID ANALGESICS;OPIOID ANALGESICS;GASTROINTESTINAL MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;SKELETAL MUSCLE RELAXANTS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS",SCHEDULE III;CSA SCHEDULE;SCHEDULE IV;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
80,29,Concomitant Medications,Generic Name,RxNorm,aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,Medicinal product categorized by disposition;Platelet aggregation inhibitor-containing product,Carboxylic acid and/or carboxylic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Salicylate-containing product,"Therapeutic Uses;Hypnotics and Sedatives;Cardiovascular Agents;Anti-Inflammatory Agents;Enzyme Inhibitors;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Fibrinolytic Agents;Fibrin Modulating Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Analgesics;Antipyretics;Antirheumatic Agents;Cyclooxygenase Inhibitors;Platelet Aggregation Inhibitors;Hematologic Agents;Central Nervous System Depressants;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Polyps;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Pregnancy Trimesters;Reproductive Physiological Phenomena;Child;Pregnancy Trimester, Third;Signs and Symptoms;Varicella Zoster Virus Infection;Melena;Hemorrhagic Disorders;Virus Diseases;Gastrointestinal Diseases;Digestive System Diseases;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Adolescent;Bronchial Diseases;Nasal Polyps;Age Groups;Gastrointestinal Hemorrhage;Pathological Conditions, Signs and Symptoms;DNA Virus Infections;Hematemesis;Chemically-Induced Disorders;Infant;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Vomiting;Disease;Blood Platelet Disorders;Hypersensitivity;Chickenpox;Infections;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Hemorrhage;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Immune System Diseases;Herpesviridae Infections;Child, Preschool;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Blood Coagulation Disorders;Hematologic Diseases;Pathologic Processes","Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Signs and Symptoms;Pain;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Streptococcal Infections;Inflammation;Skin and Connective Tissue Diseases;Bacterial Infections;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Metabolic Diseases;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Disease;Rheumatic Fever;Rheumatic Diseases;Infections;Gout;Nervous System Diseases;Joint Diseases;Immune System Diseases;Metabolism, Inborn Errors;Arthritis, Rheumatoid;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Phenols;Carboxylic Acids;Hydrocarbons, Cyclic;Aspirin;Substances;Acids, Carbocyclic;Benzoates;Hydroxybenzoates;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Benzene Derivatives;Salicylates;Hydroxy Acids;Hydrocarbons, Aromatic",,Hematologic Activity Alteration;Organ System Specific Effects;Physiologic Effect (PE);Hemostasis Alteration;Decreased Thromboxane Production;Platelet Aggregation Alteration;Immunologic Activity Alteration;Decreased Prostaglandin Production;Coagulation Activity Alteration;Decreased Eicosanoid Production;Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Hemic/Lymphatic Activity Alteration;Decreased Coagulation Activity;Decreased Immunologic Activity;Decreased Platelet Aggregation,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Inhibitor;Enzyme Interaction;Platelet Aggregation Inhibitor;Hematology Agent;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC),OPIOIDS;ANTITHROMBOTIC AGENTS;ANALGESICS;STOMATOLOGICAL PREPARATIONS;Salicylic acid and derivatives;Other agents for local oral treatment;BLOOD AND BLOOD FORMING ORGANS;Opioids in combination with non-opioid analgesics;ALIMENTARY TRACT AND METABOLISM;Platelet aggregation inhibitors excl. heparin;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;OTHER ANALGESICS AND ANTIPYRETICS,,"Ischemia;Stroke;Infarction;Cardiovascular Diseases;Vascular Diseases;Signs and Symptoms;Pain;Myocardial Ischemia;Neurologic Manifestations;Hypertension;Pregnancy Complications;Ischemic Attack, Transient;Pathological Conditions, Signs and Symptoms;Hypertension, Pregnancy-Induced;Brain Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Myocardial Infarction;Pre-Eclampsia;Brain Infarction;Heart Diseases;Cerebral Infarction;Nervous System Diseases;Necrosis;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Pathologic Processes;Brain Ischemia;Cerebrovascular Disorders",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANALGESICS;VA CLASSES;SODIUM BICARBONATE CONTAINING ANTACIDS;RESPIRATORY TRACT MEDICATIONS;PLATELET AGGREGATION INHIBITORS;COLD REMEDIES,COMBINATIONS;NON-OPIOID ANALGESICS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;OPIOID ANALGESICS;GASTROINTESTINAL MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;SKELETAL MUSCLE RELAXANTS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANALGESICS;VA CLASSES;SODIUM BICARBONATE CONTAINING ANTACIDS;RESPIRATORY TRACT MEDICATIONS;PLATELET AGGREGATION INHIBITORS;COLD REMEDIES,COMBINATIONS;NON-OPIOID ANALGESICS;OPIOID ANALGESICS;GASTROINTESTINAL MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;SKELETAL MUSCLE RELAXANTS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS",SCHEDULE III;CSA SCHEDULE;SCHEDULE IV;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
81,30,Concomitant Medications,Generic Name,RxNorm,aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,Medicinal product categorized by disposition;Platelet aggregation inhibitor-containing product,Carboxylic acid and/or carboxylic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product;Salicylate-containing product,"Therapeutic Uses;Hypnotics and Sedatives;Cardiovascular Agents;Anti-Inflammatory Agents;Enzyme Inhibitors;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Fibrinolytic Agents;Fibrin Modulating Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Analgesics;Antipyretics;Antirheumatic Agents;Cyclooxygenase Inhibitors;Platelet Aggregation Inhibitors;Hematologic Agents;Central Nervous System Depressants;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Lung Diseases;Polyps;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Pregnancy Trimesters;Reproductive Physiological Phenomena;Child;Pregnancy Trimester, Third;Signs and Symptoms;Varicella Zoster Virus Infection;Melena;Hemorrhagic Disorders;Virus Diseases;Gastrointestinal Diseases;Digestive System Diseases;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Adolescent;Bronchial Diseases;Nasal Polyps;Age Groups;Gastrointestinal Hemorrhage;Pathological Conditions, Signs and Symptoms;DNA Virus Infections;Hematemesis;Chemically-Induced Disorders;Infant;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Vomiting;Disease;Blood Platelet Disorders;Hypersensitivity;Chickenpox;Infections;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Rhinitis;Respiratory Tract Infections;Hemorrhage;Life Phases, Behavior Mechanisms and Physiologic States;Nose Diseases;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Immune System Diseases;Herpesviridae Infections;Child, Preschool;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Blood Coagulation Disorders;Hematologic Diseases;Pathologic Processes","Osteoarthritis;Arthritis;Connective Tissue Diseases;Nutritional and Metabolic Diseases;Body Temperature Changes;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Signs and Symptoms;Pain;Musculoskeletal Diseases;Neurologic Manifestations;Autoimmune Diseases;Streptococcal Infections;Inflammation;Skin and Connective Tissue Diseases;Bacterial Infections;Fever;Crystal Arthropathies;Pathological Conditions, Signs and Symptoms;Metabolic Diseases;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Disease;Rheumatic Fever;Rheumatic Diseases;Infections;Gout;Nervous System Diseases;Joint Diseases;Immune System Diseases;Metabolism, Inborn Errors;Arthritis, Rheumatoid;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Genetic Diseases, Inborn;Purine-Pyrimidine Metabolism, Inborn Errors","Phenols;Carboxylic Acids;Hydrocarbons, Cyclic;Aspirin;Substances;Acids, Carbocyclic;Benzoates;Hydroxybenzoates;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Benzene Derivatives;Salicylates;Hydroxy Acids;Hydrocarbons, Aromatic",,Hematologic Activity Alteration;Organ System Specific Effects;Physiologic Effect (PE);Hemostasis Alteration;Decreased Thromboxane Production;Platelet Aggregation Alteration;Immunologic Activity Alteration;Decreased Prostaglandin Production;Coagulation Activity Alteration;Decreased Eicosanoid Production;Generalized Systemic Effects;Decreased Platelet Activating Factor Production;Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Hemic/Lymphatic Activity Alteration;Decreased Coagulation Activity;Decreased Immunologic Activity;Decreased Platelet Aggregation,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Cyclooxygenase Inhibitors,Enzyme Inhibitor;Enzyme Interaction;Platelet Aggregation Inhibitor;Hematology Agent;Nonsteroidal Anti-inflammatory Drug;Established Pharmacologic Class (EPC),OPIOIDS;ANTITHROMBOTIC AGENTS;ANALGESICS;STOMATOLOGICAL PREPARATIONS;Salicylic acid and derivatives;Other agents for local oral treatment;BLOOD AND BLOOD FORMING ORGANS;Opioids in combination with non-opioid analgesics;ALIMENTARY TRACT AND METABOLISM;Platelet aggregation inhibitors excl. heparin;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;OTHER ANALGESICS AND ANTIPYRETICS,,"Ischemia;Stroke;Infarction;Cardiovascular Diseases;Vascular Diseases;Signs and Symptoms;Pain;Myocardial Ischemia;Neurologic Manifestations;Hypertension;Pregnancy Complications;Ischemic Attack, Transient;Pathological Conditions, Signs and Symptoms;Hypertension, Pregnancy-Induced;Brain Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Myocardial Infarction;Pre-Eclampsia;Brain Infarction;Heart Diseases;Cerebral Infarction;Nervous System Diseases;Necrosis;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Pathologic Processes;Brain Ischemia;Cerebrovascular Disorders",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANALGESICS;VA CLASSES;SODIUM BICARBONATE CONTAINING ANTACIDS;RESPIRATORY TRACT MEDICATIONS;PLATELET AGGREGATION INHIBITORS;COLD REMEDIES,COMBINATIONS;NON-OPIOID ANALGESICS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;OPIOID ANALGESICS;GASTROINTESTINAL MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;SKELETAL MUSCLE RELAXANTS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANALGESICS;VA CLASSES;SODIUM BICARBONATE CONTAINING ANTACIDS;RESPIRATORY TRACT MEDICATIONS;PLATELET AGGREGATION INHIBITORS;COLD REMEDIES,COMBINATIONS;NON-OPIOID ANALGESICS;OPIOID ANALGESICS;GASTROINTESTINAL MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;SKELETAL MUSCLE RELAXANTS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS",SCHEDULE III;CSA SCHEDULE;SCHEDULE IV;SCHEDULE II,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
82,17,Concomitant Medications,Generic Name,RxNorm,Levothyroxin,levothyroxine,10582.0,levothyroxine,10582.0,10582.0,10582,False,,,,"Endocrine System Diseases;Adrenal Insufficiency;Ischemia;Thyrotoxicosis;Infarction;Hyperthyroidism;Cardiovascular Diseases;Vascular Diseases;Myocardial Ischemia;Thyroid Diseases;Pathological Conditions, Signs and Symptoms;Chemically-Induced Disorders;Disease;Myocardial Infarction;Drug Hypersensitivity;Heart Diseases;Drug-Related Side Effects and Adverse Reactions;Necrosis;Adrenal Gland Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes","Endocrine System Diseases;Thyroiditis;Connective Tissue Diseases;Thyroid Neoplasms;Thyrotoxicosis;Hyperthyroidism;Myxedema;Neoplasms;Thyroiditis, Autoimmune;Autoimmune Diseases;Thyroid Diseases;Skin and Connective Tissue Diseases;Endocrine Gland Neoplasms;Disease;Goiter;Neoplasms by Site;Hypothyroidism;Immune System Diseases;Mucinoses;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Head and Neck Neoplasms","Amino Acids;Hormones;Thyroxine;Substances;Substances and Cells (CHEM);Thyroid Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Amino Acids, Cyclic;Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic",,Glucose Metabolism Alteration;Cellular Activity Alteration;Increased Metabolic Rate;Cellular Cycle Alteration;Carbohydrate Metabolism Alteration;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Increased Gluconeogenesis;Physiologic Effect (PE);Metabolic Rate Alteration;Metabolic Activity Alteration,Mechanism of Action (MoA);Hormone Receptor Interactions;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Thyroid Hormone Receptor Agonists,Hormone;l-Thyroxine;Established Pharmacologic Class (EPC);Chemical Structure,"THYROID THERAPY;Thyroid hormones;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;Anatomical Therapeutic Chemical (ATC1-4);THYROID PREPARATIONS",,"Endocrine System Diseases;Hypothyroidism;Thyroid Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,VA CLASSES;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;THYROID MODIFIERS,VA CLASSES;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;THYROID MODIFIERS,,"Amino Acids;Hormones;Thyroxine;Substances;Substances and Cells (CHEM);Thyroid Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Amino Acids, Cyclic;Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic",,"Endocrine System Diseases;Disease;Thyroid Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,,,
83,29,Concomitant Medications,Generic Name,RxNorm,levothyroxine,levothyroxine,10582.0,levothyroxine,10582.0,10582.0,10582,False,,,,"Endocrine System Diseases;Adrenal Insufficiency;Ischemia;Thyrotoxicosis;Infarction;Hyperthyroidism;Cardiovascular Diseases;Vascular Diseases;Myocardial Ischemia;Thyroid Diseases;Pathological Conditions, Signs and Symptoms;Chemically-Induced Disorders;Disease;Myocardial Infarction;Drug Hypersensitivity;Heart Diseases;Drug-Related Side Effects and Adverse Reactions;Necrosis;Adrenal Gland Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes","Endocrine System Diseases;Thyroiditis;Connective Tissue Diseases;Thyroid Neoplasms;Thyrotoxicosis;Hyperthyroidism;Myxedema;Neoplasms;Thyroiditis, Autoimmune;Autoimmune Diseases;Thyroid Diseases;Skin and Connective Tissue Diseases;Endocrine Gland Neoplasms;Disease;Goiter;Neoplasms by Site;Hypothyroidism;Immune System Diseases;Mucinoses;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Head and Neck Neoplasms","Amino Acids;Hormones;Thyroxine;Substances;Substances and Cells (CHEM);Thyroid Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Amino Acids, Cyclic;Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic",,Glucose Metabolism Alteration;Cellular Activity Alteration;Increased Metabolic Rate;Cellular Cycle Alteration;Carbohydrate Metabolism Alteration;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Increased Gluconeogenesis;Physiologic Effect (PE);Metabolic Rate Alteration;Metabolic Activity Alteration,Mechanism of Action (MoA);Hormone Receptor Interactions;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Thyroid Hormone Receptor Agonists,Hormone;l-Thyroxine;Established Pharmacologic Class (EPC);Chemical Structure,"THYROID THERAPY;Thyroid hormones;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;Anatomical Therapeutic Chemical (ATC1-4);THYROID PREPARATIONS",,"Endocrine System Diseases;Hypothyroidism;Thyroid Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,VA CLASSES;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;THYROID MODIFIERS,VA CLASSES;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;THYROID MODIFIERS,,"Amino Acids;Hormones;Thyroxine;Substances;Substances and Cells (CHEM);Thyroid Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Amino Acids, Cyclic;Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic",,"Endocrine System Diseases;Disease;Thyroid Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,,,
84,44,Concomitant Medications,Generic Name,RxNorm,Levothyroxine,,,,10582.0,10582.0,10582,False,,,,"Endocrine System Diseases;Adrenal Insufficiency;Ischemia;Thyrotoxicosis;Infarction;Hyperthyroidism;Cardiovascular Diseases;Vascular Diseases;Myocardial Ischemia;Thyroid Diseases;Pathological Conditions, Signs and Symptoms;Chemically-Induced Disorders;Disease;Myocardial Infarction;Drug Hypersensitivity;Heart Diseases;Drug-Related Side Effects and Adverse Reactions;Necrosis;Adrenal Gland Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes","Endocrine System Diseases;Thyroiditis;Connective Tissue Diseases;Thyroid Neoplasms;Thyrotoxicosis;Hyperthyroidism;Myxedema;Neoplasms;Thyroiditis, Autoimmune;Autoimmune Diseases;Thyroid Diseases;Skin and Connective Tissue Diseases;Endocrine Gland Neoplasms;Disease;Goiter;Neoplasms by Site;Hypothyroidism;Immune System Diseases;Mucinoses;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Head and Neck Neoplasms","Amino Acids;Hormones;Thyroxine;Substances;Substances and Cells (CHEM);Thyroid Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Amino Acids, Cyclic;Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic",,Glucose Metabolism Alteration;Cellular Activity Alteration;Increased Metabolic Rate;Cellular Cycle Alteration;Carbohydrate Metabolism Alteration;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Increased Gluconeogenesis;Physiologic Effect (PE);Metabolic Rate Alteration;Metabolic Activity Alteration,Mechanism of Action (MoA);Hormone Receptor Interactions;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Thyroid Hormone Receptor Agonists,Hormone;l-Thyroxine;Established Pharmacologic Class (EPC);Chemical Structure,"THYROID THERAPY;Thyroid hormones;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;Anatomical Therapeutic Chemical (ATC1-4);THYROID PREPARATIONS",,"Endocrine System Diseases;Hypothyroidism;Thyroid Diseases;Disease;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,VA CLASSES;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;THYROID MODIFIERS,VA CLASSES;THYROID SUPPLEMENTS;HORMONES/SYNTHETICS/MODIFIERS;THYROID MODIFIERS,,"Amino Acids;Hormones;Thyroxine;Substances;Substances and Cells (CHEM);Thyroid Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Amino Acids, Cyclic;Amino Acids, Peptides, and Proteins;Amino Acids, Aromatic",,"Endocrine System Diseases;Disease;Thyroid Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,,,
85,17,Concomitant Medications,Generic Name,RxNorm,Calcium,Calcium,1895.0,Calcium,1895.0,1895.0,1895,False,,Medicinal product categorized by chemical element;Calcium and/or calcium compound-containing product;Medicinal product categorized by structure;Metal and/or metallic compound-containing product;Mineral-containing product,Calcium-Regulating Hormones and Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),,,"Metals;Substances;Blood Proteins;Amino Acids, Peptides, and Proteins;Elements;Metals, Alkaline Earth;Proteins;Substances and Cells (CHEM);Blood Coagulation Factors;Calcium;Biological Factors;Inorganic Chemicals",,,Mechanism of Action (MoA);Chelating Activity;Binding Activity;Phosphate Chelating Activity;Physiochemical Activity,Phosphate Binder;Physical or Chemical Agent;Established Pharmacologic Class (EPC);Chemical Structure;Calcium;Vitamin or Mineral,,,,,,,,"Metals;Substances;Blood Proteins;Amino Acids, Peptides, and Proteins;Elements;Metals, Alkaline Earth;Proteins;Substances and Cells (CHEM);Blood Coagulation Factors;Calcium;Biological Factors;Inorganic Chemicals",,,,,,
86,18,Concomitant Medications,Generic Name,RxNorm,tegretol,Tegretol Oral Product,1180855.0,Tegretol Oral Product,203029.0,203029.0,203029,False,,,"Therapeutic Uses;Antimanic Agents;Cardiovascular Agents;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Membrane Transport Modulators;Cytochrome P-450 CYP3A Inducers;Metabolic Side Effects of Drugs and Substances;Cytochrome P-450 Enzyme Inducers;Analgesics, Non-Narcotic;Psychotropic Drugs;Anticonvulsants;Analgesics;Sodium Channel Blockers;Tranquilizing Agents;Central Nervous System Depressants;Molecular Mechanisms of Pharmacological Action;Sensory System Agents","Chemically-Induced Disorders;Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Disease;Drug-Related Side Effects and Adverse Reactions;Reproduction;Bone Marrow Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Hemic and Lymphatic Diseases;Reproductive Physiological Phenomena","Epilepsy;Epilepsies, Partial;Facial Neuralgia;Epilepsy, Complex Partial;Sleep Disorders, Intrinsic;Bipolar and Related Disorders;Cranial Nerve Diseases;Signs and Symptoms;Psychotic Disorders;Mental Disorders;Parasomnias;Schizophrenia;Mouth Diseases;Substance-Related Disorders;Neurologic Manifestations;Dyssomnias;Pathological Conditions, Signs and Symptoms;Brain Diseases;Epilepsy, Generalized;Chemically-Induced Disorders;Stress Disorders, Traumatic;Restless Legs Syndrome;Schizophrenia Spectrum and Other Psychotic Disorders;Facial Nerve Diseases;Bipolar Disorder;Disease;Stomatognathic Diseases;Mood Disorders;Epilepsy, Tonic-Clonic;Substance Withdrawal Syndrome;Nervous System Diseases;Trauma and Stressor Related Disorders;Trigeminal Neuralgia;Trigeminal Nerve Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Sleep Wake Disorders;Stress Disorders, Post-Traumatic","Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Substances;Carbamazepine;Substances and Cells (CHEM);Dibenzazepines;Heterocyclic Compounds, 3-Ring",,Disorganized Electrical Activity Alteration;Decreased Disorganized Electrical Activity;Decreased Organized Electrical Activity;Organized Electrical Activity Alteration;Organ System Specific Effects;Decreased Central Nervous System Disorganized Electrical Activity;Nervous System Activity Alteration;Electrical Activity Alteration;Physiologic Effect (PE),Cytochrome P450 1A Inducers;Mechanism of Action (MoA);Cytochrome P450 Inducers;Ion Channel Interactions;Sodium Channel Interactions;Transcription Factor Activity;Cytochrome P450 2B6 Inducers;Cytochrome P450 2C19 Inducers;Receptor Interactions;Cytochrome P450 3A4 Inducers;Enzyme Inducers;Cytochrome P450 3A Inducers;Unknown Cellular or Molecular Interaction;Cytochrome P450 2C9 Inducers;Membrane Transporter Interactions;Enzyme Interactions;Cytochrome P450 1A2 Inducers,Nervous System Agent;Established Pharmacologic Class (EPC);Mood Stabilizer,Anatomical Therapeutic Chemical (ATC1-4);ANTIEPILEPTICS;NERVOUS SYSTEM;Carboxamide derivatives,Medicinal product categorized by therapeutic role;Anticonvulsant agent,,Antimanic Agent;Central Nervous System Agent;Antidepressive Agent;Therapeutic Categories,CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTICONVULSANTS;VA CLASSES,,,,"Heterocyclic Compounds;Substances;Triazoles;Azoles;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Piperazines",,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
87,20,Concomitant Medications,Generic Name,RxNorm,albuterol,Albuterol,435.0,Albuterol,435.0,435.0,435,False,Selective beta-2 agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Adrenergic beta-2 Receptor Agonists;Peripheral Nervous System Agents;Bronchodilator Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic Agonists;Adrenergic Agents;Reproductive Control Agents;Physiological Effects of Drugs;Tocolytic Agents;Respiratory System Agents;Adrenergic beta-Agonists;Molecular Mechanisms of Pharmacological Action;Anti-Asthmatic Agents,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity;Disease","Asthma;Respiratory Hypersensitivity;Lung Diseases;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Ethanol;Alcohols;Albuterol;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Ethylamines;Ethanolamines;Amino Alcohols,,Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Bronchodilation;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;beta2-Adrenergic Agonist;Receptor Agonist;beta-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,"RESPIRATORY SYSTEM;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;Selective beta-2-adrenoreceptor agonists;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Asthma, Exercise-Induced;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Exercise-Induced Allergies",,"VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
88,25,Concomitant Medications,Generic Name,RxNorm,Albuterol,Albuterol 0.09 MG/ACTUAT,329498.0,Albuterol 0.09 MG/ACTUAT,435.0,435.0,435,False,Selective beta-2 agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Adrenergic beta-2 Receptor Agonists;Peripheral Nervous System Agents;Bronchodilator Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic Agonists;Adrenergic Agents;Reproductive Control Agents;Physiological Effects of Drugs;Tocolytic Agents;Respiratory System Agents;Adrenergic beta-Agonists;Molecular Mechanisms of Pharmacological Action;Anti-Asthmatic Agents,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity;Disease","Asthma;Respiratory Hypersensitivity;Lung Diseases;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Ethanol;Alcohols;Albuterol;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Ethylamines;Ethanolamines;Amino Alcohols,,Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Bronchodilation;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;beta2-Adrenergic Agonist;Receptor Agonist;beta-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,"RESPIRATORY SYSTEM;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;Selective beta-2-adrenoreceptor agonists;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Asthma, Exercise-Induced;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Exercise-Induced Allergies",,"VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
89,33,Concomitant Medications,Generic Name,RxNorm,albuteral,Albuterol Sulfate,142153.0,Albuterol Sulfate,,435.0,435,True,Selective beta-2 agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Adrenergic beta-2 Receptor Agonists;Peripheral Nervous System Agents;Bronchodilator Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic Agonists;Adrenergic Agents;Reproductive Control Agents;Physiological Effects of Drugs;Tocolytic Agents;Respiratory System Agents;Adrenergic beta-Agonists;Molecular Mechanisms of Pharmacological Action;Anti-Asthmatic Agents,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity;Disease","Asthma;Respiratory Hypersensitivity;Lung Diseases;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Ethanol;Alcohols;Albuterol;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Ethylamines;Ethanolamines;Amino Alcohols,,Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Bronchodilation;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;beta2-Adrenergic Agonist;Receptor Agonist;beta-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,"RESPIRATORY SYSTEM;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;Selective beta-2-adrenoreceptor agonists;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Asthma, Exercise-Induced;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Exercise-Induced Allergies",,"VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
90,34,Concomitant Medications,Generic Name,RxNorm,Albuterol,,,,435.0,435.0,435,False,Selective beta-2 agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Adrenergic beta-2 Receptor Agonists;Peripheral Nervous System Agents;Bronchodilator Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic Agonists;Adrenergic Agents;Reproductive Control Agents;Physiological Effects of Drugs;Tocolytic Agents;Respiratory System Agents;Adrenergic beta-Agonists;Molecular Mechanisms of Pharmacological Action;Anti-Asthmatic Agents,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity;Disease","Asthma;Respiratory Hypersensitivity;Lung Diseases;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Ethanol;Alcohols;Albuterol;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Ethylamines;Ethanolamines;Amino Alcohols,,Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Bronchodilation;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;beta2-Adrenergic Agonist;Receptor Agonist;beta-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,"RESPIRATORY SYSTEM;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;Selective beta-2-adrenoreceptor agonists;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Asthma, Exercise-Induced;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Exercise-Induced Allergies",,"VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
91,38,Concomitant Medications,Generic Name,RxNorm,Albuterol,,,,435.0,435.0,435,False,Selective beta-2 agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Adrenergic beta-2 Receptor Agonists;Peripheral Nervous System Agents;Bronchodilator Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic Agonists;Adrenergic Agents;Reproductive Control Agents;Physiological Effects of Drugs;Tocolytic Agents;Respiratory System Agents;Adrenergic beta-Agonists;Molecular Mechanisms of Pharmacological Action;Anti-Asthmatic Agents,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity;Disease","Asthma;Respiratory Hypersensitivity;Lung Diseases;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Ethanol;Alcohols;Albuterol;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Ethylamines;Ethanolamines;Amino Alcohols,,Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Bronchodilation;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;beta2-Adrenergic Agonist;Receptor Agonist;beta-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,"RESPIRATORY SYSTEM;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;Selective beta-2-adrenoreceptor agonists;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Asthma, Exercise-Induced;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Exercise-Induced Allergies",,"VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
92,43,Concomitant Medications,Generic Name,RxNorm,Albuterol,Albuterol,435.0,Albuterol,435.0,435.0,435,False,Selective beta-2 agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Autonomic Agents;Therapeutic Uses;Neurotransmitter Agents;Adrenergic beta-2 Receptor Agonists;Peripheral Nervous System Agents;Bronchodilator Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic Agonists;Adrenergic Agents;Reproductive Control Agents;Physiological Effects of Drugs;Tocolytic Agents;Respiratory System Agents;Adrenergic beta-Agonists;Molecular Mechanisms of Pharmacological Action;Anti-Asthmatic Agents,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Hypersensitivity;Disease","Asthma;Respiratory Hypersensitivity;Lung Diseases;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Ethanol;Alcohols;Albuterol;Substances;Amines;Phenethylamines;Organic Chemicals;Substances and Cells (CHEM);Ethylamines;Ethanolamines;Amino Alcohols,,Respiratory Smooth Muscle Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Nervous System Activity Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Bronchodilation;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Receptor Interactions;Adrenergic beta-Agonists,Receptor Interaction;Sympathomimetic Agent;Adrenergic Receptor Agonist;beta2-Adrenergic Agonist;Receptor Agonist;beta-Adrenergic Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,"RESPIRATORY SYSTEM;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;Selective beta-2-adrenoreceptor agonists;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4);ADRENERGICS FOR SYSTEMIC USE",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Asthma, Exercise-Induced;Bronchial Spasm;Lung Diseases, Obstructive;Respiratory Tract Diseases;Disease;Hypersensitivity;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Exercise-Induced Allergies",,"VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL","VA CLASSES;RESPIRATORY TRACT MEDICATIONS;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;ANTIASTHMA/BRONCHODILATORS;ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL",,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
93,21,Concomitant Medications,Generic Name,RxNorm,Vitamin C,Vitamin C TR,220879.0,Vitamin C TR,1151.0,1151.0,1151,False,,Carboxylic acid and/or carboxylic acid derivative-containing product;Carbohydrate-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Vitamins;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Protective Agents;Antioxidants;Micronutrients,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Brain Diseases, Metabolic;Respiratory Tract Diseases;Common Cold;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Vascular Diseases;Brain Diseases, Metabolic, Inborn;Ascorbic Acid Deficiency;Nutrition Disorders;Deficiency Diseases;Hemorrhagic Disorders;Virus Diseases;Wounds and Injuries;Brain Diseases;Metabolic Diseases;Avitaminosis;Disease;Amino Acid Metabolism, Inborn Errors;Tyrosinemias;RNA Virus Infections;Wounds, Penetrating;Infections;Methemoglobinemia;Hemic and Lymphatic Diseases;Malnutrition;Respiratory Tract Infections;Scurvy;Nervous System Diseases;Hemostatic Disorders;Picornaviridae Infections;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Hematologic Diseases;Genetic Diseases, Inborn","Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Oxidation-Reduction Activity;Reduction Activity;Free Radical Scavenging Activity;Physiochemical Activity;Enzyme Interactions,Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,"VITAMINS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Ascorbic acid (vitamin C), plain;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;Organic acids;OPHTHALMOLOGICALS;OTHER OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES",,,,"VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;IRON;MULTIVITAMINS WITH MINERALS;ELECTROLYTES/MINERALS;VITAMIN COMBINATIONS,OTHER;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS","VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS",,"Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,,,,,"Hyperoxaluria;Male Urogenital Diseases;Kidney Diseases;Urologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States"
94,24,Concomitant Medications,Generic Name,RxNorm,vitamin c,,,,1151.0,1151.0,1151,False,,Carboxylic acid and/or carboxylic acid derivative-containing product;Carbohydrate-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Vitamins;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Protective Agents;Antioxidants;Micronutrients,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Brain Diseases, Metabolic;Respiratory Tract Diseases;Common Cold;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Vascular Diseases;Brain Diseases, Metabolic, Inborn;Ascorbic Acid Deficiency;Nutrition Disorders;Deficiency Diseases;Hemorrhagic Disorders;Virus Diseases;Wounds and Injuries;Brain Diseases;Metabolic Diseases;Avitaminosis;Disease;Amino Acid Metabolism, Inborn Errors;Tyrosinemias;RNA Virus Infections;Wounds, Penetrating;Infections;Methemoglobinemia;Hemic and Lymphatic Diseases;Malnutrition;Respiratory Tract Infections;Scurvy;Nervous System Diseases;Hemostatic Disorders;Picornaviridae Infections;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Hematologic Diseases;Genetic Diseases, Inborn","Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Oxidation-Reduction Activity;Reduction Activity;Free Radical Scavenging Activity;Physiochemical Activity;Enzyme Interactions,Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,"VITAMINS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Ascorbic acid (vitamin C), plain;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;Organic acids;OPHTHALMOLOGICALS;OTHER OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES",,,,"VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;IRON;MULTIVITAMINS WITH MINERALS;ELECTROLYTES/MINERALS;VITAMIN COMBINATIONS,OTHER;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS","VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS",,"Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,,,,,"Hyperoxaluria;Male Urogenital Diseases;Kidney Diseases;Urologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States"
95,25,Concomitant Medications,Generic Name,RxNorm,Vitamin C,Vitamin C TR,220879.0,Vitamin C TR,1151.0,1151.0,1151,False,,Carboxylic acid and/or carboxylic acid derivative-containing product;Carbohydrate-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Vitamins;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Protective Agents;Antioxidants;Micronutrients,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Brain Diseases, Metabolic;Respiratory Tract Diseases;Common Cold;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Vascular Diseases;Brain Diseases, Metabolic, Inborn;Ascorbic Acid Deficiency;Nutrition Disorders;Deficiency Diseases;Hemorrhagic Disorders;Virus Diseases;Wounds and Injuries;Brain Diseases;Metabolic Diseases;Avitaminosis;Disease;Amino Acid Metabolism, Inborn Errors;Tyrosinemias;RNA Virus Infections;Wounds, Penetrating;Infections;Methemoglobinemia;Hemic and Lymphatic Diseases;Malnutrition;Respiratory Tract Infections;Scurvy;Nervous System Diseases;Hemostatic Disorders;Picornaviridae Infections;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Hematologic Diseases;Genetic Diseases, Inborn","Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Oxidation-Reduction Activity;Reduction Activity;Free Radical Scavenging Activity;Physiochemical Activity;Enzyme Interactions,Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,"VITAMINS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Ascorbic acid (vitamin C), plain;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;Organic acids;OPHTHALMOLOGICALS;OTHER OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES",,,,"VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;IRON;MULTIVITAMINS WITH MINERALS;ELECTROLYTES/MINERALS;VITAMIN COMBINATIONS,OTHER;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS","VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS",,"Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,,,,,"Hyperoxaluria;Male Urogenital Diseases;Kidney Diseases;Urologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States"
96,30,Concomitant Medications,Generic Name,RxNorm,Vitamin C,,,,1151.0,1151.0,1151,False,,Carboxylic acid and/or carboxylic acid derivative-containing product;Carbohydrate-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Vitamins;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Protective Agents;Antioxidants;Micronutrients,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Brain Diseases, Metabolic;Respiratory Tract Diseases;Common Cold;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Vascular Diseases;Brain Diseases, Metabolic, Inborn;Ascorbic Acid Deficiency;Nutrition Disorders;Deficiency Diseases;Hemorrhagic Disorders;Virus Diseases;Wounds and Injuries;Brain Diseases;Metabolic Diseases;Avitaminosis;Disease;Amino Acid Metabolism, Inborn Errors;Tyrosinemias;RNA Virus Infections;Wounds, Penetrating;Infections;Methemoglobinemia;Hemic and Lymphatic Diseases;Malnutrition;Respiratory Tract Infections;Scurvy;Nervous System Diseases;Hemostatic Disorders;Picornaviridae Infections;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Hematologic Diseases;Genetic Diseases, Inborn","Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Oxidation-Reduction Activity;Reduction Activity;Free Radical Scavenging Activity;Physiochemical Activity;Enzyme Interactions,Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,"VITAMINS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Ascorbic acid (vitamin C), plain;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;Organic acids;OPHTHALMOLOGICALS;OTHER OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES",,,,"VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;IRON;MULTIVITAMINS WITH MINERALS;ELECTROLYTES/MINERALS;VITAMIN COMBINATIONS,OTHER;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS","VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS",,"Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,,,,,"Hyperoxaluria;Male Urogenital Diseases;Kidney Diseases;Urologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States"
97,37,Concomitant Medications,Generic Name,RxNorm,Vitamin C,,,,1151.0,1151.0,1151,False,,Carboxylic acid and/or carboxylic acid derivative-containing product;Carbohydrate-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Vitamins;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Protective Agents;Antioxidants;Micronutrients,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Brain Diseases, Metabolic;Respiratory Tract Diseases;Common Cold;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Vascular Diseases;Brain Diseases, Metabolic, Inborn;Ascorbic Acid Deficiency;Nutrition Disorders;Deficiency Diseases;Hemorrhagic Disorders;Virus Diseases;Wounds and Injuries;Brain Diseases;Metabolic Diseases;Avitaminosis;Disease;Amino Acid Metabolism, Inborn Errors;Tyrosinemias;RNA Virus Infections;Wounds, Penetrating;Infections;Methemoglobinemia;Hemic and Lymphatic Diseases;Malnutrition;Respiratory Tract Infections;Scurvy;Nervous System Diseases;Hemostatic Disorders;Picornaviridae Infections;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Hematologic Diseases;Genetic Diseases, Inborn","Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Oxidation-Reduction Activity;Reduction Activity;Free Radical Scavenging Activity;Physiochemical Activity;Enzyme Interactions,Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,"VITAMINS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Ascorbic acid (vitamin C), plain;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;Organic acids;OPHTHALMOLOGICALS;OTHER OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES",,,,"VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;IRON;MULTIVITAMINS WITH MINERALS;ELECTROLYTES/MINERALS;VITAMIN COMBINATIONS,OTHER;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS","VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS",,"Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,,,,,"Hyperoxaluria;Male Urogenital Diseases;Kidney Diseases;Urologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States"
98,45,Concomitant Medications,Generic Name,RxNorm,Vitamin C,,,,1151.0,1151.0,1151,False,,Carboxylic acid and/or carboxylic acid derivative-containing product;Carbohydrate-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Vitamins;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Protective Agents;Antioxidants;Micronutrients,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Brain Diseases, Metabolic;Respiratory Tract Diseases;Common Cold;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Cardiovascular Diseases;Vascular Diseases;Brain Diseases, Metabolic, Inborn;Ascorbic Acid Deficiency;Nutrition Disorders;Deficiency Diseases;Hemorrhagic Disorders;Virus Diseases;Wounds and Injuries;Brain Diseases;Metabolic Diseases;Avitaminosis;Disease;Amino Acid Metabolism, Inborn Errors;Tyrosinemias;RNA Virus Infections;Wounds, Penetrating;Infections;Methemoglobinemia;Hemic and Lymphatic Diseases;Malnutrition;Respiratory Tract Infections;Scurvy;Nervous System Diseases;Hemostatic Disorders;Picornaviridae Infections;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Hematologic Diseases;Genetic Diseases, Inborn","Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Oxidation-Reduction Activity;Reduction Activity;Free Radical Scavenging Activity;Physiochemical Activity;Enzyme Interactions,Vitamin or Mineral;Established Pharmacologic Class (EPC);Vitamin C,"VITAMINS;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;SENSORY ORGANS;Ascorbic acid (vitamin C), plain;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;Organic acids;OPHTHALMOLOGICALS;OTHER OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;GENITO URINARY SYSTEM AND SEX HORMONES",,,,"VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;IRON;MULTIVITAMINS WITH MINERALS;ELECTROLYTES/MINERALS;VITAMIN COMBINATIONS,OTHER;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS","VITAMINS;HYPEROSMOTIC LAXATIVES;VA CLASSES;LAXATIVES;MULTIVITAMINS;VITAMIN C;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;GASTROINTESTINAL MEDICATIONS;VITAMINS,COMBINATIONS",,"Carboxylic Acids;Substances;Ascorbic Acid;Sugar Acids;Organic Chemicals;Acids, Acyclic;Substances and Cells (CHEM);Hydroxy Acids;Carbohydrates",,,,,,"Hyperoxaluria;Male Urogenital Diseases;Kidney Diseases;Urologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States"
99,22,Concomitant Medications,Generic Name,RxNorm,citalopram,Citalopram,2556.0,Citalopram,2556.0,2556.0,2556,False,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Propylamine-containing product;Medicinal product categorized by structure,"Neurotransmitter Uptake Inhibitors;Therapeutic Uses;Membrane Transport Modulators;Serotonin Agents;Neurotransmitter Agents;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Antidepressive Agents, Second-Generation;Physiological Effects of Drugs;Psychotropic Drugs;Selective Serotonin Reuptake Inhibitors;Molecular Mechanisms of Pharmacological Action;Antidepressive Agents","Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Endocrine System Diseases;Diabetes Complications;Nutritional and Metabolic Diseases;Mental Disorders;Peripheral Nervous System Diseases;Substance-Related Disorders;Alcoholism;Glucose Metabolism Disorders;Diabetes Mellitus;Metabolic Diseases;Brain Diseases;Chemically-Induced Disorders;Neurocognitive Disorders;Alcohol-Related Disorders;Disease;Depressive Disorder;Anxiety Disorders;Tobacco Use Disorder;Mood Disorders;Diabetic Neuropathies;Nervous System Diseases;Neuromuscular Diseases;Dementia;Obsessive-Compulsive Disorder;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases","Citalopram;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Substances;Amines;Organic Chemicals;Benzofurans;Substances and Cells (CHEM);Propylamines;Nitriles",,Immunologically Active Molecule Activity Alteration;Serotonin Activity Alteration;Increased Immunologic Activity;Organ System Specific Effects;Increased Serotonin Activity;Immunologic Activity Alteration;Increased Immunologically Active Molecule Activity;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Increased Immunologically Active Biogenic Amine Activity;Physiologic Effect (PE);Increased Central Nervous System Serotonin Activity;Generalized Systemic Effects,Mechanism of Action (MoA);Neurotransmitter Transporter Interactions;Receptor Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Membrane Transporter Interactions;Symporter Interactions;Ion Transporter Interactions,Serotonin Reuptake Inhibitor;Established Pharmacologic Class (EPC);Nervous System Agent,PSYCHOANALEPTICS;ANTIDEPRESSANTS;Selective serotonin reuptake inhibitors;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM,Medicinal product categorized by therapeutic role;Antidepressant agent,,,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS,OTHER;ANTIDEPRESSANTS;VA CLASSES","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIDEPRESSANTS,OTHER;ANTIDEPRESSANTS;VA CLASSES",,,"Fatty Acids;Heterocyclic Compounds, 1-Ring;Oxazoles;Fatty Acids, Volatile;Inorganic Chemicals;Sulfur Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Acetamides;Acetates;Phenothiazines;Heterocyclic Compounds, 3-Ring;Heterocyclic Compounds;Carboxylic Acids;Substances and Cells (CHEM);Acids, Acyclic;Amides;Azoles;Linezolid;Methylene Blue;Lipids;Benzimidazoles;Oxazolidinones;Substances;Pimozide;Organic Chemicals",,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
100,23,Concomitant Medications,Generic Name,RxNorm,chlorthaladone,,,,,2409.0,2409,True,,Nitrogen and/or nitrogen compound-containing product;Sulfonamide-containing product;Sulfonamide diuretic agent;Medicinal product categorized by structure;Sulfur and/or sulfur compound-containing product,Therapeutic Uses;Membrane Transport Modulators;Sodium Chloride Symporter Inhibitors;Natriuretic Agents;MeSH Pharmacologic Actions (MESHPA);Diuretics;Antihypertensive Agents;Physiological Effects of Drugs;Cardiovascular Agents;Molecular Mechanisms of Pharmacological Action,"Chemically-Induced Disorders;Male Urogenital Diseases;Urination Disorders;Pregnancy;Kidney Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Female Urogenital Diseases and Pregnancy Complications;Urologic Diseases;Renal Insufficiency;Drug Hypersensitivity;Anuria;Disease;Drug-Related Side Effects and Adverse Reactions;Reproduction;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena","Male Urogenital Diseases;Renal Insufficiency;Cardiovascular Diseases;Signs and Symptoms;Vascular Diseases;Urologic Diseases;Edema;Digestive System Diseases;Hypertension;Nephrosis;Nephritis;Pathological Conditions, Signs and Symptoms;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Glomerulonephritis;Liver Cirrhosis;Heart Diseases;Heart Failure;Female Urogenital Diseases;Nephrotic Syndrome;Fibrosis;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Pathologic Processes","Benzophenones;Inorganic Chemicals;Sulfur Compounds;Hydrocarbons, Aromatic;Heterocyclic Compounds, Fused-Ring;Imides;Heterocyclic Compounds, 2-Ring;Hydrocarbons, Cyclic;Sulfones;Chlorthalidone;Heterocyclic Compounds;Carboxylic Acids;Phthalimides;Acids, Carbocyclic;Substances and Cells (CHEM);Amides;Phthalic Acids;Sulfonamides;Benzene Derivatives;Ketones;Substances;Organic Chemicals;Hydrocarbons;Isoindoles",,Hematologic Activity Alteration;Organ System Specific Effects;Increased Renal Na+ Excretion;Physiologic Effect (PE);Blood & Lymphatic Fluid Function Alteration;Renal Ion Transport Alteration;Increased Renal H+ Excretion;Increased Diuresis;Decreased Blood Pressure;Increased Renal K+ Excretion;Renal/Urological Activity Alteration;Increased Distal Tubule K+ Excretion;Diuresis Alteration;Increased Distal Tubule Cl- Excretion;Cardiovascular Activity Alteration;Decreased Intravascular Volume;Increased Distal Tubule Na+ Excretion;Hemic/Lymphatic Activity Alteration;Increased Distal Tubule H+ Excretion;Increased Renal Cl- Excretion;Blood Pressure Alteration;Intravascular Volume Alteration;Increased Renal Ion Excretion,Mechanism of Action (MoA);Sodium Chloride Symporter Inhibitors;Sodium Chloride Symporter Interactions;Receptor Interactions;Membrane Transporter Interactions;Symporter Interactions;Ion Transporter Interactions,Thiazide-like Diuretic;Diuretic;Established Pharmacologic Class (EPC),"LOW-CEILING DIURETICS, EXCL. THIAZIDES;DIURETICS;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Sulfonamides, plain",Medicinal product categorized by therapeutic role;Sulfonamide diuretic agent;Diuretic agent,,,CARDIOVASCULAR MEDICATIONS;VA CLASSES;DIURETICS;ANTIHYPERTENSIVE COMBINATIONS;THIAZIDES/RELATED DIURETICS,CARDIOVASCULAR MEDICATIONS;VA CLASSES;DIURETICS;ANTIHYPERTENSIVE COMBINATIONS;THIAZIDES/RELATED DIURETICS,,,Substances;Organic Chemicals;Amides;Sulfones;Substances and Cells (CHEM);Sulfonamides;Inorganic Chemicals;Sulfur Compounds,,,,,
101,23,Concomitant Medications,Generic Name,RxNorm,propanolol,,,,8787.0,8787.0,8787,False,Medicinal product categorized by disposition;Beta adrenergic receptor antagonist-containing product;Adrenergic receptor antagonist-containing product,Alcohol-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Therapeutic Uses;Adrenergic beta-Antagonists;Neurotransmitter Agents;Adrenergic Antagonists;Anti-Arrhythmia Agents;MeSH Pharmacologic Actions (MESHPA);Adrenergic Agents;Antihypertensive Agents;Physiological Effects of Drugs;Vasodilator Agents;Cardiovascular Agents;Molecular Mechanisms of Pharmacological Action,"Lung Diseases;Ischemia;Atrioventricular Block;Skin Diseases, Vascular;Arrhythmias, Cardiac;Infarction;Respiratory Tract Diseases;Reproduction;Reproductive Physiological Phenomena;Cardiovascular Diseases;Vascular Diseases;Shock, Cardiogenic;Hypotension;Myocardial Ischemia;Pregnancy;Bronchial Hyperreactivity;Bronchial Diseases;Skin and Connective Tissue Diseases;Arrhythmia, Sinus;Pathological Conditions, Signs and Symptoms;Chemically-Induced Disorders;Asthma;Cardiac Conduction System Disease;Respiratory Hypersensitivity;Embolism and Thrombosis;Lung Diseases, Obstructive;Hypersensitivity;Disease;Myocardial Infarction;Livedoid Vasculopathy;Bradycardia;Drug Hypersensitivity;Heart Diseases;Heart Failure;Heart Block;Life Phases, Behavior Mechanisms and Physiologic States;Peripheral Vascular Diseases;Drug-Related Side Effects and Adverse Reactions;Shock;Necrosis;Immune System Diseases;Pulmonary Edema;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Raynaud Disease;Pathologic Processes;Skin Diseases;Sick Sinus Syndrome;Thrombosis","Essential Tremor;Chest Pain;Neoplasms, Germ Cell and Embryonal;Ischemia;Arrhythmias, Cardiac;Esophageal and Gastric Varices;Infarction;Ventricular Fibrillation;Tachycardia;Neoplasms;Cardiovascular Diseases;Vascular Diseases;Signs and Symptoms;Mental Disorders;Paraganglioma;Pain;Neoplasms, Nerve Tissue;Myocardial Ischemia;Gastrointestinal Diseases;Angina Pectoris;Neurologic Manifestations;Digestive System Diseases;Hypertension;Pheochromocytoma;Esophageal Diseases;Neoplasms by Histologic Type;Pathological Conditions, Signs and Symptoms;Tachycardia, Ventricular;Cardiac Conduction System Disease;Hypertension, Portal;Movement Disorders;Disease;Tachycardia, Supraventricular;Panic Disorder;Myocardial Infarction;Anxiety Disorders;Neuroendocrine Tumors;Heart Diseases;Heart Failure;Nervous System Diseases;Necrosis;Neuroectodermal Tumors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Liver Diseases;Pathologic Processes","Propanolamines;Alcohols;Naphthalenes;Propranolol;Hydrocarbons, Cyclic;Polycyclic Compounds;Substances;Amines;Organic Chemicals;Phenoxypropanolamines;Substances and Cells (CHEM);Hydrocarbons;Propanols;Polycyclic Aromatic Hydrocarbons;Amino Alcohols;Hydrocarbons, Aromatic",Organ System Specific Effects;Negative Chronotropy;Cardiovascular Activity Alteration;Cardiac Rate Alteration;Physiologic Effect (PE),Smooth Muscle Tone Alteration;Organ System Specific Effects;Nervous System Activity Alteration;Physiologic Effect (PE);Negative Inotropy;Respiratory Smooth Muscle Tone Alteration;Decreased Blood Pressure;Respiratory/Pulmonary Activity Alteration;Arterial Vasodilation;Vasodilation;Bronchial Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Vascular Tone Alteration;Bronchoconstriction;Cardiac Contractility Alteration;Cardiac Rhythm Alteration;Negative Chronotropy;Blood Pressure Alteration;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Peripheral Nervous System Activity Alteration;Vascular Alterations;Cardiac Rate Alteration,Adrenergic beta2-Antagonists;Mechanism of Action (MoA);Adrenergic beta-Antagonists;Adrenergic Receptor Interactions;G-Protein-linked Receptor Interactions;Receptor Interactions;Adrenergic Antagonists;Adrenergic beta1-Antagonists,Cardiovascular Agent;Receptor Antagonist;Receptor Interaction;beta-Adrenergic Blocker;Established Pharmacologic Class (EPC);Nervous System Agent,"Beta blocking agents, non-selective;CARDIOVASCULAR SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);BETA BLOCKING AGENTS",,"Migraine Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Disease;Headache Disorders, Primary;Headache Disorders;Central Nervous System Diseases;Brain Diseases",,VA CLASSES;CARDIOVASCULAR MEDICATIONS;ANTIHYPERTENSIVE COMBINATIONS;BETA BLOCKERS/RELATED,VA CLASSES;CARDIOVASCULAR MEDICATIONS;BETA BLOCKERS/RELATED,,,,,,,,
102,23,Concomitant Medications,Generic Name,RxNorm,loratadine,24 HR desloratadine 5 MG / Pseudoephedrine sulfate 240 MG Extended Release Oral Tablet,1112258.0,24 HR desloratadine 5 MG / Pseudoephedrine sulfate 240 MG Extended Release Oral Tablet,28889.0,28889.0,28889,False,Medicinal product categorized by disposition;Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Piperidine derivative-containing product,"Histamine Agents;Histamine H1 Antagonists, Non-Sedating;Therapeutic Uses;Antipruritics;Neurotransmitter Agents;Anti-Allergic Agents;MeSH Pharmacologic Actions (MESHPA);Histamine H1 Antagonists;Physiological Effects of Drugs;Dermatologic Agents;Molecular Mechanisms of Pharmacological Action;Histamine Antagonists","Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Respiratory Tract Infections;Respiratory Hypersensitivity;Rhinitis;Nose Diseases;Skin Diseases, Vascular;Hypersensitivity;Disease;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Rhinitis, Allergic;Immune System Diseases;Skin and Connective Tissue Diseases;Infections;Urticaria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Rhinitis, Allergic, Perennial;Skin Diseases","Heterocyclic Compounds;Dibenzocycloheptenes;Hydrocarbons, Cyclic;Polycyclic Compounds;Substances;Cyproheptadine;Organic Chemicals;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Hydrocarbons;Piperidines;Polycyclic Aromatic Hydrocarbons;Benzocycloheptenes;Loratadine;Hydrocarbons, Aromatic",,Immunologically Active Molecule Activity Alteration;Decreased Immunologically Active Molecule Activity;Organ System Specific Effects;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Histamine Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Decreased Immunologically Active Biogenic Amine Activity;Decreased Histamine Activity;Generalized Systemic Effects,Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Antagonists;Receptor Interactions;Histamine Receptor Interactions;Histamine H1 Receptor Antagonists,,Other antihistamines for systemic use;RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),,,,"ANTIHISTAMINE/DECONGESTANT;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES;ANTIHISTAMINES,OTHER;COLD REMEDIES,COMBINATIONS","ANTIHISTAMINE/DECONGESTANT;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES;ANTIHISTAMINES,OTHER;COLD REMEDIES,COMBINATIONS",,,,,,,,
103,23,Concomitant Medications,Generic Name,RxNorm,xyzol,,,,,398335.0,398335,True,Medicinal product categorized by disposition;Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product,,"Histamine Agents;Histamine H1 Antagonists, Non-Sedating;Neurotransmitter Agents;MeSH Pharmacologic Actions (MESHPA);Histamine H1 Antagonists;Physiological Effects of Drugs;Molecular Mechanisms of Pharmacological Action;Histamine Antagonists","Chemically-Induced Disorders;Male Urogenital Diseases;Kidney Diseases;Renal Insufficiency;Urologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Drug-Related Side Effects and Adverse Reactions;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Skin Diseases, Vascular;Respiratory Tract Diseases;Urticaria;Otorhinolaryngologic Diseases;Rhinitis, Allergic, Seasonal;Skin and Connective Tissue Diseases;Respiratory Hypersensitivity;Hypersensitivity;Disease;Infections;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nose Diseases;Rhinitis, Allergic;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Skin Diseases","Heterocyclic Compounds;Hydroxyzine;Substances;Cetirizine;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Piperazines",,Immunologically Active Molecule Activity Alteration;Decreased Immunologically Active Molecule Activity;Organ System Specific Effects;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Histamine Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Decreased Immunologically Active Biogenic Amine Activity;Decreased Histamine Activity;Generalized Systemic Effects,Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Histamine Receptor Antagonists;Receptor Interactions;Histamine Receptor Interactions;Histamine H1 Receptor Antagonists,Histamine-1 Receptor Antagonist;Receptor Interaction;Receptor Antagonist;Established Pharmacologic Class (EPC),RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4);Piperazine derivatives,,,,"ANTIHISTAMINES;ANTIHISTAMINES,PIPERAZINE;VA CLASSES","ANTIHISTAMINES;ANTIHISTAMINES,PIPERAZINE;VA CLASSES",,,,,,,,
104,23,Concomitant Medications,Generic Name,RxNorm,finesteride,,,,,25025.0,25025,True,Medicinal product categorized by disposition;5-alpha reductase inhibitor-containing product;Enzyme inhibitor-containing product,Steroid-containing product;Medicinal product categorized by structure,"Therapeutic Uses;Urological Agents;Enzyme Inhibitors;5-alpha Reductase Inhibitors;Genitourinary Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Steroid Synthesis Inhibitors;Molecular Mechanisms of Pharmacological Action;Hormone Antagonists","Chemically-Induced Disorders;Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Disease;Drug-Related Side Effects and Adverse Reactions;Reproduction;Child;Age Groups;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena","Male Urogenital Diseases;Neoplasms;Signs and Symptoms;Urogenital Neoplasms;Pathological Conditions, Anatomical;Hirsutism;Skin and Connective Tissue Diseases;Pathological Conditions, Signs and Symptoms;Genital Neoplasms, Male;Alopecia;Female Urogenital Diseases and Pregnancy Complications;Disease;Neoplasms by Site;Hypotrichosis;Prostatic Neoplasms;Virilism;Hair Diseases;Genital Diseases;Prostatic Hyperplasia;Genital Diseases, Male;Female Urogenital Diseases;Prostatic Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases","Androstanes;Azasteroids;Androstenes;Polycyclic Compounds;Substances;Steroids;Steroids, Heterocyclic;Substances and Cells (CHEM);Fused-Ring Compounds;Finasteride",,Organ System Specific Effects;Endocrine Activity Alteration;Decreased Dihydrotestosterone Secretion;Physiologic Effect (PE);Testicular Endocrine Activity Alteration,Mechanism of Action (MoA);Androgen Synthesis Inhibitors;Enzyme Inhibitors;5-alpha Reductase Inhibitors;Sex Hormone Synthesis Inhibitors;Steroid Synthesis Inhibitors;Enzyme Interactions,Enzyme Interaction;5-alpha Reductase Inhibitor;Established Pharmacologic Class (EPC);Enzyme Inhibitor,Testosterone-5-alpha reductase inhibitors;DERMATOLOGICALS;UROLOGICALS;DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY;OTHER DERMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Other dermatologicals;GENITO URINARY SYSTEM AND SEX HORMONES,,,,"HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,,,,
105,24,Concomitant Medications,Generic Name,RxNorm,pioglitazone,alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet,1368403.0,alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet,33738.0,33738.0,33738,False,Thiazolidinedione-containing product;Peroxisome proliferator-activated receptor agonist-containing product;Medicinal product categorized by disposition;Peroxisome proliferator-activated gamma receptor agonist-containing product,Sulfur and/or sulfur compound-containing product;Thiazolidinedione-containing product;Thiazole-containing product;Medicinal product categorized by structure,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,"Chemically-Induced Disorders;Heart Failure;Digestive System Diseases;Disease;Drug-Related Side Effects and Adverse Reactions;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Drug Hypersensitivity;Heart Diseases","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases","Pioglitazone;Heterocyclic Compounds;Substances;Thiazoles;Azoles;Organic Chemicals;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Thiazolidinediones;Inorganic Chemicals;Sulfur Compounds",,Glucose Metabolism Alteration;Increased Glycolysis;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Generalized Systemic Effects,Mechanism of Action (MoA);Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Transcription Factor Activity;Receptor Interactions;Peroxisome Proliferator-activated Receptor alpha Agonists;Peroxisome Proliferator-activated Receptor Activity;Insulin Receptor Agonists,Peroxisome Proliferator Receptor alpha Agonist;Receptor Interaction;Blood Glucose Regulator;Chemical Structure;Receptor Agonist;Peroxisome Proliferator Receptor gamma Agonist;Thiazolidinedione;Established Pharmacologic Class (EPC),"ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Thiazolidinediones;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,"Heterocyclic Compounds;Receptors, Cytoplasmic and Nuclear;Substances;Thiazoles;Peroxisome Proliferator-Activated Receptors;Proteins;Substances and Cells (CHEM);PPAR alpha;Azoles;Transcription Factors;PPAR gamma;Heterocyclic Compounds, 1-Ring;Organic Chemicals;Thiazolidinediones;Amino Acids, Peptides, and Proteins;Inorganic Chemicals;Sulfur Compounds",,,,,,
106,24,Concomitant Medications,Generic Name,RxNorm,vitamin d,,,,11253.0,11253.0,11253,False,,,Bone Density Conservation Agents;Vitamins;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Micronutrients,,,Vitamin D;Polycyclic Compounds;Substances;Steroids;Substances and Cells (CHEM);Secosteroids;Fused-Ring Compounds,,,,,,,,,,,,,,,,,,
107,34,Concomitant Medications,Generic Name,RxNorm,Vitamin D,,,,11253.0,11253.0,11253,False,,,Bone Density Conservation Agents;Vitamins;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Micronutrients,,,Vitamin D;Polycyclic Compounds;Substances;Steroids;Substances and Cells (CHEM);Secosteroids;Fused-Ring Compounds,,,,,,,,,,,,,,,,,,
108,45,Concomitant Medications,Generic Name,RxNorm,Vitamin D,Vitamin D,11253.0,Vitamin D,11253.0,11253.0,11253,False,,,Bone Density Conservation Agents;Vitamins;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Micronutrients,,,Vitamin D;Polycyclic Compounds;Substances;Steroids;Substances and Cells (CHEM);Secosteroids;Fused-Ring Compounds,,,,,,,,,,,,,,,,,,
109,25,Concomitant Medications,Generic Name,RxNorm,Codeine cough syrup,,,,,756905.0,756905,True,Medicinal product categorized by disposition;Opioid receptor agonist-containing product;Morphinan opioid-containing product,Alkaloid-containing product;Ether structure-containing product;Naturally occurring alkaloid-containing product;Medicinal product categorized by structure;Morphinan-containing product;Isoquinoline-containing product;Morphinan opioid-containing product,"Therapeutic Uses;Analgesics, Opioid;Sensory System Agents;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Narcotics;Physiological Effects of Drugs;Expectorants;Respiratory System Agents;Central Nervous System Depressants;Analgesics","Lung Diseases;Respiratory Tract Diseases;Reproduction;Respiratory Insufficiency;Central Nervous System Diseases;Pregnancy;Bronchial Diseases;Brain Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;Intracranial Hypertension;Drug Hypersensitivity;Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Reproductive Physiological Phenomena;Respiration Disorders","Lung Diseases;Sinusitis;Bordetella Infections;Respiratory Tract Diseases;Common Cold;Signs and Symptoms;Pain;Virus Diseases;Signs and Symptoms, Respiratory;Neurologic Manifestations;Otorhinolaryngologic Diseases;Bronchial Diseases;Paranasal Sinus Diseases;Bacterial Infections;Pathological Conditions, Signs and Symptoms;Pain, Postoperative;Postoperative Complications;Gram-Negative Bacterial Infections;Respiratory Hypersensitivity;Laryngeal Diseases;Pharyngitis;Bacterial Infections and Mycoses;Whooping Cough;Lung Diseases, Obstructive;Hypersensitivity;Disease;RNA Virus Infections;Infections;Stomatognathic Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Pharyngeal Diseases;Nervous System Diseases;Nose Diseases;Rhinitis, Allergic;Cough;Immune System Diseases;Picornaviridae Infections;Laryngitis;Bronchitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pathologic Processes;Respiration Disorders","Heterocyclic Compounds, 4 or More Rings;Phenols;Heterocyclic Compounds, Bridged-Ring;Hydrocarbons, Aromatic;Heterocyclic Compounds, Fused-Ring;Hydrocarbons, Cyclic;Catechols;Phenyl Ethers;Alkaloids;Guaiacol;Heterocyclic Compounds;Polycyclic Compounds;Hydromorphone;Ethers;Substances and Cells (CHEM);Morphine Derivatives;Polycyclic Aromatic Hydrocarbons;Benzene Derivatives;Morphinans;Opiate Alkaloids;Methyl Ethers;Substances;Organic Chemicals;Hydrocarbons;Guaifenesin;Phenanthrenes",Decreased Organized Electrical Activity;Organized Electrical Activity Alteration;Organ System Specific Effects;Decreased Central Nervous System Organized Electrical Activity;Nervous System Activity Alteration;Electrical Activity Alteration;Physiologic Effect (PE),Decreased Respiratory Secretion Viscosity;Analgesia;Electrical Activity Alteration;Central Nervous System Depression;Respiratory Secretion Alteration;Respiratory Secretion Viscosity Alteration;Decreased Organized Electrical Activity;Organized Electrical Activity Alteration;Organ System Specific Effects;Central Nervous System Activity Alteration;Nervous System Activity Alteration;Peripheral Nervous System Activity Alteration;Physiologic Effect (PE);Sensory System Activity Alteration;Increased Respiratory Secretions;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Opioid Receptor Interactions;Full Opioid Agonists;Opioid mu-Receptor Agonists;G-Protein-linked Receptor Interactions;Opioid Agonists;Receptor Interactions,Receptor Interaction;Opioid Agonist;Respiratory Agent;Receptor Agonist;Expectorant;Established Pharmacologic Class (EPC);Nervous System Agent,"OPIOIDS;Natural opium alkaloids;ANALGESICS;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Expectorants;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM",Medicinal product categorized by therapeutic role;Expectorant agent,,,,,,,,,,,,
110,25,Concomitant Medications,Generic Name,RxNorm,azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,,Macrolide antibacterial agent;Macrolide-containing product;Medicinal product categorized by structure,Therapeutic Uses;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Infective Agents,"Digestive System Diseases;Hypersensitivity;Disease;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases","Male Urogenital Diseases;Lung Diseases;Ear Diseases;Respiratory Tract Diseases;Pneumonia, Mycoplasma;Sexually Transmitted Diseases;Urologic Diseases;Otorhinolaryngologic Diseases;Staphylococcal Infections;Streptococcal Infections;Skin and Connective Tissue Diseases;Bacterial Infections;Mycobacterium Infections;Sexually Transmitted Diseases, Bacterial;Haemophilus Infections;Pathological Conditions, Signs and Symptoms;Disease Attributes;Mycobacterium Infections, Nontuberculous;Gram-Negative Bacterial Infections;Tonsillitis;Female Urogenital Diseases and Pregnancy Complications;Bacterial Infections and Mycoses;Pharyngitis;Gram-Positive Bacterial Infections;Urethral Diseases;Chlamydia Infections;Disease;Urethritis;Pneumonia, Bacterial;Infections;Actinomycetales Infections;Stomatognathic Diseases;Otitis;Pharyngeal Diseases;Respiratory Tract Infections;Skin Diseases, Infectious;Genital Diseases;Chlamydiaceae Infections;Mycoplasmatales Infections;Otitis Media;Pneumonia;Pasteurellaceae Infections;Female Urogenital Diseases;Neisseriaceae Infections;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mycoplasma Infections;Pathologic Processes;Skin Diseases;Communicable Diseases",Erythromycin;Lactones;Polycyclic Compounds;Substances;Organic Chemicals;Substances and Cells (CHEM);Macrocyclic Compounds;Polyketides;Macrolides;Azithromycin,,Striated Muscle Anabolism Alteration;Cellular Cycle Alteration;Organ System Specific Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Musculoskeletal Activity Alteration;Translation Alteration;Physiologic Effect (PE);Cellular Activity Alteration;Decreased Protein Synthesis;Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Enzyme Interactions,Macrolide;Macrolide Antimicrobial;Anti-infective;Chemical Structure;Antimicrobial;Established Pharmacologic Class (EPC),"Macrolides;ANTIINFECTIVES FOR SYSTEMIC USE;SENSORY ORGANS;ANTIINFECTIVES;Antibiotics;ANTIBACTERIALS FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",Medicinal product categorized by therapeutic role;Macrolide antibacterial agent;Antibacterial agent;Antiinfective agent,"Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Endocarditis, Bacterial;Disease;Bacterial Infections;Cardiovascular Diseases;Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Actinomycetales Infections;Mycobacterium Infections;Cardiovascular Infections;Endocarditis;Mycobacterium Infections, Nontuberculous;Heart Diseases",Antimicrobial Agent;Anti-infective Agent;Therapeutic Categories,"ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;VA CLASSES;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;ANTI-INFECTIVE,TOPICAL OPHTHALMIC","ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;VA CLASSES;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;ANTI-INFECTIVE,TOPICAL OPHTHALMIC",,Lactones;Polycyclic Compounds;Substances;Organic Chemicals;Substances and Cells (CHEM);Macrocyclic Compounds;Polyketides;Macrolides,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Substances;Pimozide;Substances and Cells (CHEM);Benzimidazoles",,,Elimination;Pharmacokinetics (PK);Hepatic Excretion;Route of Excretion,,
111,34,Concomitant Medications,Generic Name,RxNorm,Azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,,Macrolide antibacterial agent;Macrolide-containing product;Medicinal product categorized by structure,Therapeutic Uses;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Infective Agents,"Digestive System Diseases;Hypersensitivity;Disease;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases","Male Urogenital Diseases;Lung Diseases;Ear Diseases;Respiratory Tract Diseases;Pneumonia, Mycoplasma;Sexually Transmitted Diseases;Urologic Diseases;Otorhinolaryngologic Diseases;Staphylococcal Infections;Streptococcal Infections;Skin and Connective Tissue Diseases;Bacterial Infections;Mycobacterium Infections;Sexually Transmitted Diseases, Bacterial;Haemophilus Infections;Pathological Conditions, Signs and Symptoms;Disease Attributes;Mycobacterium Infections, Nontuberculous;Gram-Negative Bacterial Infections;Tonsillitis;Female Urogenital Diseases and Pregnancy Complications;Bacterial Infections and Mycoses;Pharyngitis;Gram-Positive Bacterial Infections;Urethral Diseases;Chlamydia Infections;Disease;Urethritis;Pneumonia, Bacterial;Infections;Actinomycetales Infections;Stomatognathic Diseases;Otitis;Pharyngeal Diseases;Respiratory Tract Infections;Skin Diseases, Infectious;Genital Diseases;Chlamydiaceae Infections;Mycoplasmatales Infections;Otitis Media;Pneumonia;Pasteurellaceae Infections;Female Urogenital Diseases;Neisseriaceae Infections;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mycoplasma Infections;Pathologic Processes;Skin Diseases;Communicable Diseases",Erythromycin;Lactones;Polycyclic Compounds;Substances;Organic Chemicals;Substances and Cells (CHEM);Macrocyclic Compounds;Polyketides;Macrolides;Azithromycin,,Striated Muscle Anabolism Alteration;Cellular Cycle Alteration;Organ System Specific Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Musculoskeletal Activity Alteration;Translation Alteration;Physiologic Effect (PE);Cellular Activity Alteration;Decreased Protein Synthesis;Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Enzyme Interactions,Macrolide;Macrolide Antimicrobial;Anti-infective;Chemical Structure;Antimicrobial;Established Pharmacologic Class (EPC),"Macrolides;ANTIINFECTIVES FOR SYSTEMIC USE;SENSORY ORGANS;ANTIINFECTIVES;Antibiotics;ANTIBACTERIALS FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",Medicinal product categorized by therapeutic role;Macrolide antibacterial agent;Antibacterial agent;Antiinfective agent,"Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Endocarditis, Bacterial;Disease;Bacterial Infections;Cardiovascular Diseases;Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Actinomycetales Infections;Mycobacterium Infections;Cardiovascular Infections;Endocarditis;Mycobacterium Infections, Nontuberculous;Heart Diseases",Antimicrobial Agent;Anti-infective Agent;Therapeutic Categories,"ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;VA CLASSES;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;ANTI-INFECTIVE,TOPICAL OPHTHALMIC","ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;VA CLASSES;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;ANTI-INFECTIVE,TOPICAL OPHTHALMIC",,Lactones;Polycyclic Compounds;Substances;Organic Chemicals;Substances and Cells (CHEM);Macrocyclic Compounds;Polyketides;Macrolides,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Substances;Pimozide;Substances and Cells (CHEM);Benzimidazoles",,,Elimination;Pharmacokinetics (PK);Hepatic Excretion;Route of Excretion,,
112,43,Concomitant Medications,Generic Name,RxNorm,Azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,,Macrolide antibacterial agent;Macrolide-containing product;Medicinal product categorized by structure,Therapeutic Uses;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Infective Agents,"Digestive System Diseases;Hypersensitivity;Disease;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases","Male Urogenital Diseases;Lung Diseases;Ear Diseases;Respiratory Tract Diseases;Pneumonia, Mycoplasma;Sexually Transmitted Diseases;Urologic Diseases;Otorhinolaryngologic Diseases;Staphylococcal Infections;Streptococcal Infections;Skin and Connective Tissue Diseases;Bacterial Infections;Mycobacterium Infections;Sexually Transmitted Diseases, Bacterial;Haemophilus Infections;Pathological Conditions, Signs and Symptoms;Disease Attributes;Mycobacterium Infections, Nontuberculous;Gram-Negative Bacterial Infections;Tonsillitis;Female Urogenital Diseases and Pregnancy Complications;Bacterial Infections and Mycoses;Pharyngitis;Gram-Positive Bacterial Infections;Urethral Diseases;Chlamydia Infections;Disease;Urethritis;Pneumonia, Bacterial;Infections;Actinomycetales Infections;Stomatognathic Diseases;Otitis;Pharyngeal Diseases;Respiratory Tract Infections;Skin Diseases, Infectious;Genital Diseases;Chlamydiaceae Infections;Mycoplasmatales Infections;Otitis Media;Pneumonia;Pasteurellaceae Infections;Female Urogenital Diseases;Neisseriaceae Infections;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mycoplasma Infections;Pathologic Processes;Skin Diseases;Communicable Diseases",Erythromycin;Lactones;Polycyclic Compounds;Substances;Organic Chemicals;Substances and Cells (CHEM);Macrocyclic Compounds;Polyketides;Macrolides;Azithromycin,,Striated Muscle Anabolism Alteration;Cellular Cycle Alteration;Organ System Specific Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Musculoskeletal Activity Alteration;Translation Alteration;Physiologic Effect (PE);Cellular Activity Alteration;Decreased Protein Synthesis;Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Enzyme Interactions,Macrolide;Macrolide Antimicrobial;Anti-infective;Chemical Structure;Antimicrobial;Established Pharmacologic Class (EPC),"Macrolides;ANTIINFECTIVES FOR SYSTEMIC USE;SENSORY ORGANS;ANTIINFECTIVES;Antibiotics;ANTIBACTERIALS FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",Medicinal product categorized by therapeutic role;Macrolide antibacterial agent;Antibacterial agent;Antiinfective agent,"Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Endocarditis, Bacterial;Disease;Bacterial Infections;Cardiovascular Diseases;Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Actinomycetales Infections;Mycobacterium Infections;Cardiovascular Infections;Endocarditis;Mycobacterium Infections, Nontuberculous;Heart Diseases",Antimicrobial Agent;Anti-infective Agent;Therapeutic Categories,"ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;VA CLASSES;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;ANTI-INFECTIVE,TOPICAL OPHTHALMIC","ERYTHROMYCINS/MACROLIDES;OPHTHALMIC AGENTS;VA CLASSES;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;ANTI-INFECTIVE,TOPICAL OPHTHALMIC",,Lactones;Polycyclic Compounds;Substances;Organic Chemicals;Substances and Cells (CHEM);Macrocyclic Compounds;Polyketides;Macrolides,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Substances;Pimozide;Substances and Cells (CHEM);Benzimidazoles",,,Elimination;Pharmacokinetics (PK);Hepatic Excretion;Route of Excretion,,
113,25,Concomitant Medications,Generic Name,RxNorm,Qvar,Beclomethasone Dipropionate 0.04 MG/ACTUAT [Qvar],966537.0,Beclomethasone Dipropionate 0.04 MG/ACTUAT [Qvar],226084.0,226084.0,226084,False,,Medicinal product categorized by structure;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Steroid-containing product;Pregnane-containing product,"Therapeutic Uses;Anti-Inflammatory Agents;Hormones;MeSH Pharmacologic Actions (MESHPA);Glucocorticoids;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Respiratory System Agents;Anti-Asthmatic Agents","Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Lung Diseases;Status Asthmaticus;Lung Diseases, Obstructive;Hypersensitivity;Respiratory Tract Diseases;Disease;Drug-Related Side Effects and Adverse Reactions;Bronchial Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Drug Hypersensitivity","Respiratory Tract Infections;Respiratory Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Hypersensitivity;Disease;Respiratory Tract Diseases;Rhinitis, Allergic;Rhinitis, Allergic, Perennial;Inflammation;Immune System Diseases;Pathological Conditions, Signs and Symptoms;Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pathologic Processes;Rhinitis","Pregnadienetriols;Pregnadienes;Polycyclic Compounds;Substances;Beclomethasone;Steroids;Substances and Cells (CHEM);Fused-Ring Compounds;Steroids, Chlorinated;Pregnanes",,Organ System Specific Effects;Endocrine Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Cellular Activity Alteration;Decreased Glucocorticoid Secretion;Generalized Systemic Effects;Vasoconstriction;Cellular Degradation/Digestion Alteration;Cardiovascular Activity Alteration;Decreased Cellular Migration;Cellular Motion Alteration;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Translation Alteration;Lysosomal Function Alteration;Vascular Tone Alteration;Decreased Lysosomal Function;Striated Muscle Anabolism Alteration;Adrenal Cortical Activity Alteration;Musculoskeletal Activity Alteration;Vascular Alterations;Decreased Protein Synthesis,Mechanism of Action (MoA);Glucocorticoid Receptor Agonists;Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Corticosteroid Hormone Receptor Agonists,Hormone;Receptor Interaction;Corticosteroid;Chemical Structure;Receptor Agonist;Established Pharmacologic Class (EPC),"NASAL PREPARATIONS;Corticosteroids acting locally;RESPIRATORY SYSTEM;CORTICOSTEROIDS, PLAIN;ALIMENTARY TRACT AND METABOLISM;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Glucocorticoids;DERMATOLOGICALS;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Corticosteroids, potent (group III);Corticosteroids;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;INTESTINAL ANTIINFLAMMATORY AGENTS",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Polyps;Pathological Conditions, Anatomical;Lung Diseases, Obstructive;Nose Diseases;Hypersensitivity;Respiratory Tract Diseases;Disease;Otorhinolaryngologic Diseases;Bronchial Diseases;Immune System Diseases;Nasal Polyps;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",,"RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION;VA CLASSES","RESPIRATORY TRACT MEDICATIONS;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION;VA CLASSES",,,,,,Renal Excretion;Fecal Excretion;Route of Excretion;Elimination;Pharmacokinetics (PK),,
114,25,Concomitant Medications,Generic Name,RxNorm,Vitamin D3,Cholecalciferol 50000 UNT Oral Tablet [Dialyvite Vitamin D3 Max],1303916.0,Cholecalciferol 50000 UNT Oral Tablet [Dialyvite Vitamin D3 Max],1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
115,26,Concomitant Medications,Generic Name,RxNorm,Vitamin D3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
116,29,Concomitant Medications,Generic Name,RxNorm,vitamin d3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
117,30,Concomitant Medications,Generic Name,RxNorm,vitamin d3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
118,32,Concomitant Medications,Generic Name,RxNorm,Vitamin D3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
119,25,Concomitant Medications,Generic Name,RxNorm,Acetaminophen,Acetaminophen,161.0,Acetaminophen,161.0,161.0,161,False,Medicinal product categorized by disposition;Opioid receptor agonist-containing product;Morphinan opioid-containing product,Alkaloid-containing product;Nitrogen and/or nitrogen compound-containing product;Naturally occurring alkaloid-containing product;Medicinal product categorized by structure;Morphinan-containing product;Phenol structure-containing product;Isoquinoline-containing product;Morphinan opioid-containing product,"Therapeutic Uses;Antipyretics;Anti-Inflammatory Agents;Antirheumatic Agents;Analgesics, Opioid;Sensory System Agents;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Narcotics;Physiological Effects of Drugs;Central Nervous System Depressants;Analgesics","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;Anilides;Opioids in combination with non-opioid analgesics;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OPIOIDS;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;ANTIRHEUMATICS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;CNS MEDICATIONS,OTHER;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,COMBINATIONS;DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;ANALGESICS;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINE/ANTITUSSIVE;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIHISTAMINE/ANTITUSSIVE;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;COLD REMEDIES,COMBINATIONS;NON-OPIOID ANALGESICS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;DECONGESTANT/ANTITUSSIVE/ANALGESIC",SCHEDULE V;SCHEDULE III;SCHEDULE II;SCHEDULE IV;CSA SCHEDULE,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
120,39,Concomitant Medications,Generic Name,RxNorm,acetaminophen,Acetaminophen,161.0,Acetaminophen,161.0,161.0,161,False,Medicinal product categorized by disposition;Opioid receptor agonist-containing product;Morphinan opioid-containing product,Alkaloid-containing product;Nitrogen and/or nitrogen compound-containing product;Naturally occurring alkaloid-containing product;Medicinal product categorized by structure;Morphinan-containing product;Phenol structure-containing product;Isoquinoline-containing product;Morphinan opioid-containing product,"Therapeutic Uses;Antipyretics;Anti-Inflammatory Agents;Antirheumatic Agents;Analgesics, Opioid;Sensory System Agents;Central Nervous System Agents;Anti-Inflammatory Agents, Non-Steroidal;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Analgesics, Non-Narcotic;Narcotics;Physiological Effects of Drugs;Central Nervous System Depressants;Analgesics","Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Anemia;Digestive System Diseases;Metabolic Diseases;Chemically-Induced Disorders;Anemia, Hemolytic, Congenital;Disease;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Anemia, Hemolytic;Drug-Related Side Effects and Adverse Reactions;Carbohydrate Metabolism, Inborn Errors;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Liver Diseases;Genetic Diseases, Inborn;Glucosephosphate Dehydrogenase Deficiency","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",Acetaminophen;Substances;Amines;Organic Chemicals;Amides;Substances and Cells (CHEM);Aniline Compounds;Acetanilides;Anilides,,Decreased Eicosanoid Production;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Endocrine Activity Alteration;Central Nervous System Activity Alteration;Generalized Systemic Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Peripheral Nervous System Activity Alteration;Nervous System Activity Alteration;Decreased Immunologic Activity;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Decreased Prostaglandin Production,Mechanism of Action (MoA);Prostaglandin Receptor Interactions;G-Protein-linked Receptor Interactions;Prostaglandin Receptor Antagonists;Receptor Interactions,,ANALGESICS;Anilides;Opioids in combination with non-opioid analgesics;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OPIOIDS;OTHER ANALGESICS AND ANTIPYRETICS,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neurologic Manifestations;Nervous System Diseases;Disease;Body Temperature Changes;Fever;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Pain",,"CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;ANTIRHEUMATICS;OPIOID ANALGESICS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;CNS MEDICATIONS,OTHER;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,COMBINATIONS;DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;ANALGESICS;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINE/ANTITUSSIVE;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER;NONSALICYLATE NSAIs,ANTIRHEUMATIC","CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;ANALGESICS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;CNS MEDICATIONS,OTHER;ANTIHISTAMINE/ANTITUSSIVE;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;COLD REMEDIES,COMBINATIONS;NON-OPIOID ANALGESICS;OPIOID ANALGESICS;COLD REMEDIES,OTHER;DECONGESTANT/ANTITUSSIVE/ANALGESIC",SCHEDULE V;SCHEDULE III;SCHEDULE II;SCHEDULE IV;CSA SCHEDULE,,,,,Hepatic Metabolism;Renal Excretion;Site of Metabolism;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
121,26,Concomitant Medications,Generic Name,RxNorm,Hydrocortisone 2%,,,,,197784.0,197784,True,Medicinal product categorized by disposition;Hormone-containing product;Adrenal hormone-containing product;Adrenal cortex hormone-containing product,Medicinal product categorized by structure;Steroid-containing product;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product,Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Anti-Inflammatory Agents,"Tuberculosis;Tuberculosis, Extrapulmonary;Skin Diseases, Viral;Parasitic Diseases;Skin Diseases, Parasitic;Mycoses;Virus Diseases;Skin and Connective Tissue Diseases;Bacterial Infections;Mycobacterium Infections;Chemically-Induced Disorders;Tuberculosis, Cutaneous;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Skin Diseases, Bacterial;Disease;Dermatomycoses;Infections;Actinomycetales Infections;Drug Hypersensitivity;Skin Diseases, Infectious;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases","Endocrine System Diseases;Male Urogenital Diseases;Adrenal Insufficiency;Lung Diseases;Status Asthmaticus;Rectal Diseases;Inflammatory Bowel Diseases;Connective Tissue Diseases;Respiratory Tract Diseases;Nutritional and Metabolic Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Facial Dermatoses;Pruritus;Signs and Symptoms;Cardiovascular Diseases;Vascular Diseases;Skin Diseases;Anus Diseases;Disorders of Sex Development;Colitis;Colonic Diseases;Dermatitis;Gonadal Disorders;Gastrointestinal Diseases;Musculoskeletal Diseases;Digestive System Diseases;Leg Dermatoses;Urogenital Abnormalities;Steroid Metabolism, Inborn Errors;Inflammation;Skin Manifestations;Skin and Connective Tissue Diseases;Bronchial Diseases;Colitis, Ulcerative;Pathological Conditions, Signs and Symptoms;Metabolic Diseases;Pruritus Ani;Intestinal Diseases;Congenital Abnormalities;Asthma;Respiratory Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Scalp Dermatoses;Lung Diseases, Obstructive;Hypersensitivity;Disease;Gastroenteritis;Rheumatic Diseases;Adrenogenital Syndrome;Adrenal Hyperplasia, Congenital;Dermatitis, Contact;Hemorrhoids;Hand Dermatoses;Skin Diseases, Eczematous;Foot Dermatoses;Shock;Immune System Diseases;Foot Diseases;Metabolism, Inborn Errors;Adrenal Gland Diseases;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pathologic Processes;Genetic Diseases, Inborn","Hydrocortisone;Pregnenediones;Hormones;Polycyclic Compounds;Substances;Steroids;Substances and Cells (CHEM);11-Hydroxycorticosteroids;Fused-Ring Compounds;Hormones, Hormone Substitutes, and Hormone Antagonists;Adrenal Cortex Hormones;Hydroxycorticosteroids;Pregnenes;Pregnanes;17-Hydroxycorticosteroids",,Decreased Vascular Permeability;Immunologically Active Molecule Activity Alteration;Decreased Prostaglandin Activity;Decreased Eicosanoid Activity;Endocrine Activity Alteration;Organ System Specific Effects;Decreased Fibroblast Migration;Decreased Lipid Derived Immunologically Active Molecule Activity;Physiologic Effect (PE);Carbohydrate Metabolism Alteration;Cellular Cycle Alteration;Immunologic Activity Alteration;Decreased Thromboxane Activity;Decreased Glucocorticoid Secretion;Cellular Activity Alteration;Generalized Systemic Effects;Metabolic Activity Alteration;Cellular Degradation/Digestion Alteration;Cardiovascular Activity Alteration;Decreased Cellular Migration;Cellular Motion Alteration;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Translation Alteration;Lysosomal Function Alteration;Decreased Lysosomal Function;Vascular Permeability Alteration;Striated Muscle Anabolism Alteration;Adrenal Cortical Activity Alteration;Decreased Immunologically Active Molecule Activity;Lipid Metabolism Alteration;Decreased Polymorphonuclear Leukocyte Migration;Decreased Capillary Permeability;Musculoskeletal Activity Alteration;Decreased Immunologic Activity;Vascular Alterations;Decreased Leukotriene Activity;Decreased Protein Synthesis,Mechanism of Action (MoA);Lipoxygenase Inhibitors;Enzyme Inhibitors;Glucocorticoid Receptor Agonists;Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Enzyme Interactions;Corticosteroid Hormone Receptor Agonists,Hormone;Receptor Interaction;Corticosteroid;Chemical Structure;Receptor Agonist;Established Pharmacologic Class (EPC),"CORTICOSTEROIDS, PLAIN;ALIMENTARY TRACT AND METABOLISM;AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;Corticosteroids, weak (group I);CORTICOSTEROIDS, OTHER COMBINATIONS;OPHTHALMOLOGICALS;CORTICOSTEROIDS FOR SYSTEMIC USE;CARDIOVASCULAR SYSTEM;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids for local oral treatment;ANTIINFLAMMATORY AGENTS;ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;DERMATOLOGICALS;Corticosteroids/antiinfectives/mydriatics in combination;Anatomical Therapeutic Chemical (ATC1-4);OTOLOGICALS;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;Corticosteroids;Corticosteroids, plain;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;Corticosteroids, weak, other combinations;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;VASOPROTECTIVES;Glucocorticoids;CORTICOSTEROIDS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",,,,"DERMATOLOGICAL AGENTS;ANTI-INFLAMMATORY,TOPICAL;VA CLASSES","DERMATOLOGICAL AGENTS;ANTI-INFLAMMATORY,TOPICAL;VA CLASSES",,,,,,,,
122,27,Concomitant Medications,Generic Name,RxNorm,Decadron,Decadron Pill,1170298.0,Decadron Pill,227682.0,227682.0,227682,False,Medicinal product categorized by disposition;Immunomodulator-containing product,Medicinal product categorized by structure;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Fluorinated corticosteroid-containing product;Steroid-containing product;Pregnane-containing product,"Autonomic Agents;Therapeutic Uses;Antineoplastic Agents;Anti-Inflammatory Agents;Antiemetics;Hormones;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Gastrointestinal Agents;Glucocorticoids;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Antineoplastic Agents, Hormonal","Virus Diseases;Mycoses;Chemically-Induced Disorders;Eye Infections, Fungal;Eye Diseases;Bacterial Infections and Mycoses;Disease;Drug-Related Side Effects and Adverse Reactions;Tuberculosis, Ocular;Eye Infections, Bacterial;Infections;Bacterial Infections;Eye Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Eye Infections, Viral;Drug Hypersensitivity","Inflammatory Bowel Diseases;Purpura, Thrombocytopenic;Nutritional and Metabolic Diseases;Panuveitis;Signs and Symptoms;Digestive System Diseases;Spondylarthropathies;Inflammation;Neoplasms by Histologic Type;Metabolic Diseases;Hypersensitivity, Delayed;Purpura, Thrombocytopenic, Idiopathic;Systemic Inflammatory Response Syndrome;Spondylitis;Collagen Diseases;Skin Diseases, Vesiculobullous;Hypersensitivity;Gram-Positive Bacterial Infections;Gastroenteritis;Rheumatic Diseases;Pemphigus;Spinal Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Nervous System Diseases;Addison Disease;Iris Diseases;Water-Electrolyte Imbalance;Uveitis;Central Nervous System Diseases;Sarcoidosis;Adrenal Insufficiency;Thyroiditis;Lung Diseases;Arthritis;Calcium Metabolism Disorders;Lymphoma, T-Cell, Cutaneous;Dermatitis Herpetiformis;Tuberculosis, Pulmonary;Colitis;Lymphoma, Non-Hodgkin;Hemorrhagic Disorders;Ankylosis;Bacterial Infections;Nausea;Brain Edema;Bacterial Infections and Mycoses;Blood Platelet Disorders;Sepsis;Respiratory Tract Infections;Nose Diseases;Hypersensitivity, Immediate;Iritis;Skin Diseases;Endocrine System Diseases;Tuberculosis;Spondylarthritis;Signs and Symptoms, Digestive;Bone Diseases;Bursitis;Colonic Diseases;Dermatitis;Uveal Diseases;Axial Spondyloarthritis;Gastrointestinal Diseases;Musculoskeletal Diseases;Eye Diseases;Otorhinolaryngologic Diseases;Leukemia;Skin and Connective Tissue Diseases;Colitis, Ulcerative;Mycobacterium Infections;Pathological Conditions, Signs and Symptoms;Brain Diseases;Immunoproliferative Disorders;Respiratory Hypersensitivity;Uveitis, Anterior;Corneal Diseases;Thrombotic Microangiopathies;Lymphoproliferative Disorders;Hemic and Lymphatic Diseases;Bone Diseases, Infectious;Hemorrhage;Adrenal Gland Diseases;Thrombocytopenia;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Lymphoma;Mycosis Fungoides;Connective Tissue Diseases;Respiratory Tract Diseases;Neoplasms;Lupus Erythematosus, Systemic;Autoimmune Diseases;Lymphoma, T-Cell;Spondylitis, Ankylosing;Thyroid Diseases;Skin Manifestations;Hypercalcemia;Purpura;Intestinal Diseases;Shock, Septic;Vomiting;Disease;Infections;Actinomycetales Infections;Keratitis;Lymphatic Diseases;Rhinitis, Allergic;Joint Diseases;Shock;Immune System Diseases;Blood Coagulation Disorders;Hematologic Diseases","Pregnadienetriols;Steroids, Fluorinated;Polycyclic Compounds;Pregnadienes;Substances;Dexamethasone;Steroids;Substances and Cells (CHEM);Fused-Ring Compounds;Pregnanes",,Decreased Vascular Permeability;Immunologically Active Molecule Activity Alteration;Decreased Prostaglandin Activity;Hematologic Activity Alteration;Decreased Adhesion Factor Activity;Decreased Eicosanoid Activity;Organ System Specific Effects;Endocrine Activity Alteration;Decreased Fibroblast Migration;Decreased Lipid Derived Immunologically Active Molecule Activity;Nervous System Activity Alteration;Physiologic Effect (PE);Blood & Lymphatic Fluid Function Alteration;Decreased Immunologically Active Biogenic Amine Activity;Carbohydrate Metabolism Alteration;Cellular Cycle Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Decreased Hematopoiesis;Decreased Thromboxane Activity;Hematopoiesis Alteration;Cellular Activity Alteration;Decreased Glucocorticoid Secretion;Generalized Systemic Effects;Metabolic Activity Alteration;Cellular Degradation/Digestion Alteration;Decreased Myeloid Cell Production;Decreased Immunologically Active Molecule Production;Cardiovascular Activity Alteration;Decreased Cellular Migration;Cellular Motion Alteration;Immunologically Active Molecule Production Alteration;Cellular Synthetic Activity Alteration;Striated Muscle Metabolic Alteration;Translation Alteration;Lysosomal Function Alteration;Decreased Complement Production;Hematological Cell Quantity Alteration;Decreased Histamine Activity;Decreased Lysosomal Function;Decreased Kinin Activity;Decreased Intravascular Volume;Vascular Permeability Alteration;Hemic/Lymphatic Activity Alteration;Striated Muscle Anabolism Alteration;Adrenal Cortical Activity Alteration;Decreased Immunologically Active Molecule Activity;Lipid Metabolism Alteration;Decreased Polymorphonuclear Leukocyte Migration;Intravascular Volume Alteration;Histamine Activity Alteration;Decreased Capillary Permeability;Decreased Immunologic Activity;Vascular Alterations;Musculoskeletal Activity Alteration;Decreased Leukotriene Activity;Decreased Protein Synthesis,Mechanism of Action (MoA);Lipoxygenase Inhibitors;Enzyme Inhibitors;Glucocorticoid Receptor Agonists;Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Enzyme Interactions;Corticosteroid Hormone Receptor Agonists,Hormone;Receptor Interaction;Corticosteroid;Chemical Structure;Receptor Agonist;Established Pharmacologic Class (EPC),"Corticosteroids, moderately potent, other combinations;CORTICOSTEROIDS, PLAIN;ALIMENTARY TRACT AND METABOLISM;AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE;CORTICOSTEROIDS, OTHER COMBINATIONS;OPHTHALMOLOGICALS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS FOR SYSTEMIC USE;CARDIOVASCULAR SYSTEM;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids for local oral treatment;ANTIINFLAMMATORY AGENTS;ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;ANTI-ACNE PREPARATIONS;CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;DERMATOLOGICALS;Corticosteroids/antiinfectives/mydriatics in combination;Anatomical Therapeutic Chemical (ATC1-4);OTOLOGICALS;Corticosteroids, moderately potent (group II);DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Corticosteroids;OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS;Corticosteroids, plain;NASAL PREPARATIONS;STOMATOLOGICAL PREPARATIONS;RESPIRATORY SYSTEM;SENSORY ORGANS;VASOPROTECTIVES;Corticosteroids, combinations for treatment of acne;Glucocorticoids;CORTICOSTEROIDS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",,"Lung Diseases;Polyps;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Signs and Symptoms;Pathological Conditions, Anatomical;Otorhinolaryngologic Diseases;Bronchial Diseases;Nasal Polyps;Pathological Conditions, Signs and Symptoms;Nausea;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;Vomiting;Nose Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",,ADRENAL CORTICOSTERIODS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;GLUCOCORTICOIDS,ADRENAL CORTICOSTERIODS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;GLUCOCORTICOIDS,,,,"Endocrine System Diseases;Cushing Syndrome;Disease;Depressive Disorder;Adrenal Gland Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Adrenocortical Hyperfunction;Mental Disorders;Mood Disorders",,,,
123,27,Concomitant Medications,Generic Name,RxNorm,Tamoxifen,Tamoxifen,10324.0,Tamoxifen,10324.0,10324.0,10324,False,Hormone receptor antagonist-containing product;Medicinal product categorized by disposition;Estrogen receptor antagonist-containing product,,"Bone Density Conservation Agents;Antineoplastic Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Estrogen Receptor Modulators;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Estrogen Antagonists;Selective Estrogen Receptor Modulators;Antineoplastic Agents, Hormonal;Hormone Antagonists","Chemically-Induced Disorders;Pregnancy;Embolism;Lung Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Embolism and Thrombosis;Drug Hypersensitivity;Venous Thrombosis;Respiratory Tract Diseases;Disease;Drug-Related Side Effects and Adverse Reactions;Reproduction;Pulmonary Embolism;Cardiovascular Diseases;Vascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena;Thrombosis","Endocrine System Diseases;Gonadal Disorders;Digestive System Diseases;Pancreatic Diseases;Breast Neoplasms;Puberty, Precocious;Disease;Skin and Connective Tissue Diseases;Breast Diseases;Endocrine Gland Neoplasms;Gynecomastia;Digestive System Neoplasms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neoplasms;Neoplasms by Site;Pancreatic Neoplasms;Skin Diseases","Tamoxifen;Hydrocarbons, Cyclic;Substances;Benzylidene Compounds;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Benzene Derivatives;Stilbenes;Hydrocarbons, Aromatic",,Stimulate Ovulation;Decreased Ovarian Estrogen Secretion;Decreased DNA Replication;Cellular Cycle Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Ovulation Alteration;Cellular Synthetic Activity Alteration;DNA Replication Alteration;Nucleic Acid Replication Alteration;Female Reproductive System Activity Alteration;Reproductive System Activity Alteration;Ovarian Endocrine Activity Alteration;Physiologic Effect (PE);Cellular Activity Alteration;Ovarian Function Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Steroid Receptor Modulators;Hormone Receptor Interactions;Transcription Factor Activity;Receptor Interactions;Selective Estrogen Receptor Modulators;Hormone Receptor Modulators,Estrogen Agonist/Antagonist;Receptor Antagonist;Receptor Interaction;Receptor Agonist;Established Pharmacologic Class (EPC),Anti-estrogens;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ENDOCRINE THERAPY;Anatomical Therapeutic Chemical (ATC1-4);HORMONE ANTAGONISTS AND RELATED AGENTS,,"Neoplasms, Ductal, Lobular, and Medullary;Carcinoma, Ductal;Breast Neoplasms;Disease;Carcinoma;Skin and Connective Tissue Diseases;Adenocarcinoma;Breast Diseases;Neoplasms;Neoplasms by Histologic Type;Carcinoma, Ductal, Breast;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Neoplasms by Site;Skin Diseases;Neoplasms, Glandular and Epithelial",,ANTINEOPLASTICS;VA CLASSES;ANTINEOPLASTIC HORMONES,ANTINEOPLASTICS;VA CLASSES;ANTINEOPLASTIC HORMONES,,,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Warfarin;Benzopyrans;Substances;4-Hydroxycoumarins;Coumarins;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Pyrans",,,,,
124,28,Concomitant Medications,Generic Name,RxNorm,Januvia,Januvia Pill,1167815.0,Januvia Pill,638596.0,638596.0,638596,False,Hydrolase inhibitor-containing product;Serine proteinase inhibitor-containing product;Dipeptidyl peptidase IV inhibitor-containing product;Peptide hydrolase inhibitor-containing product;Enzyme inhibitor-containing product;Proteinase inhibitor-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Azole-containing product,"Incretins;Dipeptidyl-Peptidase IV Inhibitors;Enzyme Inhibitors;Hormones;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Hypoglycemic Agents;Protease Inhibitors","Chemically-Induced Disorders;Endocrine System Diseases;Diabetes Mellitus, Type 1;Diabetic Ketoacidosis;Acid-Base Imbalance;Diabetes Complications;Autoimmune Diseases;Acidosis;Disease;Drug-Related Side Effects and Adverse Reactions;Nutritional and Metabolic Diseases;Immune System Diseases;Glucose Metabolism Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Diabetes Mellitus;Metabolic Diseases;Drug Hypersensitivity;Ketosis","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases","Heterocyclic Compounds;Substances;Triazoles;Azoles;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Sitagliptin Phosphate;Pyrazines",,Pancreatic Islet Activity Alteration;Organ System Specific Effects;Endocrine Activity Alteration;Decreased Glucagon Secretion;Physiologic Effect (PE);Increased Insulin Secretion,Mechanism of Action (MoA);Enzyme Inhibitors;Dipeptidyl Peptidase 4 Inhibitors;Protease Inhibitors;Enzyme Interactions,Enzyme Inhibitor;Enzyme Interaction;Protease Inhibitor;Anti-infective;Dipeptidyl Peptidase 4 Inhibitor;Blood Glucose Regulator;Antimicrobial;Established Pharmacologic Class (EPC),"Dipeptidyl peptidase 4 (DPP-4) inhibitors;ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",,,,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,,,,
125,28,Concomitant Medications,Generic Name,RxNorm,robitussin dm,Robitussin DM,827249.0,Robitussin DM,,1790650.0,1790650,True,Medicinal product categorized by disposition;Sigma-1 receptor agonist-containing product;NMDA receptor antagonist-containing product,Medicinal product categorized by structure;Ether structure-containing product,Therapeutic Uses;Neurotransmitter Agents;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Antitussive Agents;Expectorants;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Excitatory Amino Acid Antagonists;Excitatory Amino Acid Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Lung Diseases;Sinusitis;Bordetella Infections;Respiratory Tract Diseases;Common Cold;Signs and Symptoms;Virus Diseases;Signs and Symptoms, Respiratory;Otorhinolaryngologic Diseases;Bronchial Diseases;Paranasal Sinus Diseases;Bacterial Infections;Pathological Conditions, Signs and Symptoms;Gram-Negative Bacterial Infections;Respiratory Hypersensitivity;Laryngeal Diseases;Pharyngitis;Bacterial Infections and Mycoses;Whooping Cough;Lung Diseases, Obstructive;Hypersensitivity;Disease;RNA Virus Infections;Infections;Stomatognathic Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Pharyngeal Diseases;Nose Diseases;Rhinitis, Allergic;Cough;Immune System Diseases;Picornaviridae Infections;Laryngitis;Bronchitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Respiration Disorders","Heterocyclic Compounds, 4 or More Rings;Phenols;Heterocyclic Compounds, Bridged-Ring;Hydrocarbons, Aromatic;Heterocyclic Compounds, Fused-Ring;Hydrocarbons, Cyclic;Catechols;Phenyl Ethers;Alkaloids;Guaiacol;Heterocyclic Compounds;Polycyclic Compounds;Ethers;Substances and Cells (CHEM);Polycyclic Aromatic Hydrocarbons;Benzene Derivatives;Morphinans;Opiate Alkaloids;Methyl Ethers;Substances;Dextromethorphan;Organic Chemicals;Hydrocarbons;Guaifenesin;Phenanthrenes",,Decreased Medullary Respiratory Drive;Decreased Respiratory Secretion Viscosity;Medullary Respiratory Center Activity Alteration;Respiratory Secretion Alteration;Respiratory Secretion Viscosity Alteration;Organ System Specific Effects;Physiologic Effect (PE);Increased Respiratory Secretions;Respiratory/Pulmonary Activity Alteration,Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Serotonin Uptake Inhibitors;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Ionotropic Glutamate Receptor Antagonists;Sigma Receptor Interactions;Membrane Transporter Interactions;Symporter Interactions;Ligand-Gated Ion Channel Interactions;Ion Transporter Interactions,Receptor Antagonist;Expectorant;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Ion Channel or Pump Agent;Respiratory Agent;Receptor Agonist;Nervous System Agent;Established Pharmacologic Class (EPC);Sigma-1 Agonist,"RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;Expectorants;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Anatomical Therapeutic Chemical (ATC1-4)",Medicinal product categorized by therapeutic role;Antitussive agent;Expectorant agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,,,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
126,28,Concomitant Medications,Generic Name,RxNorm,tessalon,Tessalon Perles,220224.0,Tessalon Perles,227783.0,227783.0,227783,False,,Nitrogen and/or nitrogen compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Therapeutic Uses;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Respiratory System Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Respiratory;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders","Substances;Alkanes;Butanes;Amines;Organic Chemicals;Hydrocarbons, Acyclic;Substances and Cells (CHEM);Hydrocarbons;Butylamines",,Tracheobronchial Stretch Receptor Alteration;Organ System Specific Effects;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Sodium-Potassium Exchanging ATPase Interactions;Mechanism of Action (MoA);Antiporter Interactions;Receptor Interactions;Membrane Transporter Interactions;Ion Transporter Interactions,Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),"RESPIRATORY SYSTEM;Other cough suppressants;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",Respiratory System Agent;Antitussive Agent;Therapeutic Categories,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,,,,,,,,
127,33,Concomitant Medications,Generic Name,RxNorm,tessalon,Tessalon Perles,220224.0,Tessalon Perles,227783.0,227783.0,227783,False,,Nitrogen and/or nitrogen compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,Therapeutic Uses;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Respiratory System Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hiccup;Signs and Symptoms, Respiratory;Signs and Symptoms, Digestive;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders","Substances;Alkanes;Butanes;Amines;Organic Chemicals;Hydrocarbons, Acyclic;Substances and Cells (CHEM);Hydrocarbons;Butylamines",,Tracheobronchial Stretch Receptor Alteration;Organ System Specific Effects;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE);Respiratory/Pulmonary Activity Alteration,Sodium-Potassium Exchanging ATPase Interactions;Mechanism of Action (MoA);Antiporter Interactions;Receptor Interactions;Membrane Transporter Interactions;Ion Transporter Interactions,Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),"RESPIRATORY SYSTEM;Other cough suppressants;COUGH AND COLD PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",Respiratory System Agent;Antitussive Agent;Therapeutic Categories,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES;ANTITUSSIVES/EXPECTORANTS,,,,,,,,
128,29,Concomitant Medications,Generic Name,RxNorm,clonazepam,clonazePAM,2598.0,clonazePAM,2598.0,2598.0,2598,False,,Benzodiazepine-containing product;Medicinal product categorized by structure;Benzazepine-containing product,GABA Agents;Therapeutic Uses;GABA Modulators;Neurotransmitter Agents;Central Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Anticonvulsants;Molecular Mechanisms of Pharmacological Action,"Chemically-Induced Disorders;Glaucoma, Angle-Closure;Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Digestive System Diseases;Eye Diseases;Glaucoma;Drug Hypersensitivity;Disease;Ocular Hypertension;Reproduction;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Reproductive Physiological Phenomena","Speech Disorders;Epilepsy;Lennox Gastaut Syndrome;Neurobehavioral Manifestations;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Sleep Disorders, Intrinsic;Bipolar and Related Disorders;Signs and Symptoms;Mental Disorders;Epileptic Syndromes;Schizophrenia;Parasomnias;Pain;Peripheral Nervous System Diseases;Neurologic Manifestations;Neuralgia;Language Disorders;Behavior and Behavior Mechanisms;Tic Disorders;Dyssomnias;Neurodevelopmental Disorders;Pathological Conditions, Signs and Symptoms;Brain Diseases;Communication Disorders;Epilepsy, Generalized;Restless Legs Syndrome;Schizophrenia Spectrum and Other Psychotic Disorders;Dysarthria;Movement Disorders;Bipolar Disorder;Disease;Panic Disorder;Sleep Wake Disorders;Seizures;Anxiety Disorders;Epilepsy, Absence;Mood Disorders;Nervous System Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Articulation Disorders;Neuromuscular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Epilepsies, Myoclonic;Genetic Diseases, Inborn","Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Clonazepam;Substances;Benzodiazepines;Benzazepines;Benzodiazepinones;Substances and Cells (CHEM)",,Gamma Amino Butyric Acid (GABA) Activity Alteration;Organ System Specific Effects;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Nervous System Activity Alteration;Physiologic Effect (PE);Increased GABA Activity,Mechanism of Action (MoA);Ion Channel Interactions;GABA A Receptor Interactions;GABA A Modulators;Chloride Channel Interactions;Receptor Interactions;Membrane Transporter Interactions;Ligand-Gated Ion Channel Interactions,Benzodiazepine;Ion Channel or Pump Agent;Chemical Structure;Established Pharmacologic Class (EPC);Nervous System Agent,Anatomical Therapeutic Chemical (ATC1-4);ANTIEPILEPTICS;NERVOUS SYSTEM;Benzodiazepine derivatives,Medicinal product categorized by therapeutic role;Anticonvulsant agent,,,CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;BENZODIAZEPINE DERIVATIVE SEDATIVES/HYPNOTICS;SEDATIVES/HYPONTICS,CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;BENZODIAZEPINE DERIVATIVE SEDATIVES/HYPNOTICS;SEDATIVES/HYPONTICS,CSA SCHEDULE;SCHEDULE IV,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Substances;Benzodiazepines;Benzazepines;Substances and Cells (CHEM)","Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Substances;Benzodiazepines;Benzazepines;Substances and Cells (CHEM)",,,,,
129,29,Concomitant Medications,Generic Name,RxNorm,Vitamin B12,,,,11248.0,11248.0,11248,False,,Vitamin B12 and/or vitamin B12 derivative-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Azole-containing product,Vitamins;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Vitamin B Complex;Micronutrients,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Endocrine System Diseases;Autoimmune Diseases of the Nervous System;Diabetes Complications;Multiple Sclerosis;Nutritional and Metabolic Diseases;Anemia;Poisoning;Mental Disorders;Demyelinating Autoimmune Diseases, CNS;Nutrition Disorders;Deficiency Diseases;Peripheral Nervous System Diseases;Neurotoxicity Syndromes;Substance-Related Disorders;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Brain Diseases;Avitaminosis;Chemically-Induced Disorders;Hematologic Diseases;Vitamin B 12 Deficiency;Anemia, Megaloblastic;Alcohol-Related Disorders;Disease;Alcohol-Induced Disorders;Anemia, Pernicious;Anemia, Macrocytic;Hemic and Lymphatic Diseases;Alcohol-Induced Disorders, Nervous System;Diabetic Neuropathies;Demyelinating Diseases;Nervous System Diseases;Polyneuropathies;Immune System Diseases;Alcoholic Neuropathy;Neuromuscular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Malnutrition;Leukoencephalopathies;Vitamin B Deficiency","Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Tetrapyrroles;Heterocyclic Compounds, 4 or More Rings;Polycyclic Compounds;Substances;Azoles;Substances and Cells (CHEM);Corrinoids;Heterocyclic Compounds, 1-Ring;Macrocyclic Compounds;Vitamin B 12;Pyrroles",,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Enzyme Interactions,Vitamin or Mineral;Vitamin B12;Established Pharmacologic Class (EPC),Vitamin B12 (cyanocobalamin and analogues);BLOOD AND BLOOD FORMING ORGANS;VITAMIN B12 AND FOLIC ACID;ANTIANEMIC PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4),,"Avitaminosis;Vitamin B 12 Deficiency;Disease;Nutrition Disorders;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Malnutrition;Deficiency Diseases;Vitamin B Deficiency",,"VITAMINS;VA CLASSES;VITAMIN B;MULTIVITAMINS;CYANOCOBALAMIN;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VITAMINS,COMBINATIONS","VITAMINS;VA CLASSES;VITAMIN B;MULTIVITAMINS;CYANOCOBALAMIN;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VITAMINS,COMBINATIONS",,"Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Tetrapyrroles;Heterocyclic Compounds, 4 or More Rings;Polycyclic Compounds;Substances;Azoles;Substances and Cells (CHEM);Corrinoids;Heterocyclic Compounds, 1-Ring;Macrocyclic Compounds;Vitamin B 12;Pyrroles",,,,,,
130,32,Concomitant Medications,Generic Name,RxNorm,Vitamin B12,,,,11248.0,11248.0,11248,False,,Vitamin B12 and/or vitamin B12 derivative-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Azole-containing product,Vitamins;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Vitamin B Complex;Micronutrients,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Endocrine System Diseases;Autoimmune Diseases of the Nervous System;Diabetes Complications;Multiple Sclerosis;Nutritional and Metabolic Diseases;Anemia;Poisoning;Mental Disorders;Demyelinating Autoimmune Diseases, CNS;Nutrition Disorders;Deficiency Diseases;Peripheral Nervous System Diseases;Neurotoxicity Syndromes;Substance-Related Disorders;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Brain Diseases;Avitaminosis;Chemically-Induced Disorders;Hematologic Diseases;Vitamin B 12 Deficiency;Anemia, Megaloblastic;Alcohol-Related Disorders;Disease;Alcohol-Induced Disorders;Anemia, Pernicious;Anemia, Macrocytic;Hemic and Lymphatic Diseases;Alcohol-Induced Disorders, Nervous System;Diabetic Neuropathies;Demyelinating Diseases;Nervous System Diseases;Polyneuropathies;Immune System Diseases;Alcoholic Neuropathy;Neuromuscular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Malnutrition;Leukoencephalopathies;Vitamin B Deficiency","Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Tetrapyrroles;Heterocyclic Compounds, 4 or More Rings;Polycyclic Compounds;Substances;Azoles;Substances and Cells (CHEM);Corrinoids;Heterocyclic Compounds, 1-Ring;Macrocyclic Compounds;Vitamin B 12;Pyrroles",,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Enzyme Interactions,Vitamin or Mineral;Vitamin B12;Established Pharmacologic Class (EPC),Vitamin B12 (cyanocobalamin and analogues);BLOOD AND BLOOD FORMING ORGANS;VITAMIN B12 AND FOLIC ACID;ANTIANEMIC PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4),,"Avitaminosis;Vitamin B 12 Deficiency;Disease;Nutrition Disorders;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Malnutrition;Deficiency Diseases;Vitamin B Deficiency",,"VITAMINS;VA CLASSES;VITAMIN B;MULTIVITAMINS;CYANOCOBALAMIN;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VITAMINS,COMBINATIONS","VITAMINS;VA CLASSES;VITAMIN B;MULTIVITAMINS;CYANOCOBALAMIN;MULTIVITAMINS WITH MINERALS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VITAMINS,COMBINATIONS",,"Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Tetrapyrroles;Heterocyclic Compounds, 4 or More Rings;Polycyclic Compounds;Substances;Azoles;Substances and Cells (CHEM);Corrinoids;Heterocyclic Compounds, 1-Ring;Macrocyclic Compounds;Vitamin B 12;Pyrroles",,,,,,
131,30,Concomitant Medications,Generic Name,RxNorm,Sumatriptan,SUMAtriptan,37418.0,SUMAtriptan,37418.0,37418.0,37418,False,Serotonin 5-HT1 receptor agonist-containing product;Medicinal product categorized by disposition;Serotonin receptor agonist-containing product,Sulfur and/or sulfur compound-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Sulfonamide-containing product,Therapeutic Uses;Serotonin 5-HT1 Receptor Agonists;Serotonin Agents;Neurotransmitter Agents;Serotonin Receptor Agonists;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Cardiovascular Agents;Molecular Mechanisms of Pharmacological Action;Vasoconstrictor Agents,"Chest Pain;Migraine Disorders;Ischemia;Stroke;Arrhythmias, Cardiac;Infarction;Headache Disorders, Primary;Cardiovascular Diseases;Vascular Diseases;Signs and Symptoms;Coronary Disease;Pain;Angina Pectoris;Angina, Unstable;Myocardial Ischemia;Neurologic Manifestations;Angina Pectoris, Variant;Digestive System Diseases;Hypertension, Malignant;Hypertension;Ischemic Attack, Transient;Pathological Conditions, Signs and Symptoms;Brain Diseases;Coronary Artery Disease;Chemically-Induced Disorders;Migraine with Aura;Disease;Arteriosclerosis;Myocardial Infarction;Arterial Occlusive Diseases;Headache Disorders;Drug Hypersensitivity;Heart Diseases;Peripheral Vascular Diseases;Nervous System Diseases;Drug-Related Side Effects and Adverse Reactions;Necrosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Liver Diseases;Pathologic Processes;Brain Ischemia;Cerebrovascular Disorders","Trigeminal Autonomic Cephalalgias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Migraine Disorders;Nervous System Diseases;Cluster Headache;Disease;Headache Disorders, Primary;Headache Disorders;Central Nervous System Diseases;Brain Diseases","Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Substances;Indoles;Amines;Biogenic Amines;Organic Chemicals;Amides;Sulfones;Biogenic Monoamines;Sulfonamides;Sumatriptan;Substances and Cells (CHEM);Tryptamines;Inorganic Chemicals;Sulfur Compounds",,Immunologically Active Molecule Activity Alteration;Organ System Specific Effects;Nervous System Activity Alteration;Physiologic Effect (PE);Increased Immunologic Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Increased Immunologically Active Molecule Activity;Increased Central Nervous System Serotonin Activity;Generalized Systemic Effects;Vasoconstriction;Cardiovascular Activity Alteration;Increased Serotonin Activity;Vascular Tone Alteration;Increased Immunologically Active Biogenic Amine Activity;Arterial Vasoconstriction;Serotonin Activity Alteration;Vascular Alterations;Cerebral Arterial Vasoconstriction,Serotonin 1b Receptor Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Serotonin Agonists;Receptor Interactions;Serotonin Receptor Interactions;Serotonin 1d Receptor Agonists,Receptor Interaction;Serotonin-1b and Serotonin-1d Receptor Agonist;Receptor Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,Selective serotonin (5HT1) agonists;ANALGESICS;ANTIMIGRAINE PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM,Medicinal product categorized by therapeutic role;Antimigraine agent,,,CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;ANALGESICS;ANTIMIGRAINE AGENTS,CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;ANALGESICS;ANTIMIGRAINE AGENTS,,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
132,30,Concomitant Medications,Generic Name,RxNorm,B complex,,,,,801177.0,801177,True,,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Vitamin B2 and/or vitamin B2 derivative-containing product;Sulfur and/or sulfur compound-containing product;Thiazole-containing product,Radiation-Sensitizing Agents;Micronutrients;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Photosensitizing Agents;Physiological Effects of Drugs;Dermatologic Agents;Vitamins;Vitamin B Complex,"Chemically-Induced Disorders;Intestinal Diseases;Gastrointestinal Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hemorrhage;Drug Hypersensitivity;Digestive System Diseases;Disease;Drug-Related Side Effects and Adverse Reactions;Duodenal Diseases;Peptic Ulcer;Cardiovascular Diseases;Stomach Diseases;Vascular Diseases;Pathological Conditions, Signs and Symptoms;Liver Diseases;Pathologic Processes;Hypotension","Brain Diseases, Metabolic;Nutritional and Metabolic Diseases;Cardiovascular Diseases;Vascular Diseases;Poisoning;Mental Disorders;Nutrition Disorders;Deficiency Diseases;Peripheral Nervous System Diseases;Neurotoxicity Syndromes;Substance-Related Disorders;Hypertriglyceridemia;Beriberi;Wernicke Encephalopathy;Brain Diseases;Metabolic Diseases;Avitaminosis;Lipid Metabolism Disorders;Chemically-Induced Disorders;Vitamin B 6 Deficiency;Alcohol-Induced Disorders;Alcohol-Related Disorders;Disease;Hypercholesterolemia;Dyslipidemias;Alcohol-Induced Disorders, Nervous System;Peripheral Vascular Diseases;Nervous System Diseases;Polyneuropathies;Hyperlipidemias;Thiamine Deficiency;Alcoholic Neuropathy;Pellagra;Neuromuscular Diseases;Riboflavin Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Malnutrition;Vitamin B Deficiency","Nicotinic Acids;Amino Acids;Niacinamide;Heterocyclic Compounds, 1-Ring;Vitamin B 6;Biological Factors;Inorganic Chemicals;Sulfur Compounds;Pigments, Biological;Heterocyclic Compounds, Fused-Ring;Imides;Heterocyclic Compounds, 2-Ring;Pyrimidines;beta-Alanine;Heterocyclic Compounds, 3-Ring;Coenzymes;Heterocyclic Compounds;Enzymes and Coenzymes;Pteridines;Thiazoles;Picolines;Substances and Cells (CHEM);Azoles;Thiamine;Pyridines;Pantothenic Acid;Acids, Heterocyclic;Substances;Organic Chemicals;Riboflavin;Alanine;Flavins;Amino Acids, Peptides, and Proteins",,Glucose Metabolism Alteration;Cholesterol Synthesis Alteration;Decreased Lipogenesis;Triglyceride Metabolism Alteration;Cholesterol Metabolism Alteration;Increased Metabolic Rate;Lipid Metabolism Alteration;Polysaccharide Metabolism Alteration;Cellular Activity Alteration;Sterol Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Glycogenolysis;Glycogen Metabolism Alteration;Decreased Cholesterol Synthesis;Physiologic Effect (PE);Metabolic Rate Alteration;Generalized Systemic Effects,Enzyme Activators;Mechanism of Action (MoA);Enzyme Interactions,,"VITAMINS;Other cicatrizants;SENSORY ORGANS;CICATRIZANTS;Vitamin B1, plain;ALIMENTARY TRACT AND METABOLISM;Other ophthalmologicals;DERMATOLOGICALS;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;Other plain vitamin preparations;PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS;OPHTHALMOLOGICALS;OTHER OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);OTHER PLAIN VITAMIN PREPARATIONS",,"Nutritional and Metabolic Diseases;Cardiovascular Diseases;Vascular Diseases;Coronary Disease;Nutrition Disorders;Deficiency Diseases;Myocardial Ischemia;Skin and Connective Tissue Diseases;Coronary Artery Disease;Avitaminosis;Vitamin B 6 Deficiency;Disease;Arteriosclerosis;Arterial Occlusive Diseases;Heart Diseases;Riboflavin Deficiency;Pellagra;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Malnutrition;Skin Diseases;Vitamin B Deficiency",,"VITAMINS,COMBINATIONS;VITAMINS;MULTIVITAMINS;VA CLASSES",,,,,,,,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Flatulence;Signs and Symptoms, Digestive;Disease;Skin Manifestations;Diarrhea;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Flushing"
133,30,Concomitant Medications,Generic Name,RxNorm,"zinc, chelated",,,,253210.0,253210.0,253210,False,,,,,,,,,,,,,,,,,,,,,,,,
134,33,Concomitant Medications,Generic Name,RxNorm,budesonide,Budesonide 0.5 MG/ML Inhalant Solution,252559.0,Budesonide 0.5 MG/ML Inhalant Solution,19831.0,19831.0,19831,False,,Medicinal product categorized by structure;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Steroid-containing product;Pregnane-containing product,"Autonomic Agents;Therapeutic Uses;Anti-Inflammatory Agents;Hormones;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Bronchodilator Agents;Glucocorticoids;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Respiratory System Agents;Anti-Asthmatic Agents","Lung Diseases;Status Asthmaticus;Respiratory Tract Diseases;Acute Disease;Bronchial Spasm;Bronchial Diseases;Disease Attributes;Pathological Conditions, Signs and Symptoms;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Pathologic Processes","Inflammatory Bowel Diseases;Respiratory Tract Diseases;Gastrointestinal Diseases;Digestive System Diseases;Otorhinolaryngologic Diseases;Intestinal Diseases;Respiratory Hypersensitivity;Hypersensitivity;Disease;Gastroenteritis;Infections;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nose Diseases;Rhinitis, Allergic;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",Pregnenediones;Polycyclic Compounds;Substances;Steroids;Substances and Cells (CHEM);Fused-Ring Compounds;Budesonide;Pregnenes;Pregnanes,,Organ System Specific Effects;Endocrine Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Decreased Glucocorticoid Secretion;Cellular Activity Alteration;Cellular Degradation/Digestion Alteration;Generalized Systemic Effects;Decreased Cellular Migration;Striated Muscle Metabolic Alteration;Cellular Motion Alteration;Cellular Synthetic Activity Alteration;Translation Alteration;Lysosomal Function Alteration;Decreased Lysosomal Function;Striated Muscle Anabolism Alteration;Adrenal Cortical Activity Alteration;Musculoskeletal Activity Alteration;Decreased Protein Synthesis,Mechanism of Action (MoA);Glucocorticoid Receptor Agonists;Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Corticosteroid Hormone Receptor Agonists,Hormone;Receptor Interaction;Corticosteroid;Chemical Structure;Receptor Agonist;Established Pharmacologic Class (EPC),"NASAL PREPARATIONS;Corticosteroids acting locally;RESPIRATORY SYSTEM;CORTICOSTEROIDS, PLAIN;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;ALIMENTARY TRACT AND METABOLISM;Glucocorticoids;DERMATOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Corticosteroids, potent (group III);ADRENERGICS, INHALANTS;Corticosteroids;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;INTESTINAL ANTIINFLAMMATORY AGENTS",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Polyps;Pathological Conditions, Anatomical;Lung Diseases, Obstructive;Nose Diseases;Hypersensitivity;Respiratory Tract Diseases;Disease;Otorhinolaryngologic Diseases;Bronchial Diseases;Immune System Diseases;Nasal Polyps;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",,"VA CLASSES;GLUCOCORTICOIDS;RESPIRATORY TRACT MEDICATIONS;ADRENAL CORTICOSTERIODS;ANTI-INFLAMMATORIES,NASAL;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION;HORMONES/SYNTHETICS/MODIFIERS;ANTIASTHMA,OTHER;NASAL AND THROAT AGENTS,TOPICAL","VA CLASSES;GLUCOCORTICOIDS;RESPIRATORY TRACT MEDICATIONS;ADRENAL CORTICOSTERIODS;ANTI-INFLAMMATORIES,NASAL;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION;HORMONES/SYNTHETICS/MODIFIERS;ANTIASTHMA,OTHER;NASAL AND THROAT AGENTS,TOPICAL",,,,,,,,
135,33,Concomitant Medications,Generic Name,RxNorm,Prilosec,PriLOSEC,203345.0,PriLOSEC,203345.0,203345.0,203345,False,Hydrolase inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product;Proton pump inhibitor-containing product;Cytochrome P450 inhibitor-containing product,Benzimidazole-containing product;Medicinal product categorized by structure,Therapeutic Uses;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Gastrointestinal Agents;Proton Pump Inhibitors;Anti-Ulcer Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Endocrine System Diseases;Duodenal Ulcer;Signs and Symptoms, Digestive;Heartburn;Paraneoplastic Endocrine Syndromes;Gastroesophageal Reflux;Helicobacter Infections;Neoplasms;Signs and Symptoms;Esophagitis;Gastrointestinal Diseases;Esophageal Motility Disorders;Digestive System Diseases;Otorhinolaryngologic Diseases;Duodenal Diseases;Peptic Ulcer;Esophageal Diseases;Gastrointestinal Neoplasms;Endocrine Gland Neoplasms;Bacterial Infections;Pathological Conditions, Signs and Symptoms;Intestinal Diseases;Gram-Negative Bacterial Infections;Bacterial Infections and Mycoses;Disease;Gastroenteritis;Zollinger-Ellison Syndrome;Infections;Stomatognathic Diseases;Digestive System Neoplasms;Neoplasms by Site;Paraneoplastic Syndromes;Pharyngeal Diseases;Stomach Ulcer;Stomach Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Deglutition Disorders","Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;2-Pyridinylmethylsulfinylbenzimidazoles;Substances;Omeprazole;Organic Chemicals;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Sulfoxides;Pyridines;Inorganic Chemicals;Sulfur Compounds;Benzimidazoles",,Inhibition Gastric Acid Secretion;Digestive/GI System Activity Alteration;Organ System Specific Effects;Physiologic Effect (PE);Gastric Acid Alteration,Mechanism of Action (MoA);Enzyme Inhibitors;Proton Pump Interactions;Receptor Interactions;Cytochrome P450 2C19 Inhibitors;Proton Pump Inhibitors;Cation Transporter Interactions;Cytochrome P450 Inhibitors;Membrane Transporter Interactions;Enzyme Interactions;Ion Transporter Interactions,Proton Pump Inhibitor;Gastrointestinal Agent;Established Pharmacologic Class (EPC);Ion Channel or Pump Agent,Proton pump inhibitors;ALIMENTARY TRACT AND METABOLISM;DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD);DRUGS FOR ACID RELATED DISORDERS;Anatomical Therapeutic Chemical (ATC1-4),,,,"GASTROINTESTINAL MEDICATIONS;GASTRIC MEDICATIONS,OTHER;VA CLASSES","VA CLASSES;GASTRIC MEDICATIONS,OTHER;GASTROINTESTINAL MEDICATIONS;H. PYLORI AGENTS;ANTIULCER AGENTS",,,,,,,Hepatic Metabolism;Site of Metabolism;Elimination;Pharmacokinetics (PK);Metabolism,
136,34,Concomitant Medications,Generic Name,RxNorm,Rybelsus,,,,2200645.0,2200645.0,2200645,False,Glucagon-like peptide 1 receptor agonist-containing product;Medicinal product categorized by disposition,Peptide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,,"Endocrine System Diseases;Neoplasms, Germ Cell and Embryonal;Thyroid Neoplasms;Carcinoma, Neuroendocrine;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neoplasms;Multiple Endocrine Neoplasia Type 2a;Neoplasms, Nerve Tissue;Neoplastic Syndromes, Hereditary;Thyroid Diseases;Neoplasms by Histologic Type;Endocrine Gland Neoplasms;Multiple Endocrine Neoplasia;Neoplasms, Glandular and Epithelial;Chemically-Induced Disorders;Disease;Multiple Endocrine Neoplasia Type 2b;Neuroendocrine Tumors;Neoplasms by Site;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Neoplasms, Multiple Primary;Carcinoma;Adenocarcinoma;Neuroectodermal Tumors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Head and Neck Neoplasms;Genetic Diseases, Inborn",,"Pancreatic Hormones;Hormones;Substances;Glucagon-Like Peptides;Proteins;Substances and Cells (CHEM);Protein Precursors;Hormones, Hormone Substitutes, and Hormone Antagonists;Gastrointestinal Hormones;Peptides;Peptide Hormones;Proglucagon;Amino Acids, Peptides, and Proteins",,Pancreatic Islet Activity Alteration;Digestive/GI System Activity Alteration;Organ System Specific Effects;GI Motility Alteration;Endocrine Activity Alteration;Decreased Glucagon Secretion;Decreased Gastric Motility;Decreased GI Motility;Physiologic Effect (PE);Increased Insulin Secretion,Mechanism of Action (MoA);Glucagon-like Peptide-1 (GLP-1) Agonists;Glucagon-like Peptide-1 (GLP-1) Receptor Interactions;Glucagon Receptor Interactions;G-Protein-linked Receptor Interactions;Receptor Interactions,Receptor Interaction;Blood Glucose Regulator;GLP-1 Receptor Agonist;Receptor Agonist;Established Pharmacologic Class (EPC),"ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Glucagon-like peptide-1 (GLP-1) analogues;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",,,,"HYPOGLYCEMIC AGENTS,OTHER;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","HYPOGLYCEMIC AGENTS,OTHER;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,"Pancreatic Hormones;Hormones;Substances;Glucagon-Like Peptides;Proteins;Substances and Cells (CHEM);Protein Precursors;Hormones, Hormone Substitutes, and Hormone Antagonists;Gastrointestinal Hormones;Peptides;Peptide Hormones;Glucagon-Like Peptide 1;Amino Acids, Peptides, and Proteins;Proglucagon",,,,,,
137,34,Concomitant Medications,Generic Name,RxNorm,Synjardy,,,,1664316.0,1664316.0,1664316,False,Sodium glucose cotransporter subtype 2 inhibitor-containing product;Medicinal product categorized by disposition,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Hypoglycemic Agents;MeSH Pharmacologic Actions (MESHPA);Sodium-Glucose Transporter 2 Inhibitors;Physiological Effects of Drugs;Molecular Mechanisms of Pharmacological Action,"Endocrine System Diseases;Male Urogenital Diseases;Acid-Base Imbalance;Renal Insufficiency;Diabetes Complications;Nutritional and Metabolic Diseases;Diabetic Ketoacidosis;Urologic Diseases;Digestive System Diseases;Acidosis;Diabetes Mellitus;Glucose Metabolism Disorders;Metabolic Diseases;Chemically-Induced Disorders;Kidney Diseases;Female Urogenital Diseases and Pregnancy Complications;Disease;Drug Hypersensitivity;Ketosis;Drug-Related Side Effects and Adverse Reactions;Female Urogenital Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases","Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Diabetes Mellitus;Metabolic Diseases","Hydrocarbons, Aromatic;Glycosides;Substances;Benzhydryl Compounds;Hydrocarbons, Cyclic;Guanidines;Substances and Cells (CHEM);Metformin;Organic Chemicals;Hydrocarbons;Glucosides;Biguanides;Benzene Derivatives;Amidines;Carbohydrates",,Glucose Metabolism Alteration;Renal Ion Transport Alteration;Polysaccharide Metabolism Alteration;Decreased Glycogenesis;Organ System Specific Effects;Increased Renal Organic Ion Excretion;Generalized Systemic Effects;Metabolic Activity Alteration;Decreased Gluconeogenesis;Renal Organic Ion Transport Alteration;Glycogen Metabolism Alteration;Increased Glucose Transport into Cells;Cell Glucose Transport Alteration;Physiologic Effect (PE);Renal/Urological Activity Alteration;Carbohydrate Metabolism Alteration,Mechanism of Action (MoA);Insulin Receptor Agonists;Insulin Receptor Interactions;Sodium-Glucose Transporter Interactions;Receptor Protein Kinase Interactions;Sodium-Glucose Transporter 2 Inhibitors;Sodium-Glucose Transporter Inhibitors;Receptor Interactions;Monosaccharide Transporter Interactions;Membrane Transporter Interactions;Symporter Interactions;Ion Transporter Interactions,Blood Glucose Regulator;Biguanide;Chemical Structure;Sodium-Glucose Cotransporter 2 Inhibitor;Established Pharmacologic Class (EPC),"Sodium-glucose co-transporter 2 (SGLT2) inhibitors;ALIMENTARY TRACT AND METABOLISM;DRUGS USED IN DIABETES;Biguanides;Anatomical Therapeutic Chemical (ATC1-4);BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs",,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Cardiovascular Diseases",,"BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;ORAL HYPOGLYCEMIC AGENTS,ORAL;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Substances;Guanidines;Organic Chemicals;Substances and Cells (CHEM);Biguanides;Amidines,,,,Elimination;Renal Excretion;Pharmacokinetics (PK);Route of Excretion,,
138,34,Concomitant Medications,Generic Name,RxNorm,Omega 3,,,,4301.0,4301.0,4301,False,,,,,"Lipid Metabolism Disorders;Hypertriglyceridemia;Disease;Hyperlipidemias;Nutritional and Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Dyslipidemias;Metabolic Diseases","Oils;Substances;Fish Oils;Fats;Dietary Fats;Fatty Acids, Unsaturated;Substances and Cells (CHEM);Dietary Fats, Unsaturated;Fatty Acids;Fatty Acids, Omega-3;Lipids",,Cell Membrane Alteration;Triglyceride Metabolism Alteration;Decreased Lipogenesis;Lipid Metabolism Alteration;Generalized Systemic Effects;Cellular Structure Alteration;Physiologic Effect (PE);Cellular Activity Alteration;Cellular Communication Alteration;Increased Lipolysis;Metabolic Activity Alteration,Mechanism of Action (MoA);Oxidation-Reduction Activity;Oxidation Activity;Unknown Cellular or Molecular Interaction;Physiochemical Activity,Omega-3 Fatty Acid;Established Pharmacologic Class (EPC);Chemical Structure,,,"Myocardial Ischemia;Arrhythmias, Cardiac;Disease;Pathological Conditions, Signs and Symptoms;Vascular Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Coronary Disease;Pathologic Processes;Heart Diseases",,,,,"Oils;Substances;Fish Oils;Fats;Dietary Fats;Fatty Acids, Unsaturated;Substances and Cells (CHEM);Dietary Fats, Unsaturated;Fatty Acids;Fatty Acids, Omega-3;Lipids",,,,,,
139,34,Concomitant Medications,Generic Name,RxNorm,Cefpodoxime,cefpodoxime 200 MG Oral Tablet,309078.0,cefpodoxime 200 MG Oral Tablet,20489.0,20489.0,20489,False,Cephalosporin antibacterial agent;Medicinal product categorized by disposition;Third generation cephalosporin antibacterial agent,Nitrogen and/or nitrogen compound-containing product;Beta-lactam-containing product;Third generation cephalosporin antibacterial agent;Medicinal product categorized by structure;Beta-lactam antibacterial agent;Cephalosporin antibacterial agent,Therapeutic Uses;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Anti-Infective Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Male Urogenital Diseases;Lung Diseases;Ear Diseases;Sinusitis;Respiratory Tract Diseases;Enterobacteriaceae Infections;Proteus Infections;Moraxellaceae Infections;Community-Acquired Infections;Klebsiella Infections;Escherichia coli Infections;Urologic Diseases;Sexually Transmitted Diseases;Otorhinolaryngologic Diseases;Maxillary Sinusitis;Staphylococcal Infections;Staphylococcal Skin Infections;Streptococcal Infections;Bronchial Diseases;Paranasal Sinus Diseases;Gonorrhea;Skin and Connective Tissue Diseases;Bacterial Infections;Cystitis;Sexually Transmitted Diseases, Bacterial;Haemophilus Infections;Pathological Conditions, Signs and Symptoms;Disease Attributes;Gram-Negative Bacterial Infections;Tonsillitis;Female Urogenital Diseases and Pregnancy Complications;Bacterial Infections and Mycoses;Pharyngitis;Lung Diseases, Obstructive;Gram-Positive Bacterial Infections;Skin Diseases, Bacterial;Disease;Urinary Bladder Diseases;Urinary Tract Infections;Pneumonia, Bacterial;Infections;Stomatognathic Diseases;Pharyngeal Diseases;Respiratory Tract Infections;Otitis;Nose Diseases;Genital Diseases;Skin Diseases, Infectious;Soft Tissue Infections;Otitis Media;Pneumonia;Female Urogenital Diseases;Pasteurellaceae Infections;Neisseriaceae Infections;Urogenital Diseases;Bronchitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Skin Diseases;Communicable Diseases","Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Cephacetrile;Cefotaxime;Lactams;Substances;beta-Lactams;Organic Chemicals;Amides;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Thiazines;Cephalosporins;Ceftizoxime;Inorganic Chemicals;Sulfur Compounds",,Decreased Cell Wall Synthesis & Repair;Cell Wall Alteration;Cellular Structure Alteration;Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Enzyme Inhibitors;Mechanism of Action (MoA);Enzyme Interactions;Transpeptidase Inhibitors,Antibacterial;Anti-infective;Chemical Structure;Antimicrobial;Established Pharmacologic Class (EPC);Cephalosporin Antibacterial,Third-generation cephalosporins;ANTIINFECTIVES FOR SYSTEMIC USE;OTHER BETA-LACTAM ANTIBACTERIALS;ANTIBACTERIALS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),Antibacterial agent;Antiinfective agent;Third generation cephalosporin antibacterial agent;Medicinal product categorized by therapeutic role;Beta-lactam antibacterial agent;Cephalosporin antibacterial agent,"Bacterial Infections and Mycoses;Disease;Infections;Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,CEPHALOSPORIN 3RD GENERATION;ANTIMICROBIALS;VA CLASSES;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS,CEPHALOSPORIN 3RD GENERATION;ANTIMICROBIALS;VA CLASSES;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS,,"Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Substances;Lactams;beta-Lactams;Organic Chemicals;Amides;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Thiazines;Cephalosporins;Inorganic Chemicals;Sulfur Compounds",,,,,,
140,35,Concomitant Medications,Generic Name,RxNorm,methemazole,,,,,6835.0,6835,True,,Sulfur and/or sulfur compound-containing product;Nitrogen and/or nitrogen compound-containing product;Thiourea-containing product;Medicinal product categorized by structure,"MeSH Pharmacologic Actions (MESHPA);Antithyroid Agents;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Hormone Antagonists","Chemically-Induced Disorders;Pregnancy;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Lactation;Drug-Related Side Effects and Adverse Reactions;Reproduction;Disease;Postpartum Period;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena","Endocrine System Diseases;Thyroid Crisis;Thyrotoxicosis;Thyroid Diseases;Disease;Hyperthyroidism;Goiter;Diseases, Life Phases, Behavior Mechanisms and Physiologic States","Heterocyclic Compounds;Substances;Sulfhydryl Compounds;Azoles;Organic Chemicals;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Imidazoles;Methimazole;Inorganic Chemicals;Sulfur Compounds",,Organ System Specific Effects;Endocrine Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Decreased Protein Modification;Post Translation Protein Modification Alteration;Decreased Iodine Organification;Cellular Activity Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Thyroid Hormone Iodination Alteration;Translation Alteration;Thyroid Gland Activity Alteration;Decreased Thyroid Hormone Iodination;Striated Muscle Anabolism Alteration;Iodine Organification Alteration;Musculoskeletal Activity Alteration;Decreased Protein Synthesis,Mechanism of Action (MoA);Uncouplers;Organic Anion Transporter Interactions;Enzyme Inhibitors;Protein Synthesis Inhibitors;Receptor Interactions;Anion Transporter Interactions;Membrane Transporter Interactions;Enzyme Interactions;Thyroid Hormone Synthesis Inhibitors;Ion Transporter Interactions,Enzyme Interaction;Established Pharmacologic Class (EPC);Thyroid Hormone Synthesis Inhibitor;Enzyme Inhibitor,"THYROID THERAPY;Anatomical Therapeutic Chemical (ATC1-4);SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;Sulfur-containing imidazole derivatives;ANTITHYROID PREPARATIONS",Medicinal product categorized by therapeutic role;Antithyroid agent,,,ANTITHYROID AGENTS;VA CLASSES;HORMONES/SYNTHETICS/MODIFIERS;THYROID MODIFIERS,ANTITHYROID AGENTS;VA CLASSES;HORMONES/SYNTHETICS/MODIFIERS;THYROID MODIFIERS,,,,,,,,
141,36,Concomitant Medications,Generic Name,RxNorm,mirapex,Mirapex Pill,1180461.0,Mirapex Pill,218402.0,218402.0,218402,False,Dopamine receptor agonist-containing product;Medicinal product categorized by disposition,,Therapeutic Uses;Neurotransmitter Agents;Central Nervous System Agents;Molecular Mechanisms of Pharmacological Action;MeSH Pharmacologic Actions (MESHPA);Dopamine Agonists;Anti-Dyskinesia Agents;Physiological Effects of Drugs;Protective Agents;Dopamine Agents;Antioxidants;Antiparkinson Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Parkinsonian Disorders;Mental Disorders;Movement Disorders;Nervous System Diseases;Neurodegenerative Diseases;Disease;Depressive Disorder;Nutritional and Metabolic Diseases;Proteostasis Deficiencies;Parkinson Disease;Basal Ganglia Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Central Nervous System Diseases;Brain Diseases;Metabolic Diseases;Synucleinopathies;Mood Disorders","Benzothiazoles;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Heterocyclic Compounds, 2-Ring;Substances;Thiazoles;Azoles;Organic Chemicals;Pramipexole;Heterocyclic Compounds, 1-Ring;Substances and Cells (CHEM);Inorganic Chemicals;Sulfur Compounds",,Increased Central Nervous System Dopamine Activity;Dopamine Activity Alteration;Organ System Specific Effects;Increased Dopamine Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Nervous System Activity Alteration;Physiologic Effect (PE),Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Dopamine Receptor Interactions;Dopamine Agonists;Receptor Interactions,Receptor Interaction;Receptor Agonist;Nonergot Dopamine Agonist;Established Pharmacologic Class (EPC);Nervous System Agent,DOPAMINERGIC AGENTS;ANTI-PARKINSON DRUGS;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;Dopamine agonists,Medicinal product categorized by therapeutic role;Antiparkinson agent,,,CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIPARKINSON AGENTS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIPARKINSON AGENTS;VA CLASSES,,,,,,,,
142,36,Concomitant Medications,Generic Name,RxNorm,dupixent,,,,1876402.0,1876402.0,1876402,False,Interleukin receptor antagonist-containing product;Medicinal product categorized by disposition;Interleukin-4 receptor alpha antagonist-containing product;Immunomodulator-containing product,Nitrogen and/or nitrogen compound-containing product;Polypeptide-containing product;Medicinal product categorized by structure;Antibody-containing product;Monoclonal antibody-containing product;Protein-containing product,,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Skin Diseases, Genetic;Skin Diseases, Eczematous;Hypersensitivity;Disease;Dermatitis, Atopic;Genetic Diseases, Inborn;Immune System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Skin Diseases;Skin and Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Dermatitis","Substances;Blood Proteins;Immunoglobulins;Immunoproteins;Proteins;Substances and Cells (CHEM);Serum Globulins;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Amino Acids, Peptides, and Proteins;Antibodies;Globulins",,Physiologic Effect (PE);Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects,Mechanism of Action (MoA);Interleukin 4 Receptor alpha Antagonists;Cytokine Receptor Superfamily Interactions;Interleukin 4 Receptor Interactions;Receptor Interactions,Receptor Antagonist;Receptor Interaction;Interleukin Agent;Interleukin-4 Receptor alpha Antagonist;Immunologic Agent;Established Pharmacologic Class (EPC),"DERMATOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);OTHER DERMATOLOGICAL PREPARATIONS;Agents for dermatitis, excluding corticosteroids",,,,"DERMATOLOGICAL AGENTS;VA CLASSES;DERMATOLOGICALS,SYSTEMIC,OTHER","DERMATOLOGICAL AGENTS;VA CLASSES;DERMATOLOGICALS,SYSTEMIC,OTHER",,"Substances;Blood Proteins;Immunoglobulins;Immunoproteins;Proteins;Substances and Cells (CHEM);Serum Globulins;Antibodies, Monoclonal;Amino Acids, Peptides, and Proteins;Antibodies;Globulins",,,,,,
143,37,Concomitant Medications,Generic Name,RxNorm,Chinese Medicine,,,,,1368530.0,1368530,True,,,,,,,,,,,,,,,,,,,,,,,,
144,37,Concomitant Medications,Generic Name,RxNorm,Vitamin B,,,,11251.0,11251.0,11251,False,,,,,,,,,,,,,,,,,,,,,,,,
145,38,Concomitant Medications,Generic Name,RxNorm,Fluticasone,,,,41126.0,41126.0,41126,False,,Androstane-containing product;Medicinal product categorized by structure;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Fluorinated corticosteroid-containing product;Steroid-containing product,"Autonomic Agents;Therapeutic Uses;Anti-Inflammatory Agents;Hormones;Sympathomimetics;Anti-Allergic Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Bronchodilator Agents;Glucocorticoids;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Respiratory System Agents;Dermatologic Agents;Anti-Asthmatic Agents","Lung Diseases;Status Asthmaticus;Respiratory Tract Diseases;Bronchial Diseases;Skin and Connective Tissue Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Skin Diseases, Infectious;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Skin Diseases","Respiratory Tract Infections;Respiratory Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Hypersensitivity;Respiratory Tract Diseases;Rhinitis, Allergic;Disease;Immune System Diseases;Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Rhinitis, Allergic, Perennial;Rhinitis",Androstanes;Androstenes;Polycyclic Compounds;Substances;Steroids;Fluticasone;Substances and Cells (CHEM);Fused-Ring Compounds;Androstadienes,,Decreased Vascular Permeability;Organ System Specific Effects;Endocrine Activity Alteration;Decreased Fibroblast Migration;Physiologic Effect (PE);Cellular Cycle Alteration;Decreased Glucocorticoid Secretion;Cellular Activity Alteration;Generalized Systemic Effects;Cellular Degradation/Digestion Alteration;Cardiovascular Activity Alteration;Decreased Cellular Migration;Cellular Motion Alteration;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Translation Alteration;Lysosomal Function Alteration;Decreased Lysosomal Function;Vascular Permeability Alteration;Striated Muscle Anabolism Alteration;Adrenal Cortical Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Decreased Capillary Permeability;Musculoskeletal Activity Alteration;Vascular Alterations;Decreased Protein Synthesis,Mechanism of Action (MoA);Glucocorticoid Receptor Agonists;Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Corticosteroid Hormone Receptor Agonists,Hormone;Receptor Interaction;Corticosteroid;Chemical Structure;Receptor Agonist;Established Pharmacologic Class (EPC),"NASAL PREPARATIONS;RESPIRATORY SYSTEM;CORTICOSTEROIDS, PLAIN;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Glucocorticoids;DERMATOLOGICALS;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Corticosteroids, potent (group III);ADRENERGICS, INHALANTS;Corticosteroids;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Polyps;Pathological Conditions, Anatomical;Lung Diseases, Obstructive;Nose Diseases;Hypersensitivity;Respiratory Tract Diseases;Disease;Otorhinolaryngologic Diseases;Bronchial Diseases;Immune System Diseases;Nasal Polyps;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",,"DERMATOLOGICAL AGENTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORY,TOPICAL;ANTI-INFLAMMATORIES,NASAL;ANTIHISTAMINES,NASAL;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA,OTHER;NASAL AND THROAT AGENTS,TOPICAL","DERMATOLOGICAL AGENTS;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORY,TOPICAL;ANTI-INFLAMMATORIES,NASAL;ANTIHISTAMINES,NASAL;ANTIASTHMA/BRONCHODILATORS;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA,OTHER;NASAL AND THROAT AGENTS,TOPICAL",,,,,,,,
146,40,Concomitant Medications,Generic Name,RxNorm,norgestimate/ethinyl estradiol,,,,214559.0,214559.0,214559,False,Progesterone receptor agonist-containing product;Medicinal product categorized by disposition;Hormone-containing product;Estrogen receptor agonist-containing product,Steroid-containing product;Medicinal product categorized by structure,"Contraceptives, Oral, Combined;Estrogens;Therapeutic Uses;Contraceptives, Oral, Synthetic;Contraceptive Agents;Contraceptives, Oral;Contraceptive Agents, Female;Hormones;MeSH Pharmacologic Actions (MESHPA);Reproductive Control Agents;Contraceptive Agents, Hormonal;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Contraceptives, Oral, Hormonal","Nutritional and Metabolic Diseases;Mental Disorders;Substance-Related Disorders;Intracranial Arterial Diseases;Digestive System Diseases;Heart Valve Diseases;Behavior and Behavior Mechanisms;Metabolic Diseases;Coronary Artery Disease;Thromboembolism;Thrombophilia;Genital Diseases, Female;Peripheral Vascular Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Nervous System Diseases;Female Urogenital Diseases;Phlebitis;Central Nervous System Diseases;Liver Diseases;Reproductive Physiological Phenomena;Cerebrovascular Disorders;Lung Diseases;Cardiovascular Diseases;Coronary Disease;Pulmonary Embolism;Vasculitis;Diabetes Mellitus;Embolism;Embolism and Thrombosis;Female Urogenital Diseases and Pregnancy Complications;Tobacco Use Disorder;Uterine Neoplasms;Heart Diseases;Drug-Related Side Effects and Adverse Reactions;Endometrial Neoplasms;Skin Diseases;Endocrine System Diseases;Reproduction;Vascular Diseases;Pregnancy;Genital Neoplasms, Female;Breast Neoplasms;Hypertension;Skin and Connective Tissue Diseases;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Brain Diseases;Arteriosclerosis;Breast Diseases;Arterial Occlusive Diseases;Neoplasms by Site;Hemic and Lymphatic Diseases;Drug Hypersensitivity;Hemorrhage;Cerebral Arterial Diseases;Genital Diseases;Uterine Hemorrhage;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Thrombosis;Male Urogenital Diseases;Respiratory Tract Diseases;Neoplasms;Venous Thrombosis;Thrombophlebitis;Myocardial Ischemia;Urogenital Neoplasms;Liver Neoplasms;Neoplasms, Hormone-Dependent;Glucose Metabolism Disorders;Chemically-Induced Disorders;Behavior;Disease;Digestive System Neoplasms;Headache Disorders;Tobacco Use;Urogenital Diseases;Hematologic Diseases","Endocrine System Diseases;Male Urogenital Diseases;Menopause;Menopause, Premature;Adnexal Diseases;Amenorrhea;Neoplasms;Menorrhagia;Ovarian Diseases;Signs and Symptoms;Primary Ovarian Insufficiency;Hot Flashes;Gonadal Disorders;Urogenital Neoplasms;Pathologic Processes;Breast Neoplasms;Hypogonadism;Skin and Connective Tissue Diseases;Climacteric;Pathological Conditions, Signs and Symptoms;Uterine Diseases;Genital Neoplasms, Male;Female Urogenital Diseases and Pregnancy Complications;Infertility, Female;Disease;Breast Diseases;Neoplasms by Site;Menstruation Disturbances;Genital Diseases, Female;Prostatic Neoplasms;Hemorrhage;Life Phases, Behavior Mechanisms and Physiologic States;Genital Diseases;Genital Diseases, Male;Uterine Hemorrhage;Sexual Development;Female Urogenital Diseases;Prostatic Diseases;Infertility;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena;Skin Diseases","Gonadal Steroid Hormones;Ethinyl Estradiol;Polycyclic Compounds;Substances;Hormones;Estradiol Congeners;Norpregnanes;Steroids;Gonadal Hormones;Estrogenic Steroids, Alkylated;Substances and Cells (CHEM);Norsteroids;Norpregnatrienes;Fused-Ring Compounds;Hormones, Hormone Substitutes, and Hormone Antagonists;Norpregnenes;Norgestrel",Coagulation Activity Alteration;Hemic/Lymphatic Activity Alteration;Hemostasis Alteration;Increased Coagulation Activity;Hematologic Activity Alteration;Organ System Specific Effects;Cardiovascular Activity Alteration;Blood Pressure Alteration;Increased Blood Pressure;Physiologic Effect (PE),Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Inhibit Ovulation;Smooth Muscle Tone Alteration;Organ System Specific Effects;Decreased Uterine Smooth Muscle Contraction or Tone;Ovulation Alteration;Female Reproductive System Activity Alteration;Nervous System Activity Alteration;Ovarian Follicular Phase Alteration;Physiologic Effect (PE);Bone Formation Stimulation;Bone Formation Alteration;Decreased Embryonic Implantation;Vaginal Function Alteration;Bone Alteration;Inhibit Ovarian Follicular Phase;Reproductive System Activity Alteration;Uterine Function Alteration;Uterine Smooth Muscle Contraction or Tone;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Peripheral Nervous System Activity Alteration;Ovarian Function Alteration,Mechanism of Action (MoA);Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Sex Hormone Receptor Agonists;Receptor Interactions;Hormone Receptor Agonists;Progestational Hormone Receptor Agonists;Estrogen Receptor Agonists,Hormone;Estrogen;Receptor Interaction;Chemical Structure;Receptor Agonist;Progestin;Established Pharmacologic Class (EPC),"Estrogens;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Natural and semisynthetic estrogens, plain;Progestogens and estrogens, fixed combinations;HORMONES AND RELATED AGENTS;ESTROGENS;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens and estrogens, sequential preparations;ENDOCRINE THERAPY;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES",Medicinal product categorized by therapeutic role;Contraceptive agent,"Pregnancy;Musculoskeletal Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Osteoporosis, Postmenopausal;Disease;Reproduction;Nutritional and Metabolic Diseases;Bone Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Bone Diseases, Metabolic;Metabolic Diseases;Reproductive Physiological Phenomena;Osteoporosis",,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,"Hormones;Substances;Gonadal Hormones;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones;Progesterone Congeners",,,,Hepatic Metabolism;Renal Excretion;Aromatic hydroxylation;Site of Metabolism;Enzymatic Pathway of Metabolism;Fecal Excretion;Route of Excretion;Elimination;Pharmacokinetics (PK);Metabolism,,
147,42,Concomitant Medications,Generic Name,RxNorm,"""Viro-grip"" cold medicine",Tylenol Cold Relief (APAP 500 MG / diphenhydrAMINE hydrochloride 12.5 MG) Oral Tablet,1052645.0,Tylenol Cold Relief (APAP 500 MG / diphenhydrAMINE hydrochloride 12.5 MG) Oral Tablet,,1117392.0,1117392,True,NMDA receptor antagonist-containing product;Histamine receptor antagonist-containing product;Alpha adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Medicinal product categorized by disposition;Sigma-1 receptor agonist-containing product;Propylamine derivative histamine receptor antagonist product,Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Medicinal product categorized by structure;Propylamine-containing product;Alcohol-containing product;Propylamine derivative histamine receptor antagonist product,Histamine Agents;Therapeutic Uses;Neurotransmitter Agents;Anti-Allergic Agents;Cardiovascular Agents;Excitatory Amino Acid Antagonists;Vasoconstrictor Agents;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Nasal Decongestants;Excitatory Amino Acid Agents;Autonomic Agents;Antipruritics;Bronchodilator Agents;Histamine H1 Antagonists;Antitussive Agents;Dermatologic Agents;Histamine Antagonists;Respiratory System Agents;Molecular Mechanisms of Pharmacological Action;Anti-Asthmatic Agents,"Male Urogenital Diseases;Lung Diseases;Status Asthmaticus;Respiratory Tract Diseases;Infant, Premature;Urethral Obstruction;Glaucoma, Angle-Closure;Gastrointestinal Diseases;Urologic Diseases;Eye Diseases;Digestive System Diseases;Intestinal Obstruction;Duodenal Diseases;Peptic Ulcer;Bronchial Diseases;Age Groups;Glaucoma;Infant, Newborn;Infant;Chemically-Induced Disorders;Intestinal Diseases;Asthma;Respiratory Hypersensitivity;Duodenal Obstruction;Female Urogenital Diseases and Pregnancy Complications;Lung Diseases, Obstructive;Urethral Diseases;Hypersensitivity;Ocular Hypertension;Disease;Urinary Bladder Diseases;Drug Hypersensitivity;Life Phases, Behavior Mechanisms and Physiologic States;Urinary Bladder Neck Obstruction;Genital Diseases;Prostatic Hyperplasia;Drug-Related Side Effects and Adverse Reactions;Genital Diseases, Male;Immune System Diseases;Female Urogenital Diseases;Prostatic Diseases;Stomach Diseases;Urogenital Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate","Lung Diseases;Sinusitis;Skin Diseases, Vascular;Respiratory Tract Diseases;Common Cold;Signs and Symptoms;Urticaria;Virus Diseases;Signs and Symptoms, Respiratory;Otorhinolaryngologic Diseases;Bronchial Diseases;Paranasal Sinus Diseases;Skin and Connective Tissue Diseases;Pathological Conditions, Signs and Symptoms;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;RNA Virus Infections;Infections;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Nose Diseases;Rhinitis, Allergic;Cough;Immune System Diseases;Picornaviridae Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Skin Diseases;Respiration Disorders","Heterocyclic Compounds, 4 or More Rings;Heterocyclic Compounds, 1-Ring;Pheniramine;Heterocyclic Compounds, Bridged-Ring;Hydrocarbons, Aromatic;Heterocyclic Compounds, Fused-Ring;Hydrocarbons, Cyclic;Phenethylamines;Propanols;Alkaloids;Heterocyclic Compounds;Alcohols;Pseudoephedrine;Polycyclic Compounds;Chlorpheniramine;Substances and Cells (CHEM);Ethylamines;Polycyclic Aromatic Hydrocarbons;Pyridines;Morphinans;Propanolamines;Opiate Alkaloids;Substances;Dextromethorphan;Amines;Organic Chemicals;Hydrocarbons;Phenanthrenes;Amino Alcohols",,Immunologically Active Molecule Activity Alteration;Medullary Respiratory Center Activity Alteration;Smooth Muscle Tone Alteration;Organ System Specific Effects;Nervous System Activity Alteration;Decreased Immunologically Active Biogenic Amine Activity;Physiologic Effect (PE);Respiratory Smooth Muscle Tone Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Decreased Medullary Respiratory Drive;Respiratory/Pulmonary Activity Alteration;Generalized Systemic Effects;Vasoconstriction;Bronchial Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Vascular Tone Alteration;Bronchodilation;Decreased Immunologically Active Molecule Activity;Autonomic Nervous System Activity Alteration;Musculoskeletal Activity Alteration;Histamine Activity Alteration;Peripheral Nervous System Activity Alteration;Vascular Alterations;Decreased Immunologic Activity;Decreased Histamine Activity,Adrenergic Receptor Interactions;Ion Channel Interactions;G-Protein-linked Receptor Interactions;Adrenergic Agonists;Adrenergic alpha-Agonists;Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Histamine H1 Receptor Antagonists;Ionotropic Glutamate Receptor Interactions;Serotonin Transporter Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Neurotransmitter Transporter Interactions;Sigma-1 Receptor Agonists;Histamine Receptor Antagonists;Serotonin Uptake Inhibitors;Sigma-1 Receptor Interactions;Adrenergic beta-Agonists;Membrane Transporter Interactions;Symporter Interactions;Ligand-Gated Ion Channel Interactions;NMDA Receptor Antagonists;Sigma Receptor Interactions;Histamine Receptor Interactions;Ion Transporter Interactions,Receptor Antagonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Receptor Interaction;Ion Channel or Pump Agent;Sympathomimetic Agent;Histamine-1 Receptor Antagonist;Adrenergic Receptor Agonist;Receptor Agonist;alpha-Adrenergic Agonist;Nervous System Agent;Established Pharmacologic Class (EPC);Sigma-1 Agonist,"NASAL PREPARATIONS;Substituted alkylamines;NASAL DECONGESTANTS FOR SYSTEMIC USE;Sympathomimetics;RESPIRATORY SYSTEM;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;ANTIHISTAMINES FOR SYSTEMIC USE;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;Anatomical Therapeutic Chemical (ATC1-4)",Medicinal product categorized by therapeutic role;Antitussive agent,"Signs and Symptoms, Respiratory;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Respiratory Tract Diseases;Disease;Cough;Signs and Symptoms;Pathological Conditions, Signs and Symptoms;Respiration Disorders",,"RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE",,,,,,Enzyme Inhibitors;Monoamine Oxidase Inhibitors;Mechanism of Action (MoA);Enzyme Interactions,,,
148,42,Concomitant Medications,Generic Name,RxNorm,biotin,Biotin Pill,1154424.0,Biotin Pill,1588.0,1588.0,1588,False,,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure;Imidazole-containing product,Vitamins;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Vitamin B Complex;Micronutrients,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Avitaminosis;Disease;Deficiency Diseases;Nutritional and Metabolic Diseases;Nutrition Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Malnutrition;Metabolic Diseases;Genetic Diseases, Inborn;Vitamin B Deficiency","Heterocyclic Compounds;Enzymes and Coenzymes;Imidazoles;Substances;Azoles;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Biotin;Coenzymes",,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Enzyme Interactions,,VITAMINS;ALIMENTARY TRACT AND METABOLISM;Other plain vitamin preparations;Anatomical Therapeutic Chemical (ATC1-4);OTHER PLAIN VITAMIN PREPARATIONS,,,,"VITAMINS;VA CLASSES;VITAMIN B;HERBS/ALTERNATIVE THERAPIES;MULTIVITAMINS;VITAMIN B,OTHER;VITAMINS,COMBINATIONS","VITAMINS;VA CLASSES;VITAMIN B;MULTIVITAMINS;VITAMIN B,OTHER;VITAMINS,COMBINATIONS",,,,,,,,
149,43,Concomitant Medications,Generic Name,RxNorm,Antivert,Meclizine Oral Tablet [Antivert],368885.0,Meclizine Oral Tablet [Antivert],91818.0,91818.0,91818,False,Medicinal product categorized by disposition;Histamine H1 receptor antagonist-containing product;Piperazine derivative histamine receptor antagonist product;Histamine receptor antagonist-containing product,Piperazine derivative-containing product;Piperazine and/or piperazine derivative-containing product;Medicinal product categorized by structure;Piperazine derivative histamine receptor antagonist product,Histamine Agents;Autonomic Agents;Therapeutic Uses;Antiemetics;Neurotransmitter Agents;Anti-Allergic Agents;Central Nervous System Agents;Cholinergic Antagonists;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Gastrointestinal Agents;Histamine Antagonists;Histamine H1 Antagonists;Physiological Effects of Drugs;Molecular Mechanisms of Pharmacological Action;Cholinergic Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Vestibular Diseases;Neurologic Manifestations;Ear Diseases;Nervous System Diseases;Vertigo;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Otorhinolaryngologic Diseases;Motion Sickness;Disease;Labyrinth Diseases;Signs and Symptoms;Pathological Conditions, Signs and Symptoms","Heterocyclic Compounds;Benzhydryl Compounds;Hydrocarbons, Cyclic;Substances;Meclizine;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Heterocyclic Compounds, 1-Ring;Benzene Derivatives;Piperazines;Hydrocarbons, Aromatic",,Immunologically Active Molecule Activity Alteration;Organ System Specific Effects;Nervous System Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Biogenic Amine Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Decreased GI Motility;Generalized Systemic Effects;Digestive/GI System Activity Alteration;Emesis Suppression;Central Nervous System Depression;Decreased Immunologically Active Molecule Activity;Acetylcholine Activity Alteration;Decreased Acetylcholine Activity;GI Motility Alteration;Central Nervous System Activity Alteration;Histamine Activity Alteration;Decreased Immunologic Activity;Decreased Histamine Activity,Mechanism of Action (MoA);Cholinergic Muscarinic Antagonists;Cholinergic Antagonists;Cholinergic Muscarinic Receptor Interactions;G-Protein-linked Receptor Interactions;Cholinergic Interactions;Histamine Receptor Antagonists;Receptor Interactions;Histamine Receptor Interactions;Histamine H1 Receptor Antagonists,Antiemetic;Gastrointestinal Agent;Established Pharmacologic Class (EPC),RESPIRATORY SYSTEM;ANTIHISTAMINES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4);Piperazine derivatives,,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Motion Sickness;Disease;Signs and Symptoms;Pathological Conditions, Signs and Symptoms",Anti-emetic Agent;Gastrointestinal Agent;Central Nervous System Agent;Therapeutic Categories,CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIVERTIGO AGENTS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIVERTIGO AGENTS;VA CLASSES,,,,,,,,
150,43,Concomitant Medications,Generic Name,RxNorm,Guaifenesin,Guaifenesin Pill,1159705.0,Guaifenesin Pill,5032.0,5032.0,5032,False,,Medicinal product categorized by structure;Ether structure-containing product,Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Expectorants;Respiratory System Agents,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Lung Diseases;Sinusitis;Bordetella Infections;Respiratory Tract Diseases;Common Cold;Signs and Symptoms;Virus Diseases;Signs and Symptoms, Respiratory;Otorhinolaryngologic Diseases;Bronchial Diseases;Paranasal Sinus Diseases;Bacterial Infections;Pathological Conditions, Signs and Symptoms;Gram-Negative Bacterial Infections;Respiratory Hypersensitivity;Laryngeal Diseases;Pharyngitis;Bacterial Infections and Mycoses;Whooping Cough;Lung Diseases, Obstructive;Hypersensitivity;Disease;RNA Virus Infections;Infections;Stomatognathic Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Respiratory Tract Infections;Pharyngeal Diseases;Nose Diseases;Rhinitis, Allergic;Cough;Immune System Diseases;Picornaviridae Infections;Laryngitis;Bronchitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Respiration Disorders","Hydrocarbons, Aromatic;Methyl Ethers;Phenols;Guaifenesin;Hydrocarbons, Cyclic;Catechols;Substances;Ethers;Organic Chemicals;Substances and Cells (CHEM);Hydrocarbons;Phenyl Ethers;Benzene Derivatives;Guaiacol",,Decreased Respiratory Secretion Viscosity;Respiratory Secretion Alteration;Respiratory Secretion Viscosity Alteration;Organ System Specific Effects;Physiologic Effect (PE);Increased Respiratory Secretions;Respiratory/Pulmonary Activity Alteration,,Expectorant;Respiratory Agent;Established Pharmacologic Class (EPC),"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Expectorants;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Anatomical Therapeutic Chemical (ATC1-4)",Medicinal product categorized by therapeutic role;Expectorant agent,,,"DECONGESTANT/EXPECTORANT;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,COMBINATIONS;ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER","DECONGESTANT/EXPECTORANT;VA CLASSES;RESPIRATORY TRACT MEDICATIONS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,COMBINATIONS;ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER",SCHEDULE V;CSA SCHEDULE;SCHEDULE III;SCHEDULE II,,,,,,,
151,43,Concomitant Medications,Generic Name,RxNorm,Flonase,Flonase Nasal Product,1801248.0,Flonase Nasal Product,83373.0,83373.0,83373,False,,Androstane-containing product;Medicinal product categorized by structure;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Fluorinated corticosteroid-containing product;Steroid-containing product,Autonomic Agents;Therapeutic Uses;Anti-Inflammatory Agents;Anti-Allergic Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Bronchodilator Agents;Physiological Effects of Drugs;Respiratory System Agents;Dermatologic Agents;Anti-Asthmatic Agents,"Lung Diseases;Status Asthmaticus;Respiratory Tract Diseases;Bronchial Diseases;Skin and Connective Tissue Diseases;Chemically-Induced Disorders;Asthma;Respiratory Hypersensitivity;Lung Diseases, Obstructive;Hypersensitivity;Disease;Infections;Drug Hypersensitivity;Skin Diseases, Infectious;Drug-Related Side Effects and Adverse Reactions;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Skin Diseases","Respiratory Tract Infections;Respiratory Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Hypersensitivity;Respiratory Tract Diseases;Rhinitis, Allergic;Disease;Immune System Diseases;Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate;Rhinitis, Allergic, Perennial;Rhinitis",Androstanes;Androstenes;Polycyclic Compounds;Substances;Steroids;Fluticasone;Substances and Cells (CHEM);Fused-Ring Compounds;Androstadienes,,Decreased Vascular Permeability;Organ System Specific Effects;Endocrine Activity Alteration;Decreased Fibroblast Migration;Physiologic Effect (PE);Cellular Cycle Alteration;Decreased Glucocorticoid Secretion;Cellular Activity Alteration;Generalized Systemic Effects;Cellular Degradation/Digestion Alteration;Cardiovascular Activity Alteration;Decreased Cellular Migration;Cellular Motion Alteration;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Translation Alteration;Lysosomal Function Alteration;Decreased Lysosomal Function;Vascular Permeability Alteration;Striated Muscle Anabolism Alteration;Adrenal Cortical Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Decreased Capillary Permeability;Musculoskeletal Activity Alteration;Vascular Alterations;Decreased Protein Synthesis,Mechanism of Action (MoA);Glucocorticoid Receptor Agonists;Hormone Receptor Interactions;Steroid Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions;Hormone Receptor Agonists;Corticosteroid Hormone Receptor Agonists,Hormone;Receptor Interaction;Corticosteroid;Chemical Structure;Receptor Agonist;Established Pharmacologic Class (EPC),"NASAL PREPARATIONS;RESPIRATORY SYSTEM;CORTICOSTEROIDS, PLAIN;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Glucocorticoids;DERMATOLOGICALS;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Corticosteroids, potent (group III);Corticosteroids;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",,"Asthma;Respiratory Hypersensitivity;Lung Diseases;Polyps;Pathological Conditions, Anatomical;Lung Diseases, Obstructive;Nose Diseases;Hypersensitivity;Respiratory Tract Diseases;Disease;Otorhinolaryngologic Diseases;Bronchial Diseases;Immune System Diseases;Nasal Polyps;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypersensitivity, Immediate",,"ANTI-INFLAMMATORIES,NASAL;NASAL AND THROAT AGENTS,TOPICAL;VA CLASSES","ANTI-INFLAMMATORIES,NASAL;NASAL AND THROAT AGENTS,TOPICAL;VA CLASSES",,,,,,,,
152,43,Concomitant Medications,Generic Name,RxNorm,Ondansetron,Ondansetron,26225.0,Ondansetron,26225.0,26225.0,26225,False,Medicinal product categorized by disposition;5-HT3 receptor antagonist-containing product,,Autonomic Agents;Therapeutic Uses;Antipruritics;Serotonin Agents;Antiemetics;Neurotransmitter Agents;Central Nervous System Agents;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Gastrointestinal Agents;Physiological Effects of Drugs;Serotonin 5-HT3 Receptor Antagonists;Dermatologic Agents;Molecular Mechanisms of Pharmacological Action;Serotonin Antagonists,"Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Chemically-Induced Disorders;Substance-Related Disorders;Alcohol-Related Disorders;Disease;Alcoholism;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Mental Disorders","Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Carbazoles;Heterocyclic Compounds, 2-Ring;Substances;Indoles;Azoles;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Imidazoles;Ondansetron;Heterocyclic Compounds, 3-Ring",,Immunologically Active Molecule Activity Alteration;Organ System Specific Effects;Nervous System Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Biogenic Amine Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Immunologic Activity Alteration;Decreased GI Motility;Decreased Serotonin Activity;Decreased Central Nervous System Serotonin Activity;Generalized Systemic Effects;Digestive/GI System Activity Alteration;Emesis Suppression;Serotonin Activity Alteration;Central Nervous System Depression;Decreased Immunologically Active Molecule Activity;Decreased Peripheral Nervous System Serotonin Activity;GI Motility Alteration;Central Nervous System Activity Alteration;Decreased Immunologic Activity,Mechanism of Action (MoA);Ion Channel Interactions;G-Protein-linked Receptor Interactions;Ligand-Gated Ion Channel Interactions;Receptor Interactions;Serotonin 3 Receptor Antagonists;Serotonin 5HT-3 Antagonists;Membrane Transporter Interactions;Serotonin Receptor Interactions;Serotonin 5HT-3 Receptor Interactions;Serotonin Antagonists,Receptor Antagonist;Receptor Interaction;Serotonin-3 Receptor Antagonist;Established Pharmacologic Class (EPC);Nervous System Agent,Serotonin (5HT3) antagonists;Anatomical Therapeutic Chemical (ATC1-4);ANTIEMETICS AND ANTINAUSEANTS;ALIMENTARY TRACT AND METABOLISM,Medicinal product categorized by therapeutic role;Antiemetic agent,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Postoperative Complications;Signs and Symptoms, Digestive;Vomiting;Disease;Signs and Symptoms;Postoperative Nausea and Vomiting;Pathological Conditions, Signs and Symptoms;Nausea;Pathologic Processes",,GASTROINTESTINAL MEDICATIONS;ANTIEMETICS;VA CLASSES,GASTROINTESTINAL MEDICATIONS;ANTIEMETICS;VA CLASSES,,,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, 4 or More Rings;Aporphines;Substances;Substances and Cells (CHEM);Benzylisoquinolines;Isoquinolines;Alkaloids;Apomorphine",,,,,
153,43,Concomitant Medications,Generic Name,RxNorm,ofloxacin otic,Ofloxacin Otic Solution,377450.0,Ofloxacin Otic Solution,1160453.0,1160453.0,1160453,False,Medicinal product categorized by disposition;Fluoroquinolone antibacterial agent,Nitrogen and/or nitrogen compound-containing product;Quinoline-containing product;Medicinal product categorized by structure;Quinolone antibacterial agent;Fluoroquinolone antibacterial agent,"Cytochrome P-450 CYP1A2 Inhibitors;Antineoplastic Agents;Therapeutic Uses;Enzyme Inhibitors;Anti-Bacterial Agents;MeSH Pharmacologic Actions (MESHPA);Metabolic Side Effects of Drugs and Substances;Topoisomerase Inhibitors;Topoisomerase II Inhibitors;Anti-Infective Agents;Cytochrome P-450 Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action;Anti-Infective Agents, Urinary","Chemically-Induced Disorders;Disease;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity","Tuberculosis;Male Urogenital Diseases;Lung Diseases;Ear Diseases;Respiratory Tract Diseases;Eye Infections, Bacterial;Enterobacteriaceae Infections;Tuberculosis, Pulmonary;Helicobacter Infections;Skin Diseases;Proteus Infections;Suppuration;Klebsiella Infections;Escherichia coli Infections;Corneal Ulcer;Sexually Transmitted Diseases;Eye Diseases;Urologic Diseases;Otorhinolaryngologic Diseases;Staphylococcal Infections;Inflammation;Bronchial Diseases;Skin and Connective Tissue Diseases;Gonorrhea;Bacterial Infections;Conjunctival Diseases;Sexually Transmitted Diseases, Bacterial;Pathological Conditions, Signs and Symptoms;Disease Attributes;Cystitis;Haemophilus Infections;Mycobacterium Infections;Gram-Negative Bacterial Infections;Female Urogenital Diseases and Pregnancy Complications;Bacterial Infections and Mycoses;Gram-Positive Bacterial Infections;Lung Diseases, Obstructive;Skin Diseases, Bacterial;Chlamydia Infections;Disease;Conjunctivitis;Urinary Bladder Diseases;Otitis Media, Suppurative;Conjunctivitis, Bacterial;Urinary Tract Infections;Infections;Corneal Diseases;Eye Infections;Actinomycetales Infections;Keratitis;Prostatitis;Epididymitis;Otitis;Respiratory Tract Infections;Otitis Externa;Skin Diseases, Infectious;Genital Diseases;Chlamydiaceae Infections;Soft Tissue Infections;Genital Diseases, Male;Otitis Media;Neisseriaceae Infections;Female Urogenital Diseases;Pasteurellaceae Infections;Prostatic Diseases;Urogenital Diseases;Bronchitis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Pathologic Processes;Salmonella Infections;Communicable Diseases","Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Substances;Quinolines;Substances and Cells (CHEM);Fluoroquinolones;Quinolones;Ofloxacin",,Transcription to RNA Alteration;Decreased DNA Replication;Cellular Cycle Alteration;Decreased DNA Integrity;Decreased Transcription to RNA;Nucleic Acid Transcription Alteration;Cellular Synthetic Activity Alteration;Nucleic Acid Replication Alteration;DNA Replication Alteration;Physiologic Effect (PE);Cellular Activity Alteration;DNA Integrity Alteration;Generalized Systemic Effects,Mechanism of Action (MoA);Topoisomerase 2 Inhibitors;Enzyme Inhibitors;Nucleic Acid Synthesis Inhibitors;Topoisomerase Inhibitors;Topoisomerase 4 Inhibitors;Enzyme Interactions;DNA Gyrase Inhibitors,Quinolone Antimicrobial;Anti-infective;Chemical Structure;Antimicrobial;Established Pharmacologic Class (EPC),ANTIINFECTIVES FOR SYSTEMIC USE;SENSORY ORGANS;ANTIINFECTIVES;ANTIBACTERIALS FOR SYSTEMIC USE;Fluoroquinolones;OPHTHALMOLOGICALS;QUINOLONE ANTIBACTERIALS;Anatomical Therapeutic Chemical (ATC1-4);Antiinfectives;OTOLOGICALS,Antibacterial agent;Antiinfective agent;Medicinal product categorized by therapeutic role;Quinolone antibacterial agent;Fluoroquinolone antibacterial agent,,Antimicrobial Agent;Anti-infective Agent;Therapeutic Categories,"OTIC AGENTS;ANTI-INFECTIVE,TOPICAL OTIC;VA CLASSES;ANTIBACTERIALS,TOPICAL OTIC","OTIC AGENTS;ANTI-INFECTIVE,TOPICAL OTIC;VA CLASSES;ANTIBACTERIALS,TOPICAL OTIC",,"Heterocyclic Compounds;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds, 2-Ring;Substances;Quinolines;Substances and Cells (CHEM);Quinolones",,,,,,
154,45,Concomitant Medications,Generic Name,RxNorm,Zinc,Zinc,11416.0,Zinc,11416.0,11416.0,11416,False,,Zinc and/or zinc compound-containing product;Metal and/or metallic compound-containing product;Medicinal product categorized by structure;Mineral-containing product,Micronutrients;Trace Elements;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs,,,"Organometallic Compounds;Metals;Zinc;Amino Acids;Substances;Methionine;Elements;Metals, Heavy;Organic Chemicals;Substances and Cells (CHEM);Transition Elements;Amino Acids, Neutral;Amino Acids, Sulfur;Amino Acids, Essential;Amino Acids, Peptides, and Proteins;Inorganic Chemicals;Sulfur Compounds",,,,,,,,,,,,,,,,,,
